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Abstract

Fibrosis around the implanted medical devices is a severe problem that can plague longterm device reliability. Activation of macrophage phenotype (macrophage polarization) has
emerged as a new and possible means for reducing fibrosis in the fields of biomaterials and
regenerative medicine. Macrophages are phagocytic cells that respond to microenvironmental
cues that direct their phenotype. Macrophage activation has been widely studied in mouse and
human in the context of tumor biology, yet little information is available regarding how
macrophage activation could be used in a biomaterials context. Further, rats rather than mice are
the common subjects in biomaterials experiments. A significant need is to determine if directed
macrophage activation can be achieved in a biomaterials context.
Cultured rat-derived macrophages (NR8383, peritoneal and spleen) were tested with
modulators (dexamethasone, LPS, IL-4 and IL10) to ensure activation towards the expected
phenotype. Phenotypic characterization involved gene expression assays (ARG2, CD163, CD206,
NOS2, IL-12), protein analysis (IL-6, IL-10, TNF-α), and flow cytometry (for receptors CD86,
CD163, CD206, MHC II). The successful in vitro immunomodulation suggested the feasibility of
modulation in vivo.
Microdialysis has been used for cytokine sampling (from various tissues including rat
mammary tissue for Leptin, CCL2 and IL-6; procedures developed in this work), but can also be
employed for modulator delivery. To achieve in vivo immunomodulation, microdialysis
experiments were performed to locally deliver either IL-4 or IL-10. No significant differences in
dialysate cytokine levels (CCL2, IL-1β, and IL-6) or histological sections (H&E and Masson’s
trichrome) of tissue surrounding the probe were observed between control and treatment groups.

However, gene expression analysis of tissue to which IL-4 was delivered suggests down-regulation
in CCL2 and IL-6. To enhance modulator amount and surface area, a polyvinyl alcohol (PVA)
sponge model was employed. The IL-4 impregnated sponges had reduced IL-1β concentrations
compared to controls. However, no significant differences in gene expression were observed. For
IL-10, down regulation of CCL2 (also at protein level), IL-1β, IL-12 and NOS2 genes was
observed. This initial work in macrophage activation for biomaterials in rats provides a
fundamental framework for future work in this field.

©2014 by Geetika Bajpai
ALL Rights Reserved
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Chapter 1: General Introduction

1.1 Foreign Body Response and Wound Healing
Surgical implantation of biomaterial medical devices leads to a series of cellular and
molecular cascades that are broadly termed the foreign body response (FBR). The FBR [1, 2] is a
mechanism to protect the host against foreign materials. For medical devices, the FBR leading to
encapsulation of the device is not desirable as it results in chronic inflammation and prevents
complete healing. The ultimate result of the FBR is the encapsulation of the implant in a
collagenous bag owing to its big size (> 5µm) which the body is unable to destroy.
Encapsulated devices have questionable “reliability”. For example, glucose sensors after
being encapsulated might still be functional, but signals will be relevant only to the
microenvironment of the collagenous bag and will not reflect glucose levels of the normal body
homeostasis. Implantable glucose sensors are approved to be used only for up to seven days by the
FDA [3]. This is an issue as the patient has to use a new device every 7 days and go through the
implantation procedure associated with it. Thus, it would be desirable to enhance the implant life
by modulating the FBR. Figure 1 depicts the microenvironment of the sensor as a result of FBR.
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Figure 1. Microenvironment of sensor due to FBR
The picture depicts the various events that take place around the implanted biomaterial: the
adsorption of proteins onto the surface, cellular infiltration, followed by capillary formation and
collagen deposition that ultimately lead to fibrosis. (Adapted from Sensors (Basel). 2009; 9(11):
9275–9299)
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Implantation of any device requires surgery resulting in wounding, trauma and perturbation
of the local tissue homeostasis. Thus, the wound healing process is initiated after any device is
implanted including sensors. Sometimes investigators consider FBR as a distinct phenomenon not
related to the events that take place in the normal wound healing process, but FBR and wound
healing are similar processes, except that the chronic presence of the artificial biomaterial leads to
encapsulation and thus deviation from the normal wound healing process. The FBR begins with
the wound healing. A brief review of the process is required and where the contrasts lie in the two
processes will be dissected as the discussion of the stages of FBR and wound healing progresses.
Generally, wound healing can be divided into “inflammatory stage”, “reparative stage” and
“remodeling stage”. It is crucial to point out that wound healing is a continuous dynamic process;
however, for the sake of understanding and convenience, it is divided into stages.
The inflammatory stage begins with the initial injury. Figure 2 shows the various stages of
wound healing. The inflammatory stage facilitates healing and aims at destroying or neutralizing
the injurious agent. Platelets play a role in fibrin matrix formation, which causes blood clot
formation. thereby stopping the bleeding. Platelets adhere to the fibrin matrix, aggregate and
release platelet derived growth factor (PDGF) and other chemokines (small proteins between 8-12
kDa that mediate kinesis or movement of cells toward a specific site) that later aids in neutrophil
recruitment [4, 5]. After cessation of blood loss, blood vessels dilate to allow other chemical
mediators, proteins and cells (first neutrophils and then macrophages) to arrive at the injured site.
This results in swelling at the site of the injury caused by the influx of fluid. The fluid is called the
exudate. At this stage, signs of inflammation are called erythema (redness), edema (swelling), heat
and pain. Neutrophils are short lived cells (24 to 48 hrs) and are the first ones to arrive at the site
within the first few hours of injury. These phagocytic cells help in debriment (removal of debris
3

and dead cells) of the wound [6]. Neutrophils subside within 48 hours and monocyte/ macrophages
start to migrate to the site. Macrophages remain at the site throughout the wound healing phase
and carry out wide variety of functions which will be discussed in later sections.
The reparative or proliferative stage begins to close the wound area or, in other words, to
rebuild the wound area with new tissue. The new tissue is called granulation tissue and it is
comprised of collagen, extracellular matrix, macrophages and fibroblasts. Formation of new blood
vessels takes place via angiogenesis. Fibroblasts and myofibroblasts cells multiply to fill up the
wound area. Fibroblasts secrete collagen and deposit matrix to close the wound area. Finally, a
process known as “epithelialization” results into resurfacing of the wound by epithelial cells.
Resolution of the wound takes place in the final remodeling phase. During this phase, matrix
components mature. Collagen is converted from type III to type I collagen [7, 8]. Healing is
achieved and scar tissue is formed.
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Figure 2. Stages of wound healing
The Figure shows the progression of wound healing through various stages with the various
mediators at each stage. (Adapted from www.worldwidewounds.com)
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As mentioned before, FBR stages are similar to the wound healing stages. FBR involves
similar steps of blood material interactions, blood clotting, adsorption of proteins at the material
surface, cellular infiltration and granulation tissue formation. Complete healing is inhibited
because of the persistent presence of the implant which results in chronic inflammation, foreign
body giant cell formation (FBGC, multinucleated macrophages formed by fusion of 10 or more
macrophages) and encapsulation of the implant in an avascular collagenous bag [1]. Why healing
does not occur as normal healing around the implant is an active area of research. Understanding
of underlying mechanisms would help in modulating the biological outcome of the implants so
that their performance and longevity can be enhanced in vivo.
Among the key cellular players in FBR are macrophages [2]. Since devices/biomaterials
are too big to be phagocytosed, macrophages fuse to form foreign body giant cells that remain at
the implant site secreting mediators to destruct the surface. Macrophages carry out wide variety of
roles and secrete a wide array of chemical mediators which will be discussed in following sections.
These cells exist in different phenotypic states promoting inflammation or healing [9]. One of the
possible ways to modulate the outcome of FBR is through the modulation of macrophage
phenotypes using stimulants (cytokines or glucocorticoid drugs such as dexamethasone) towards
a phenotype that promotes healing. The aim of this dissertation is to understand the macrophage
phenotypic changes in response to modulators using a microdialysis probe implant model and PVA
sponge implant models in vivo.
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1.2 Macrophages

1.2.1 Macrophage and Mononuclear Phagocytic System
The mononuclear phagocytic system (MPS) includes dendritic cells (DC), monocytes, and
macrophages [10]. Dendritic cells specialize in antigen presentation. Macrophages are phagocytic
cells of the innate immune system originally discovered by Illya Mechnikov in 1884.
Macrophages originate from monocytes, which are white blood cells. Monocytes originate from
common myeloid progenitors in the bone marrow. The macrophage colony stimulating factor
(MCSF-1) and the granulocyte colony stimulating factor (GM-CSF) direct the production of
mononuclear phagocytes from the progenitor cells [11]. At the macrophage and DC progenitor
(MDP) stage, commitment to mononuclear phagocyte lineage is determined. From MDPs,
monocytes and common DC progenitors (CDP) are derived. Monocytes differentiate into
macrophages or DC, but CDPs are committed to DC lineage only. Monocytes circulate in the blood
stream and migrate to tissues. Almost every tissue type has a resident tissue macrophage
population. Based on the in-tissue distribution macrophages have a given special names.

1.2.2 Macrophage Heterogeneity
Mature macrophages are heterogeneous cells varying in cell surface receptor expression,
morphology and functions [12, 13]. Peripheral blood monocytes that give rise to various tissue
macrophages are also heterogeneous [14]. Human peripheral blood monocytes have been
classified into classical, intermediate and non-classical subsets depending on the relative
expression of cell surface receptors CD14 (LPS Co-receptor), CD16 (Fcγ RIII) and CD64 (Fcγ
7

RIV), and also chemokine receptor expression CCR2 and CX3CR1 [15]. These subsets have
relative expression of TNFR (tumor necrosis factor receptor) as well. Non-classical subsets have
highest expression of TNFR2 receptor. The intermediate subsets have low expression of TNFR2
while classical subsets have the lowest of all three. The TNFR1 expression is highest in
intermediate subsets, then classical subsets, and lowest in non-classical subsets.
Mouse and rat macrophage marker subsets also share similar heterogeneity. Mouse
monocytes have three subsets based on the cell surface receptor expression of Ly6C
(differentiation marker on monocyte/dendritic cell precursors in mid stage development), CD43
(transmembrane sialoglycoprotein on monocytes, T cells and B cells) and CD11b (integrin alpha
M/Macrophage-1 antigen), and chemokine receptor CCR2 (receptor for chemokine CCL2) and
CX3CR1 (receptor for chemokine fractalkine involved in cell adhesion) [16-18]. The classical
subset is defined as Ly6ChighCD43lowCD11b+CCR2highCX3CR1low. The intermediate subset is
defined

as

Ly6ChighCD43highCD11b+.

The

non-classical

subset

is

defined

as

Ly6ClowCD43highCD11b+ with low expression of CCR2 but high expression of CX3CR1
chemokine receptor. In rats, monocyte subsets exist as CD43high and CD43low. The CD43low
monocytes have higher expression of CCR2, CCR7 and CD32 whereas CD43high monocytes have
higher expression of CD4, CX3CR1 and CD11c [12].
The spleen can be used as an example to show macrophage heterogeneity. The rodent
spleen is rich in sub-populations of macrophages. Macrophages in the red pulp part of the spleen
have express high levels of F4/80 antigen and mannose receptor (MR) [19]. Their key role is in
the clearance of senescent erythrocytes. Marginal zone (MZ) macrophages in the spleen lack
expression of antigen F4/80 [20]. Macrophages found in the white pulp of the spleen express pan
macrophage marker CD68 but lack F4/80 antigen marker.
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The peritoneal cavity contains distinct populations of macrophages which vary in receptor
expression and size [21]. The subset one has relatively larger cell size and expresses markers
CD11b and F4/80. They are the predominant subset in unstimulated animals (not treated with
LPS or thioglycolate). Upon stimulation of the peritoneal cavity with thioglycolate or
lipopolysaccharide (LPS) they significantly decrease in number and another subset becomes the
dominant population. The other subset has lower levels of CD11b and F4/80 expression but they
have high expression of MHCII marker. Both the subsets have phagocytic and nitric oxide (NO)
production capabilities.

1.2.3 Macrophage Functions
It has now been well established that macrophages perform a wide variety of functions and
are not limited to simply phagocytosis in host defense. Macrophages have been shown to regulate
developmental processes. Not only do they clear debris of dead cells but also play a role in
apoptosis [22]. Thus, they initiate and protect cells from apoptosis. Macrophages play a role in
tissue patterning. Studies in PU.1-/- strain of mice (which lack the transcription factor required for
differentiation of immune cells and macrophages) showed altered hindbrain vasculature [23].
Studies in mice that lack csf1 gene (Csf1op/op mice) (colony stimulating factor-1), which have
severe deficiency of MPS, show abnormal vascular patterning in the hindbrain [24].
Macrophages participate in lipid metabolism. Macrophages have been correlated with fat
mass in studies involving whole body lipid metabolism [25].

Studies have shown that

macrophages are involved in maintenance of blood pressure [26]. Another critical function of
macrophages in homeostasis is in maintenance of hematopoietic cell levels. Macrophages clear
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millions of neutrophils and erythrocytes from circulation every day. They also clear dead cells
from the spleen, thymus and other tissues. This process does not cause them to release proinflammatory molecules.
Macrophages not only play role in innate immune response by phagocytosis of pathogens
they are also involved in activating adaptive immune responses. Along with DCs, they are the
major cells in antigen presentation to T-lymphocytes and are thus included in the category of
professional antigen presenting cells. Presentation of antigens is a crucial step for activation of
adaptive immunity. They express MHCII receptors on their surface that are engaged in antigen
presentation to CD4 T helper cells.
As mentioned previously, macrophages play critical roles in inflammation, tissue repair
and healing. Upon injury, macrophages migrate from blood to the site in response to chemokines
specifically CCL2. Infiltrated macrophages secrete various inflammatory mediators to clear
pathogens from the site. They remove neutrophils at the wound site, a process known as
efferocytosis. Studies have shown that neutrophil clearance is a critical part of wound healing.
Macrophages are capable of secreting various cytokines, chemical mediators (NO and
prostaglandins) and growth factors such as PDGF (platelet derived growth factor), TGF
(transforming growth factor) and FGF (fibroblast growth factor). These factors promote
proliferation and migration of cells such as fibroblasts at the wound site, which indirectly
influences the extracellular matrix (ECM) formation. They also secrete pro-angiogenic factors
such as VEGF (vascular endothelial growth factor), which promote vascularization at the wound
site to promote wound healing [27]. Macrophages are also a source of chemokines, inflammatory
and anti-inflammatory cytokines such as IL-1β, IL-4, IL-6, IL-10 and TNF-α. These cytokines are
secreted during various stages of FBR/wound healing progression as discussed before.
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1.3 Macrophage Polarization/Activation
It is clear that macrophages are highly versatile and pleiotropic in nature, carrying out a
wide variety of functions. This certainly begs the question: how macrophages are able to carry
out such diverse functions? The answer lies in their phenotypic plasticity. Macrophages get
activated by engagement of specific cell surface receptors with a variety of stimulants such as
bacterial products, lipid products [28] and cytokines present in local milieu and are able to adapt
to the microenvironment accordingly. Macrophages have been classified according to the
activation patterns which follows the previously established Th1/Th2 (T helper type 1 / T helper
type II) paradigm. According to new recommendations and nomenclature guidelines by Suttles et
al. [29], macrophage polarization should be referred as macrophage activation, and macrophage
phenotypes should be stated according to the stimulus and not just broad M1/M2. For instance,
macrophage activated in response to IL-4 should be stated as M(IL-4) and so on. Since this is a
very recent recommendation, this dissertation will use the new nomenclature, but will also
provide background on what nomenclature has been for three decades in the field.

1.3.1 Classically Activated Macrophages
Inflammatory macrophages or “M1” macrophages are elicited in response to bacterial
endotoxin lipopolysaccharide (LPS) or inflammatory cytokines including but not limited to
Interferon-Ү (IFN-γ) and Interleukin-1 (IL-1). The M1 profile activation is also termed as
“classical activation” of the macrophages. The classically activated macrophages are generally
recognized as IL-12high, IL-23high and IL-10low profiles [30]. They are inflammatory in nature
secreting pro-inflammatory cytokines including, but not limited to, interleukin-1β (IL-1β),
11

interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), and mediators, inducible nitric oxide
synthase (iNOS), which results in nitric oxide (NO) production enhancing microbicidal activities.
Classical activation also causes enhancement of certain surface receptors, CD86, CD80 and
MHCII. Macrophages generated in response to LPS will be referred as M(LPS).

1.3.2 Alternatively Activated Macrophages
The “alternative activation” of macrophages was first described by Stein et al., [31]. The
alternatively activated macrophages or “M2” macrophages are generated in response to cytokines
IL-4 and IL-13. The alternatively activated profile is recognized as IL-10high, IL-12low and IL-23low
profile. They are considered to be anti-inflammatory in nature. The M2 profile has been subclassified as “M2a”, “M2b” and “M2c”. M2a profile is generated in response to IL-4 which
according to new nomenclature should be referred as M(IL-4)[29]. The M2b profile is generated
via IL-1R ligands, immune complexes with LPS which now will be referred to as M(Ic). The M2c
profile activation occurs in response to IL-10, TGF-β and glucocorticoids such as dexamethasone.
Again, this is based on previous norms, but according to new nomenclature (to avoid confusion),
M (IL-10) or M(dex) will be used. Overall, the M2 profile shows shifts in arginine metabolism
viz high arginase activity. The M2 profile show enhancement of cell surface receptors CD206,
CD163 and CD209 [32]. The M2 macrophages help in the development of Th2 responses such as
parasite encapsulation, allergies and tissue remodeling.
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1.3.3 Biomarkers and Identification of Differentially Polarized Macrophages
Combinations of assays have been used for the identification of various macrophage
phenotypes. There is no agreed upon standard as to which assay should be used. Measurement of
secreted cytokines using ELISA, identification of cell surface receptor expression using flow
cytometry assays or immunohistochemistry, and/or measurements of RNA transcript using qRTPCR analysis have been the most commonly used methods. Some researchers have used
transcriptomics analyses as well to elucidate the detailed changes in the gene expression profile of
differentially polarized states of macrophages and for the identification of novel markers [33].
Table 1 shows the list of cell surface receptor expression profiles of differentially polarized states
of macrophages. The M2 subsets are harder to identify due to the relative expression profile of
various markers. To summarize,
M1 phenotype will be expected to have: MHCIIhigh CD86 highCD80high,CCR7highCD163-CD204M2a profile will be expected to have: CD209highCD206highCD163lowCD16low
M2c profile will be expected to have: CD163highCD16highCD206lowCD209low
To date, most of the in vitro studies have been performed in mouse macrophages. Thus
most of the biomarker information has come from these studies. In alternatively activated mouse
macrophages, Ym1, Fizz1 and arginase 1 serve as important biomarkers [34]. However, expression
of Ym1 and Fizz1 in human macrophages is not present. Ym1 and Fizz1 markers have not been
studied in rats in detail [35]. This clearly indicates interspecies differences and therefore the need
to evaluate macrophage phenotypes on a case-by-case basis. The identification of novel markers
is still open ground.
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Table 1. List of markers and their degrees of expression between differentially-activated
macrophages

-

Markers

M(LPS/IFN-Ү)

M(IC)

CD 80

++

-

+

-

[9], [36]

CD86

++

-

+

_

[9], [36]

MHC II

+++

+

+

_

[37], [38], [39]

CD 40

++

-

_

[40]

CD 36

_

+

+++

[33]

CD 163

-

+

+++

[41], [42]

CD 206

-

+++

+

[29], [41], [36]

CD209

-

+++

+

[30], [43]

Stabilin 1

-

+++

+

[43]

CD 204

-

+

+++

[43]

Dectin 1

-

+++

+

[43], [44]

CD16/32

-

+

+++

[45]

CD14

-

+

+++

[45], [46]

CCR7

+++

-

-

[9], [47]

CD68

++

+

+

[9], [42]

M(IL-4)

-

indicates no expression

+ indicates expression present
++ indicates moderate expression
+++ indicates abundant expression
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M(IL-10)
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1.3.4 Clinical Implications
Different phenotypic states of macrophages have been implicated in various pathological
conditions including, but not limited to, atherosclerosis, tumor biology and metabolic disorder.
Elucidation of pathways governing macrophage polarization/activation will be of significant
interest for the development of novel clinical strategies in a given pathological condition. There
is an enormous interest in the various macrophage phenotypic states in the field of regenerative
medicine. The idea is to “re-educate” the macrophages to phenotypically adapt a desired
phenotypic profile in a given pathological condition. For example, research in tumor biology has
shown presence of alternatively activated M2-like macrophages that promote tumor progression.
It would be desired to modulate the phenotype to an “M1”-like pro-inflammatory state to have
tumoricidal properties.
A long term aim in the biomaterials community is to enhance the implant life and reduce
fibrotic encapsulation around the implant. In this case it would be desirable to shift the
macrophages towards pro-wound healing and tissue remodeling “M2c or M(IL-10)” phenotype.
This is a novel strategy and not enough literature is available with respect to modulating
macrophages to reduce fibrosis. The idea is to be able to achieve M2c/M(IL-10) phenotype in
vivo based on several published in vitro results. However, it is important to mention that
classification has been applied for the sake of simplicity and understanding. In vivo, macrophages
exist as a continuum of various polarization/activation states. In vivo it is extremely challenging
to isolate and identify differently activated phenotypic states due to relative expression of various
markers. Phenotypes present in vivo are mixed that do not really fit the M1/M2 paradigm [48].
Thus, as mentioned before, an in-depth understanding of full spectrum of macrophage phenotypic
states needs to be carefully dissected on a case-by-case basis.
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1.4 Cytokines
Cytokines are proteins that are involved in cell signaling and communication. The
chemokines, interferons and interleukins are all classified as cytokines in broad terms. They are
produced by macrophages as discussed above and also by variety of other cell types, including
T- cells, B-cells, fibroblasts and endothelial cells. So far more than 100 cytokines have been
identified [49]. The mechanism of action involves binding of cytokines to their receptor which
results into the further signaling cascade downstream of receptors. Cytokines play roles in a
variety of mechanisms such as apoptosis, cell proliferation, cell migration, survival and growth.
The cytokines that have been measured experimentally for this dissertation will be discussed in
more detail in the sections below.

1.4.1 Interleukin-1
The IL-1 family is one of the major pro-inflammatory cytokine families. IL-1 is involved
in the initiation and regulation of inflammatory phases of wound healing and FBR [50, 51]. This
family is represented by two ligands: IL-1α and IL-1β; one receptor, antagonist IL-1Ra (receptor
antagonist); and two receptors, IL-1R tI (type I receptor) and IL-1R tII (type II receptor). Ligands
IL-1α and IL-1β are biochemically distinct, but are structurally related [52]. A short stretch of
amino acid homology (about 20%) exists between them. Both forms are encoded by separate genes
located on chromosome 2. The IL-1 gene is comprised of six introns and seven exons. Both the
forms are produced as precursor proteins of size 31 kilo Dalton (kDa), and biological activity is
acquired upon cleavage by specific enzymes resulting in mature active forms that are of 17 kDa
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each [53]. Both the forms are non-glycosylated. IL-1 Ra is the natural receptor inhibitor of IL-1α
and β forms.
IL-1 is produced in response to antigenic challenge or injury. Macrophages are the primary
source of IL-1 production but other cell types such as epithelial, epidermal, other lymphoid and
vascular tissues also secrete IL-1 [54]. IL-1 is the key player in immediate events of host defense
reaction to the pathogen. It works in a paracrine mode by stimulating neighboring cells to
synthesize and release chemokines for the recruitment of various cell types such as
polymorphonuclear cells, monocytes and T lymphocytes. It also signals other cells to secrete other
cytokines such as IL-2, IL-4 and IL-6.
Binding of IL-1 to its receptor IL-1R leads to signal transduction pathway that ultimately
activate transcription factor NF-қB. The NF-қB is an important transcription factor involved in
many processes of cell survival, apoptosis and proliferation. The IL-1R has two receptor associated
kinases IRAK (interleukin receptor associated kinases) 1 and 2 that take part in the activation of
NF-қB. Binding IL-1Ra to IL-1R blocks the signaling.

1.4.2 Interleukin-4
The IL-4 is a pleotropic cytokine with a molecular weight of ~15 kDa. It is known for its
role in differentiation of naïve T helper cells to a Th2 phenotype. It is regarded as an anti inflammatory cytokine. Sources of its secretion are T cells, macrophages, basophils, eosinophils
and mast cells. IFN- producing CD4+ T cells are suppressed by IL-4. It also controls the
immunoglobulin class-switching in B cells from IgE to IgG.
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IL-4 regulates the macrophage alternative activation as mentioned in previous section. IL4 has been implicated in fibrosis; thus, it is crucial in wound healing and FBR studies [55]. IL-4
induces giant cell formation in cultured macrophages [56]. Giant cells also surround the implanted
biomaterials and thus formation of foreign body giant cells has been linked to IL-4 [57].
IL-4 binds to IL-4Rα receptor (Kd 20 to 300 pM), a second common gamma chain then
recognizes the IL-4-IL-4Rα complex. This arrangement is described as type-1 receptors. A type 2
receptor is comprised of IL-4Rα bound to either IL-13Rα1 or another IL-4Rα. This receptor
arrangement can recognizes both IL-4 and IL-13. Engagement of IL-4 with a type 1 receptor (IL4Rα and γc chain) results in to phosphorylation of Janus kinases (JAK) 1 and JAK3.
Phosphorylated JAK1 and JAK3 then phosphorylate the “signal transducer and activator of
transcription” (STAT) 6 protein, which then dimerizes and translocate to the nucleus. STAT6 is a
key transcription factor for processes IgE production, Th2 differentiation and allergic reactions.
Interaction of IL-4 with a type 2 receptor (IL-4Rα and IL13-Rα1) leads to phosphorylation of
JAK2 and tyrosine kinases (TYK) 2 which in turn leads to an insulin substrate receptor 1/2 (IRS)
signaling pathway leading to cell growth and survival.

1.4.3 Interleukin-6
IL-6 is a 38 kDa pleiotropic cytokine whose primary function in vivo is the initiation of the
acute phase response during inflammation and infection. It is mainly regarded as a proinflammatory cytokine, but it has anti-inflammatory properties as well [58]. It is a multi-functional
cytokine playing important roles in cell survival, proliferation and apoptosis [59, 60]. IL-6
expression is induced by LPS along with TNF-α and IL-1 from activated macrophages [61, 62]. It
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regulates the expression of other cytokines and chemokines, and the differentiation of
macrophages and dendritic cells during acquired immune responses [59, 60, 62-64]. In wound
healing it appears during the early inflammatory phase, and expression is also present during the
later phases of granulation tissue formation. Studies have shown lack of IL-6 results in impaired
wound healing and epithelialization.
IL-6 receptor is comprised of a ligand binding subunit gp80 and a signal transducing
subunit gp130. Ligand binding results in phosphorylation of JAK, which then phosphorylates
STAT3. Phosphorylated STAT3 translocates to the nucleus where it controls the expression of
genes involved in survival and apoptosis. Other signaling pathways induced by IL-6 other than the
JAK/STAT pathway include the MAPK and PI3K pathways. Because of the many important roles
of this cytokine, its expression is tightly regulated in a cell. Transcription factors NF-кB, NF-IL6, CREB and AP-1 have been shown to modulate IL-6 gene expression [65-68]. Among all
transcription factors recognized, NF-кB is the key nuclear factor controlling the expression of IL6.

1.4.4 Interleukin-10
The IL-10 is 18 kDa type II cytokine and is also known as “human cytokine synthesis
inhibitory factor” with important immunoregulatory fucntions. IL-10 was first identified by
Mosmann and colleagues [69]. IL-10 is secreted by monocytes, macrophages and T helper type II
cells and T regulatory cells. IL-10 is a pleiotropic cytokine. It inhibits the cell mediated branch of
the immune system by inhibiting pro-inflammatory type 1 cytokines IL-1, TNF-α and INF-,
down-regulating MHCII antigens and co-stimulatory molecules in macrophages. It enhances the
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humoral branch of immune system by enhancing B cell survival, proliferation and antibody
production [70]. It can block NF-кB activity.
IL-10 is involved in tissue remodeling during the later stages of wound healing [71].
Scarless healing was observed in fetal wounds as opposed to postnatal wounds that usually heal
with scars [72]. Scarless and regenerative healing in fetal wounds was linked with IL-10. This led
to the hypothesis that makes IL-10 a very attractive potential candidate for wound healing and
biomaterial studies as anti-fibrotic agent. Few studies have shown positive effects IL-10 on wound
healing and FBR [73-75]. However, there are other studies which show IL-10 induces fibrosis
[76]. One study shows that mice deficient in IL-10 have expedited healing of wounds [77]. It is
clear that there is dire need of thorough detailed studies on IL-10 as a potential anti-fibrotic agent
in biomaterials and wound healing field. Also, the doses and timing of IL-10 delivery need to be
thoroughly investigated.
IL-10 has two cell surface receptors IL-10R1 and IL-10R2. IL-10R1 binds IL-10 with high
affinity (~1 nM), and IL-10R2 binds IL-10 with comparatively less affinity (~0.5 nM) [78]. Both
the receptors belong to type I membrane proteins containing extra cellular and cytoplasmic
domains that are connected by a membrane-spanning helix. IL-10 first binds to IL-10R1 and then
IL-10R2 binds to IL-10-IL-10R1 complex resulting in functional tetramer complex. Functional
receptor complex then results in phosphorylation of receptor associated Janus Kinases1 (JAK1)
and Tyrosine Kinases 2 (TYK2). This results in the phosphorylation of specific tyrosine sites on
the receptor which in turn act as the docking site for the STAT3 transcription factor. STAT3 then
gets phosphorylated by receptor associated JAK1 and TYK2 [79]. Upon phosphorylation, STAT3
migrates to the nucleus and regulates the transcription of pro-apoptotic genes and genes for in cell
cycle progression. STAT3 also results in activation of transcription factor “suppressor of cytokine
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synthesis 3” (SOC3), which results in negative feedback regulation of IL-10/JAK1/STAT3,
signaling and suppression of inflammatory cytokines IL-1β, IL-6 and TNF-α [80].

1.4.5 Tumor necrosis factor TNF-α
Tumor necrosis factor is the principal mediator of inflammatory responses in response to
bacteria and other microbes causing infection [81]. The source of TNF is activated monocytes/
macrophages but other cell types like antigen stimulated T cells, mast cells, neutrophils and NK
cells can also produce TNF. Circulating TNF-α protein is 51 kDa homotrimer. Two receptors for
TNF have been recognized: Type 1 TNF receptor (TNF-RI) and Type II TNF receptor (TNF-RII)
[82]. Most of the cell types have both of the receptors. Binding of TNF to these receptors lead to
the activation of TNF receptor associated factors (TRAFs) in the cytoplasmic domain of the
receptors which in turn activate transcription factors such as NF-kB and activation protein 1 (AP1) leading to apoptosis.

1.5 Cell Surface Receptors

1.5.1 CD206
CD206 or mannose receptor C type 1 (MRC1) is present on macrophages and is involved
in endocytosis and phagocytosis. It is involved in the recognition of mannose, fucose and Nacetylglucosamine residues in a Ca2+ dependent manner. It is a 162-175 kDa, C type lectin 1
transmembrane protein. It is present on other cell types as well such as epithelial cells, smooth
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muscle cells, kidney mesangial cells and hepatic epithelium. CD206 is also involved in the
presentation of antigens to T lymphocytes. In M2 macrophages, CD206 expression is enhanced
by IL-4.

1.5.2 CD163
CD163 is 130 kDa type 1 transmembrane protein and is heavily glycosylated [83]. Its
expression is restricted to monocytes and macrophages. Predominant expression of CD163 is
found on the macrophages present in the red pulp of the spleen, alveolar macrophages and Kupffer
cells of the liver. Tissue resident macrophages have higher expression of CD163 when compared
to blood monocytes suggesting CD163 to be a differentiation marker from monocyte to
macrophage lineage. Macrophages present during the acute phase and chronic phase of healing are
also positive for CD163.
The CD163 receptor expression is controlled by glucocorticoids and cytokine IL-10. In
vitro treatment of monocytes/macrophages with dexamethasone and IL-10 lead to enhanced
expression of CD163 [84]. The M2c subset of M2 macrophages are identified by higher expression
of this receptor. Inflammatory agents like LPS also control the expression of CD163 receptor.
LPS treatment results into shedding of ectodomain of the receptor as early within 1 hour [85, 86].
The major biological function of CD163 is in the clearance of hemoglobin. The clearance of
deformed red blood cells or senescent cells releases hemoglobin into plasma. Haptoglobin binds
to free hemoglobin in the plasma, and this complex is recognized by the CD163 receptor leading
to internalization.
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1.5.3 MHCII and CD86
MHCII receptors are heterodimers of α (~35 kDa) and β (~25 kDa) transmembrane
glycoprotein sub-units [87]. MHCII expression is present on macrophages, dendritic cells and Bcells. MHCII receptors play important role in antigen presentation to CD4+ T lymphocytes. MHCII
molecules recognize short peptide residues (12-13 amino acids long). MHCII expression is
enhanced in inflammatory M1 macrophages upon activation via LPS or TNF. CD86 is also known
as B7-2 protein. Its expression is present on cells of myeloid lineage (dendritic cells and
macrophages). CD86 provides the co-stimulatory signal for the activation of T cells. Its expression
is also enhanced in M1 macrophages.

1.6 Crucial Enzymes of Polarization States

1.6.1 Nitric Oxide Synthase (NOS)
The nitric oxide synthase enzyme catalyzes the production of nitric oxide (NO) via Larginine in the body. In the M1 macrophages, arginine metabolism is shifted towards the
production of NO which is an inflammatory mediator resulting from enhanced expression of iNOS.
The NOS enzyme exists in various isoforms. NOS1 is present on neuronal tissue or smooth muscle
cells. NOS2 or iNOS is present on monocytes and macrophages and plays a role in immune
responses via its inducible action. NOS3 or eNOS is present on endothelial cells. Regulation of
iNOS in macrophages occurs via receptor CD14 which is involved in LPS recognition. This leads
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to NF-kB activation, which in turn enhances iNOS activity. Increase in iNOS activity upon IFN-
exposure is linked to the activation of the JAK-STAT pathway.

1.6.2 Arginase
The enzyme arginase is involved in the metabolism of L-arginine to L-ornithine and urea.
There are two isoforms of the enzyme, arginase 1 (Arg1) and arginase 2 (Arg2). Both enzymes
catalyze the same reaction. However, their tissue distribution and regulations are different. The
main location for arg1 is liver, and thus is it also called as hepatic arginase. Its subcellular location
is cytosolic, but arg2 is mitochondrial. Both the isoforms are encoded by different genes, present
on different chromosomes, independently. Arg2 is involved in the production of L-ornithine,
which is further utilized for the production of polyamines. The polyamine production is linked to
cellular proliferation and survival. Arginase expression is enhanced by IL-4, IL-13 and TGF-β,
and thus regarded as the marker of M2 macrophages.

1.7 Adipokines
Adipocytes within the white adipose tissue secrete signaling proteins which are collectively
called adipokines [88, 89]. Adipokines are involved in appetite and energy balance, homeostasis,
immunity, lipid metabolism, insulin sensitivity, angiogenesis and inflammation and acute phase
response. Some of the examples of adipokines include classical cytokines such as IL-6, IL-8 and
TNF-α, hormones such as leptin, adiponectin and resistin, growth factors such as vascular
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endothelial growth factor (VEGF) and acute phase factors such as haptoglobulin and
metallotheionein.

1.7.1 Leptin
Leptin, a product of obese genes, is a 16 kDa non-glycosylated protein hormone secreted
mainly by adipose tissues in proportion to body mass index [90, 91]. Leptin is involved in normal
mammary gland development, appetite regulation and thermogenesis. There are six receptor
isoforms differing in cytoplasmic domain length including four short isoforms (OB-Ra, OB-Rc,
OB-Rd and OB-Rf), one soluble form (OB-Re) and one ubiquitous long isoform (Ob-Rb), and
they belong to the class I cytokine family of receptors [90]. Binding of leptin to OB-Rb receptor
causes activation of JAK2/STAT3 (Janus Kinases-2/Signal transducer and activator of
transcription-3) signal transduction pathway [92]. JAK-2 activation results in phosphorylation of
conserved residues in the cytoplasmic domain of Ob-Rb. Phosphorylated residues then act as
binding sites for transcription factors such as STAT-3 and STAT-5. Leptin can also trigger the
MAPK (mitogen activated protein kinase) pathway either through JAK-2 associated receptor
phosphorylation or without receptor phosphorylation. PI-3K /AKT /GSK3 (Phosphatidylinositol
3-kinases/Protein kinase B/Glycogen synthase kinase 3) and AMPK (5' AMP-activated protein
kinase) pathways are also activated by leptin. Ultimately these pathways activate several genes,
such as c-fos, c-jun, junB, egr-1 and SOCS3, involved in cell proliferation and angiogenesis. ObRb also activates, through unknown mechanisms, PLC-γ (Phospholipase C), P38 and PKC kinases,
NO and NF-кB [93].
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1.8 Microdialysis Sampling
Microdialysis is a well-established, minimally-invasive, diffusion-based sampling
technique. It has been employed for the sampling of analytes from the extracellular space for over
a decade, especially in the field of pharmacokinetics and neuroscience. A microdialysis probe is
made up of a semi-permeable membrane, an inlet tubing and an outlet tubing. A syringe pump is
used to pump the perfusion fluid (which matches in ionic strength with the extracellular fluid) from
the inlet tubing and comes out of the outlet tubing and referred to as dialysate. Analytes can diffuse
into the semi-permeable membrane due to concentration gradient and can be collected from the
outlet tubing as the perfusion fluid is continuously moving. Figure 3 shows a typical microdialysis
probe. Microdialysis sampling has been successfully employed for the collection of proteins such
as cytokines. As proteins diffuse very slowly owing to their bigger size, a larger MWCO
membranes (around 100 kDa) are needed. Ultrafiltration is a problem with larger MWCO
membranes. To overcome this loss of fluid, Dextran or albumin are added. Dextran is complex
branched polysaccharide comprising of glucose molecules. Dextran is synthesized by Leuconostoc
mesenteroides and Streptococcus mutans from sucrose. Dextran size ranges from 3 to up-to 2000
kDa. Dextran, in microdialysis application, is used as an osmotic agent to prevent the loss of fluid
across the semipermeable membrane (ultrafiltration). The addition of dextran to the perfusion
fluid balances the osmotic pressure owing to its larger size and increase in solute concentration
inside the membrane which overcomes the transmembrane hydrostatic pressure that drives the
ultrafiltration. However, not any dextran can be added for this application. The size of the dextran
should be large so that it does not diffuse out of the probe. Typically, Dextran 70 or higher ranges
have been used.
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Cytokines are typically present in low picomolar to femtomolar concentrations in the
biological matrix and have low diffusivity which results in poor recovery of cytokines. Merits of
the technique include continuous real time sampling over time in awake-and-freely moving
animals and acquisition of analytically-clean samples that can be subjected to immunoassays
without further processing. More details on the microdialysis technique are presented in chapter 6.
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Figure 3. Schematic of microdialysis probe and functioning
A typical cannula style microdialysis probe has been shown in the Figure. The probe has an inlet
and outlet tubing. Semi-permeable membrane is at the bottom. The zoomed out part of membrane
region depicts the diffusion of analytes.
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A microdialysis probe system can also be employed as a model system to study wound
healing and FBR [94]. Insertion of a microdialysis probe requires surgical incisions leading to
disruption of local tissue trauma and homeostasis disruption. Long term implantation of probe
elicits the FBR finally leading to the fibrotic encapsulation of the probe. Implementation of
microdialysis probe as a wound healing/ FBR model system allows for the sampling of cytokines
over time as the stages of FBR progress. Since it’s a diffusion-based technique, drugs of interest
can also be delivered with the microdialysis probe at the site simultaneously with the sampling,
and the effects brought about by the drug on the target analyte(s) can be monitored over time.

1.9 PVA Sponge Model of Wound healing and FBR
The polyvinyl alcohol (PVA) sponge model has been employed extensively for
understanding wound healing. Usage of PVA-sponges dates back to 1950 in reconstructive
surgery, but they were later discontinued in reconstructive surgery due to poor performance in
long term applications [95]. However, it has been employed for research purposes [96]. It has been
used for studying granulation/reparative tissue ingrowth. It also elicits FBR, resulting in giant cell
formation and fibrosis after ~ 2 weeks. The use of PVA sponges allows for the sampling of wound
fluid and variety of cytokines, and chemokines present can be quantified representative of the time
point targeted. Thus, a temporal profile of cytokines and chemokines can be obtained. One of the
other major advantages of employing the PVA sponge model is isolation of wound cells, which
can further be characterized by either flow cytometry or gene expression assays. The collection of
wound fluid and wound cells allows for both qualitative and quantitative assessment of the
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FBR/wound microenvironment. Another advantage of the PVA sponge is the delivery of drugs
into the sponge space to understand the drug effects on FBR/wound microenvironment. The PVAsponge can be loaded with the drug of interest or drugs can directly be injected into the implanted
PVA-sponge, and its effect on cells and cytokines or in other words manipulation of the process
can be assessed from the samples collected. One major drawback of the PVA-sponge model is the
usage of relatively higher number of animals, as the animal needs to be euthanized to collect data
on a chosen time point of study. Thus to collect data on various times points and to have enough
biological replicates many animals are needed.

1.10 Dissertation Aims
A long term aim in the biomaterials community is to enhance the implant life and reduce fibrotic
encapsulation around the implant. Macrophages are the key cellular players that are involved in
the cascade of events that lead to fibrosis around the implanted device. The recent discovery that
macrophages can be immunomodulated to a desired phenotype offers a potential opportunity to
minimize the FBR. In this case it would be desirable to shift the macrophages towards the prowound healing and tissue remodeling “M2c or M(IL-10)” phenotype. This is a novel strategy and
not enough literature is available with respect to modulating macrophages to reduce fibrosis in
vivo. The hypothesis that M(IL-10) phenotype is desired in vivo is based on in vitro cell culture
stimulation studies. Thus, this is a new field and lacks translational studies.
A few points to consider are:
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1. Most of the data on in vitro polarization/activation of macrophages has come from murine
macrophages. Rats serve as important model organisms, and studies describing
macrophage polarization biology in rats are lacking.

2. Also, in vivo, it is extremely challenging to isolate and identify differently activated
phenotypic states due to relative expression of various markers. What phenotype is present
at a given stage of the FBR progression is crucial to delineate in order to immunomodulate
them to a desired profile. Thus, as mentioned before, an in-depth understanding of full
spectrum of macrophage phenotypic state needs to be carefully dissected on a case-by-case
basis.

Thus, the research objectives were to:
1. Establish immunomodulation of rat derived macrophages in response to various
modulators. Successful immunomodulation of rat splenic macrophages was achieved in
vitro in response to the modulators.

2. Perform in vivo microdialysis delivery experiments to establish the effects of IL-4/IL-10
around the implant site by comparing and measuring recovered cytokines (CCL2, IL-1β,
IL-6, IL-10) and histology differences between the control and treatment probe. However,
no differences between control and treatment probe could be established.
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3. The challenges with microdialysis FBR model led to the use of sponge model. The
objective were to measure and compare the cytokines in the wound fluid and to isolate and
characterize the wound macrophages from control and treatment sponges in vivo in rats.
Mild immunomodulation of macrophages was observed at protein and gene expression
level in response to IL-10 treatment. Histological studies would need to be performed in
separate experiments to determine how the extent of FBR was modulated.

Thus, in the context of persistent biological problem of FBR and how the new field of
immunomodulation of macrophages can be a potential opportunity to solve the problem,
this study is a fundamental step taken in the direction of understanding
immunomodulation of macrophages in vitro and in vivo in rats as model system

The focus of the research revolves around understanding inflammatory responses to
biomaterials. Especially of interest are macrophages and macrophage-derived proteins such as
cytokines and chemokines and how they collectively modulate the outcome of FBR/wound
healing. As mentioned previously, macrophages are the key cellular mediators in host responses
to biomaterials. A thorough understanding of their secreted proteins and phenotypic adaptations in
responses to microenvironmental cues at various stages of FBR/wound healing can provide great
insight that may help in designing better in vivo sensors. The long term aim of the research is to
modulate the macrophage phenotype towards the wound healing phenotype at the implant site
which may lead to better outcomes of the FBR and thus leading to complete healing at the site
without encapsulation.
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The use of microdialysis probes allows for the real time sampling of proteins as well from
the FBR- microenvironment created due to the insertion of the microdialysis probe. With the
implanted microdialysis probe, a temporal profile of target proteins at various days of FBR can be
generated. A microdialysis probe can also be used as a delivery device for the target drug at the
site. Thus, a modulator/target drug can be delivered simultaneously along with the collection of
target proteins. The advantage is that changes brought by delivery of modulator on a target protein
can be monitored over time.
This dissertation explores the phenotypic changes of macrophages and secreted proteins
by modulators in vitro and in vivo in FBR models of microdialysis and PVA sponges in rat subjects.
As mentioned in previous sections, most of the macrophage polarization biology understanding
has come from mouse primary cell lines in vitro. Given the complex nature of the subject and
considering interspecies differences, it is important to understand the dynamics of macrophage
polarization in rats, which serve as important model organisms in biomaterial studies. In chapter
2, modulation and derivation of various macrophage phenotypes in response to dexamethasone,
IL-4, IL-10, LPS and chitohexose have been established in primary macrophages from rat spleen.
Chitohexose is chitosan derived sugar. In a recently published study, Hexa-N-acteyl chitohexose
has been shown to direct macrophages to the alternative pathway both in vitro and in vivo in mice
models of septicemia [97]. Chitohexose is available in two different acetylated forms, Hexa-NAcetyl Chitohexose (COS-6) and Chitohexose-6-HCl (CHX). In chapter 3, development of flow
cytometry assay for the analysis of cell surface receptors of differentially polarized macrophage
phenotypes has been presented. Chapters 2 and chapter 3 provide in vitro data on biomarkers in
differentially polarized phenotypes of rat macrophages. Together, they provide a guide on what
biomarkers to expect when trying to modulate macrophages in in vivo settings. This also helps to
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answer very a important question on how in vitro studies translate in vivo. Chapter 4 and chapter
5 presents the analysis of macrophage phenotypes and quantification of secreted proteins in
response to IL-4 and IL-10 as modulators using microdialysis and PVA sponges as FBR models,
respectively. Chapter 6 presents the detection and quantification of adipokines using microdialysis
technique in rat mammary gland. This is a novel technique that can be employed in mammary
tumor models in rats where an altered phenotype of macrophages is present and together with
adipocyte can lead to cancer progression. Thus, knowledge of local concentration of cytokine
mediators of inflammation is of critical importance. Chapter 7 presents the overall summary and
future directions. Overall, the results presented in this dissertation forward our understanding of
macrophage phenotype modulation in vitro and in vivo in rat model systems.
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Chapter 2: Derivation and Characterization of Primary Macrophages in Response to LPS,
IL-4, IL-10, Dexamethasone and Chitohexose

2.1 Introduction
Due to their larger size, rats serve as important biological models in various studies
involving the foreign body response, oncology, regenerative medicine, and reproduction [47, 98101]. However, there are few studies that have been performed focusing on macrophage activation
biology in the rat. Much of the macrophage polarization data in the literature has come from in
vitro studies of mouse- and human-derived mononuclear phagocytes. It is clear that interspecies
differences exist and thus extrapolation of the data is difficult and needs evaluation on a case-by
case-basis [34, 37].
As discussed in chapter 1, this dissertation’s focus lies in the field of regenerative medicine
and the foreign body response to implanted materials. In this context, a significant amount of
research is performed in rat models. To more fully be able to test different mediators in an in vivo
context, requires greater understanding of how they perform in vitro Therefore, the objective was
to understand the macrophage activation biology in vitro in rat-derived macrophages both from
immortalized cell lines as well as primary cells in response to IL-4, IL-10, dexamethasone and
chitohexose, and use the information obtained as a guide map as to what to expect when using
modulators in vivo. The cytokines IL-4, IL-10 and the glucocorticoid drug, dexamethasone, have
been well-established in as driving macrophages toward the M2 phenotype [102]. In a recently
published study [103], Hexa-N-acetyl-Chitohexose has been shown to direct macrophages to the
alternative pathway both in vitro and in vivo in mice models of septicemia. Chitohexose is available
45

in two different acetylated forms, Hexa-N-Acetyl-Chitohexose (COS-6) and Chitohexose-6-HCl
(CHX). We activated and characterized macrophages in response to IL-4, IL-10, chitohexose and
LPS.

2.2 Materials and Methods
2.2.1 Reagents
LPS from Salmonella typhimurium, dexamethasone, paraformaldehyde and non-enzymatic
cell dissociation reagent were purchased from Sigma-Aldrich (St Louis, Saint Louis, MO, USA).
Recombinant IL-4 and IL-10 were purchased from R&D systems (Minneapolis, MN, USA).
Chitohexose-6HCl was purchased from Carbosynth (Compton, Berkshire, UK). Hexa-N-acetyl
Chitohexose was purchased from Dextra Laboratories, (Reading, Berkshire, UK).

2.2.2 Cell Cultures
Peritoneal Macrophages: Under the approval of the University of Arkansas Institutional
Animal Care and Use Committee, IACUC, resident peritoneal macrophages, were harvested by
peritoneal cavity lavage from CO2 asphyxiated adult male Sprague-Dawley rats (Harlan
Laboratories Inc, Madison, WI, USA) weighing between 250-300 g. Intraperitoneal injection of
40 mL of ice-cold PBS (pH 7.4, Gibco, Life Technologies, Grand Island, NY, USA) supplemented
with 10 U/mL heparin was given to rinse the cavity. The peritoneum was massaged gently and
fluid containing the resident cells was then collected.
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Spleen-derived macrophages: Spleens were minced, processed and passed through a 40
µm cell strainer (BD Biosciences, San Jose, CA, USA) to yield a single-cell suspension. Red blood
cells were lysed by ACK lysis solution (Life Technologies, Grand Island, NY, USA) by adding 1
mL of ACK to the pellet for 15 min on ice then washed twice with PBS by centrifugation at 1200
rpm. Selection of monocytes/macrophages was based on adherence on the flask surface within 2
hours of incubation time. After 2 hours, flasks were washed twice with warm (37ºC) PBS to
remove non-adherent cells. Cells were maintained in Ham’s 12 K medium (ATCC, Manassas,
VA, USA) supplemented with 10% FBS and 1% antibiotic antimycotic solution (Sigma-Aldrich,
St Louis, MO, USA).
NR8383 Cultures: NR8383 (CRL-2192) rat alveolar macrophages cell line was obtained
from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained in
Ham’s F12 K medium supplemented with 15 % (v/v%) of heat inactivated fetal bovine serum
(FBS), (Hyclone, Waltham, MA, USA) and 1% antibiotic, antimycotic solution (Sigma-Aldrich,
Saint Louis, MO, USA) according to ATCC recommendations. All cultures were incubated at 37ºC
in 5% CO2.

2.2.3 Studies of IL-4 and IL-10 on LPS mediated TNF-α Secretion
Splenic (1×106 cells/well) or peritoneal (5 ×105 cells/well) macrophages were cultured in a
12-well plate. LPS (50 or 100 ng/mL) was added to the cultures alone or in combination with IL10 (25 ng/mL) and IL-4 (25 ng/mL or 50 ng/mL) followed by incubation up to 24 hours. After
incubation times were complete, cell culture supernatants were harvested, and centrifuged at 1500
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rpm to ensure the solution was cell free for subsequent TNF-α ELISA. Collected solutions were
stored at -80º C until analysis (Same day or within 24 hours).

2.2.4 Dexamethasone and IL-4 Dose Response on Secretion of IL-10 by Splenic Macrophages
Splenic macrophages were cultured at a concentration of 1×106 cells/well in 12 well plates.
Cells were stimulated with IL-4 (10 ng/mL to 100 ng /mL) and dexamethasone (10 nM to 100
nM). IL-10 in the cell culture medium was quantified at both the 24 hr and 48 hr incubation times.
After completion of incubation times, cell culture supernatants were collected and centrifuged at
1500 rpm to ensure it was cell free for subsequent IL-10 ELISA and were stored at -80º C until
analysis (Same day or within 24 hours).

2.2.5 Chitohexose Stimulation of NR8383 Cells and Peritoneal Macrophages
NR8383 cells or peritoneal macrophages were cultured at 1×106 cells/well in a 12 well
plate. Hexa-N-acetyl-Chitohexose (COS6) or Chitohexose-6HCL (CHX) treatment were given at
10 µg/mL alone or in combination with LPS (50 ng/mL). After agent addition, cultures were
incubated for 24 hours. Cell culture supernatants were harvested and levels of IL-6, TNF-α and
IL-10 were quantified using ELISAs.

2.2.6 ELISA for Cytokine Determination
TNF-α, IL-6 and IL-10 levels in the cell culture supernatant were measured by sandwich
ELISAs (Opt-EIA sets, BD Pharmingen, San Jose, CA, USA). Costar® polystyrene 96 well plates
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were used. Recombinant rat TNF or IL-6 or IL-10 were used as the protein standards. The assay
concentration ranges were 16 to 1000 pg/mL, 32 to 2000 pg/mL and 75 to 5000 pg/mL for IL-10,
TNF-α and IL-6 ELISA, respectively. The assays were performed as per the manufacturer’s
instructions.

2.2.7 RNA Isolation
Splenic macrophages were cultured at 3×106 cells /well in 6 well plates for 6 hours or 24
hours. Cells were treated with 50 or 100 nM of dexamethasone, 25 or 50 ng/mL of IL-4, 25 or 50
ng/mL of IL-10 and 50 or 100 ng/mL of LPS. Total RNA was extracted by directly lysing the
cells on the culture plate with 1 mL of TRIzol® reagent (Life Technologies, Grand Island, NY,
USA). Lysed cells were harvested using cell scrapers (Thermo Fisher, Waltham, MA, USA). The
resulting lysate was passed through a 22 g needle and at least five freeze (-20º C, 5 min) and thaw
(RT, 5 min) cycles to ensure complete homogenization of cells. Chloroform (250 µL) was then
added to allow phase separation. Samples were then spun at 12,000g for 30 min at 4º C. The top
aqueous layer containing RNA was precipitated by 550 µL of isopropanol per sample followed by
incubation at room temperature for 15 min and centrifugation at 12,000g for 20 min. The
precipitated RNA pellet was washed once with 1 mL of ethanol and then followed by column clean
up using an RNeasy mini kit (Qaigen, Valencia, CA, USA). RNA concentration was assessed by
measuring the absorbance at 260 nm using a Nanodrop spectrophotometer (Thermo scientific,
Waltham, MA, USA). RNA quality and integrity check was performed by measuring the 260
nm/280 nm ratio and by integrity of 28s and 18s rRNA bands by denaturing gel electrophoresis.
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2.2.8 Quantitative Real Time PCR Assays
A total of 1 µg of RNA was converted to cDNA using the High Capacity RNA to cDNA
kit (Applied Biosystems, Life Technologies, Grand Island, NY, USA). A Techne TC-3000
thermocycler was used to perform the reverse transcriptase reaction for 60 min at 37ºC, followed
by 5 min at 95ºC. Quantitative real time PCR was performed in duplicates. Each reaction was
performed in a total volume of 50 µL using TaqMan® Gene Expression Master Mix and pre
developed TaqMan® probe/primer assay reagents (Life technologies, Grand Island, NY, USA)
using ABI prism 7500 sequence detection platform (PE Applied Biosystems, Life Technologies,
Grand Island, NY, USA). Relative expression was normalized to the reference condition and to
the levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Gene expression assays were
performed after 6 hour or 24 hour of stimulation time points. The following TaqMan®
probe/primer assay reagents were used: TNF: Rn01525859_g1; TGF: Rn00572010_m1;
Arg1:Rn00567522_m1;

CD163:

Rn01492519_m1;

NOS2:

Rn00561646_m1;

IL-12a:

Rn00584538_m1; CD206: Rn01487342_m1; IL-10: Rn01483987_m1

2.2.9 Statistical Analysis
All data are plotted as mean ± SD. ANOVA with Bonferroni correction was performed to
determine the statistical significance using the OriginPro 9.1 statistical package (OriginLab Ltd,
Northampton, MA). Gene expression data analysis was performed using the Relative Expression
Software Tool (version REST-MCS©). Significance was determined by Pair Wise Fixed
Reallocation and Randomization Test © using REST.
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2.3 Results and Discussion
2.3.1 IL-10 and IL-4 Effects on LPS-induced TNF- Release in Primary Cultures Splenic
and Peritoneal Macrophages
The anti-inflammatory activity of IL-4 and IL-10 was determined by quantifying secreted
TNF-α in response to LPS. LPS acts via TLR-4 receptors on macrophages which ultimately leads
to secretion of TNF-α. This cytokine plays an important role in a wide range of immune functions
such as augmentation of phagocytic capacity, cytotoxicity of tumor cells and can lead to endotoxic
shock. TNF-α is produced by rat splenic and peritoneal macrophages in response to LPS treatment.
Figure 4A shows the concentration of TNF-α released from splenic macrophages in response to
50 ng/mL of LPS alone or in combination with IL-4 (100 ng/mL) or IL-10 (50 ng/mL). The media
from controls (no LPS) had detectable levels of TNF-α of ~ 75 pg/mL. The TNF-α concentration
was ~600 pg/mL in LPS treated cells. Addition of LPS with IL-10 resulted in significant (p<0.001)
reduction TNF-α concentrations (~ 70 pg/mL) relative to LPS-treated macrophages. No detectable
levels of TNF-α were obtained from macrophages given a combination of IL-4 (100 ng/mL) with
LPS.
Figure 4B and Figure 4C show the concentration of TNF-α released from splenic and peritoneal
macrophages, respectively. Cells were treated with a higher dose (100 ng/mL) of LPS alone or in
combination with either IL-10 or IL-4 at 25 ng/mL. Control cells had no detectable levels of TNFα released in the cell culture supernatant. Treatment with LPS at 100 ng/mL resulted in TNF-α
concentrations of 630 pg/mL and 250 pg/mL in splenic and peritoneal macrophages, respectively.
LPS plus IL-4 (25 ng/mL) significantly reduced the TNF-α concentration to 440 pg/mL (p<0.001)
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in splenic macrophages. LPS combined with IL-4 (25 ng/mL) in peritoneal macrophages resulted
in TNF-α levels of 210 pg/mL but this not a statistically significant difference. Co-incubation of
LPS (100 ng/mL) and IL-10 (25 ng/mL) significantly reduced the TNF-α concentrations to 440
pg/mL at p<0.001 and 170 pg/mL at p<0.005 in splenic and peritoneal macrophages, respectively.
At similar concentrations (25 ng/mL) of IL-4 (19.2 fM) and IL-10 (13.2 fM), IL-10 seems to be
more effective in dampening the TNF-α release in response to LPS in macrophages (at p<0.02).
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Figure 4. TNF-α secretory profile of spleen and peritoneal macrophages in IL-4/IL-10
combination with LPS
A Spleen-derived macrophage 24 hr response to LPS (50 ng/mL) in combination with various
cytokines (IL-10, 50 ng/mL and IL-4, 100 ng/mL) B Spleen-derived and C peritoneal-derived
macrophage 24 hr response to LPS (100 ng/mL) in combination with various cytokines (IL-10, 25
ng/mL and IL-4, 25 ng/mL), n=3. Data are plotted as mean ± SD. ANOVA with Bonferroni post
hoc test demonstrated the following significance for spleen-derived macrophages: LPS vs
LPS+IL4 : ***p<0.001; LPS vs. LPS+IL-10, ***p<0.001, LPS+IL4 vs LPS+IL-10: **p<0.02. For
peritoneal macrophages: LPS vs. LPS+IL-10: *p<0.05. Control represents the cells grown in
media alone.
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The anti-inflammatory activity of IL-4 and IL-10 was determined by quantifying secreted
TNF-α in response to LPS. Both IL-4 and IL-10 antagonize the LPS mediated release of TNF-.
Previous studies have confirmed the IL-4 and IL-10 mediated down regulation of TNF-α secretion
in human and mice macrophages [70, 104, 105]. This study confirms these observations in rat
splenic and peritoneal macrophages. Interestingly, IL-4 mediated TNF-α dampening was
significant in splenic macrophages, but not in peritoneal macrophages. These results suggest that
spleen-derived macrophages may be more responsive to IL-4 in antagonizing LPS mediated
release of TNF-α than peritoneal macrophages [106]. IL-10 significantly affected the LPS
mediated TNF- release in both peritoneal and splenic macrophages. The data suggests, at the
same concentration/dose IL-10 seems to be more effective in dampening the TNF- release as
compared to IL-4 in both peritoneal and splenic macrophages. Some studies have attempted to
elucidate the mechanisms of IL-4 and IL-10 mediated TNF- suppression, but the complete
mechanisms are still unclear [45, 107, 108].
IL-4 (10 to 100 ng/mL) and dexamethasone (10 to 100 nM) were tested on splenic
macrophages to quantify for the release of IL-10 after 24 hr and 48 hr incubation. None of these
treatments produced quantifiable levels of IL-10. However, IL-10 and IL-6 levels increase in the
culture supernatant following stimulation with LPS (Figure 5A, B and C). There are reports on
alternatively activated human and mice macrophages where detectable levels of IL-10 have been
quantified in response to IL-4 [46, 109, 110]. Rodriguez-Prados, et al., quantified ~ 0.2 ng/mL of
IL-10 when peritoneal macrophages from C57BL/6 mice were treated with 20 ng/mL of IL-4/IL13 [110]. Zanin et al. used peritoneal macrophages from Swiss mice and cultured them with 10
ng/mL of IL-4 [109]. They were able to detect up to 2000 pg/mL of IL-10 in response to IL-4.
Rey-Giraud, et al., used monocytes from whole blood from human subjects [46]. They found
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detectable levels of IL-10 (~0.1 ng/mL) in IL-4 (10 ng/mL) induced macrophages. However, in
this work, we could not detect secreted IL-10 in response to various doses of IL-4 or
dexamethasone. Lolmede, et al., [40] failed to detect IL-10 in response to IL-4 in human bloodderived macrophages. The variations and differences in these results may be due to difference in
the species, in vitro culture conditions, serum factors, different ELISA manufacturer and/or other
laboratory conditions.

2.3.2 Chitohexose Causes Classical Activation in NR8383 and Peritoneal Macrophages
Figure 5 (A, B and C) shows the secretory profile of NR8383 cells when stimulated with
CHX and COS-6 with or without LPS. LPS treatment resulted in 2190 pg/mL of TNF-α secretion
(Figure 5A) whereas combined with CHX or COS-6 resulted in significantly (p<0.001) increased
TNF-α concentrations of 4320 and 4780 pg/mL, respectively. IL-6 (Figure 5B) and IL-10
secretory profile (Figure 5C) are in line with TNF-α secretion. CHX/COS-6 alone failed to cause
any detectable amount of TNF- release. Figure 6 (A, B and C) shows the secretory profile of
peritoneal derived macrophages in response to CHX (10 µg/mL) alone or in combination with LPS
(50 ng/mL). CHX in combination with LPS resulted in secreted TNF-α levels at 2160 pg/mL as
opposed to 1425 pg/mL with LPS alone which is significant at p<0.001. Secretion of IL-6 is
highest in combination with CHX at 12660 pg/mL as compared to LPS alone at 3220 pg/mL. These
experiments confirm that observed synergism of CHX/COS-6 with LPS is not related to acetyl
modification in CHX or COS-6 and is also not a phenomenon limited to an
immortalized/continuous macrophage cell line.
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Figure 5. Secretory profile of NR8383 cells with chitohexose
A, B and C TNF-α, IL-6 and IL-10 secretory profile of NR8383 cells, respectively, Stimulated
with LPS (50 ng/mL) alone or with COS6 and CHX (10 µg/mL) for 24 hours. Error bars represent
the ± SD (N=3 and N=6 for LPS+CHX and LPS+COS6). Significance is denoted by *** p<0.001,
**p<0.004, *p<0.02
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Figure 6. Secretory profile of CHX/LPS stimulated peritoneal macrophages
A, B and C. TNF-α, IL-6 and IL-10 secretory profile of peritoneal macrophages, respectively.
Stimulated with LPS (50 ng/mL) alone or with CHX 10 µg/ml) for 24 hours. Error bars represent
the ± SD (N=3). Significance is denoted by ***p<0.001, *p<0.02
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A synergistic inflammatory response upon co-treatment of cells with LPS and small
molecular weight acetylated chitosans was observed. Tokoro et al., [111] found that CHX and
COS-6 had growth inhibitory effect on Meth-A solid tumors in BALB/c mice at a dose of 1 mg/kg.
They also showed release of IL-1 which is an inflammatory cytokine from casein elicited
macrophages upon treatment with CHX and COS-6 as stimulants in vitro. Anti-tumor effects have
been associated with M1-like macrophages suggesting that these compounds lead to classical
activation of macrophages. In this study, CHX and COS-6 have shown to have no effect on their
own but immunopotentiating effect in conjunction with LPS.
Feng et al., showed oligochitosan mediated a stimulatory effect on the release of TNF-α
and IL-1β in the mouse RAW 264.7 macrophage like cell line [112]. Gaun et al., evaluated the
effects of chitosan hydrolysate, low molecular weight chitosan (LMWC) and oligomixture (a
heterogeneous mixture of saccharides) on the nitric oxide production in RAW 264.7 cells and
further effect on the NF-қB activation [113]. Their results were interesting. They found that
LMWC, chitosan hydrolysate and oligomixture alone had no effect on NO production and iNOS
up-regulation. However, when these cells were treated with a combination of IFN- and
hydrolysate/oligomixture the NO production was significantly affected. On the other hand, LMWC
and IFN- treatment resulted in inhibition of NO production. In this study, similar trend of
heightened inflammatory response of CHX and COS-6 upon co-stimulation with LPS was
observed. In another similar study by Jeong et al., [114], NO oxide production was shown to be
enhanced upon treatment of RAW 264.7 cells with IFN- and high molecular weight water soluble
chitosan (WSC). WSC alone had no effect on the production of NO in RAW246.7 cells.
Synergistic response resulted in TNF-α secretion and required NF-қB activation. These studies
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demonstrate the classical activation of macrophages under study via chito-oligosan sugars.
However, the exact mechanism and receptors involved require further investigation.
The observed enhanced inflammatory response in this study can be due to a possible
species difference between rat and mice. Dr. Jeannine Durdik’s colleagues at National Institute of
Immunology, India have confirmed that the compound used in this study is not stimulating RAW
246.7 cells [115]. Further this agrees with mice models of septicemia [97], and results obtained in
this study on rat continuous alveolar macrophage cell line (NR8383) and peritoneal derived
macrophage, suggest a possible species difference on how COS-6/CHX interact with macrophages
in these two species.
2.3.3 Gene Expression Responses to Immunomodulation of Splenic Macrophages
Splenic macrophage phenotypes were characterized by gene expression assays at 6 hour
and 24 hour time points after stimulation with different effector molecules. Figure 7 shows the
gene expression profile of adherent splenic macrophages after 6 hours of stimulation with LPS
(100 ng/mL), IL-4 (25 ng/mL), IL-10 (25 ng/mL) and dexamethasone (100 nM). Here, LPS
significantly up-regulated the expression of four genes; IL-12a, TNF-α, iNOS (NOS2) at p<0.05
and IL-10 at p<0.01. Expression of NOS2 is ~8.5 fold higher as compared to other treatments.
Expression of IL12a is ~ 6 fold higher and that of IL-10 and TNF-α is ~4.5 and ~2.5 fold higher,
respectively.
IL-4 has significantly up-regulated CD206 at p<0.05 and IL12a at p<0.01. Dexamethasone
has caused significant up-regulation (up to ~2.5 fold higher) of IL-10 at p<0.001 as compared to
IL-4. Expression of IL-12a is significantly (p< 0.01) up -regulated in both dexamethasone and IL4 treated cells.
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Figure 7. Gene expression of splenic macrophages at 6 hr
Gene expression profile of LPS (50 ng/mL), IL-4 (50ng/mL), IL-10 (50 ng/mL) and
Dexamethasone (50 nM) treated splenic-derived macrophages at 6 hour time point. The log base
2 transformed expression ratios (fold change) represent the mean values of 3 independent
experiments per treatment (±SD represented by error bars). GAPDH was used as reference gene
and control cells grown in media alone have been used as reference condition. Significance is
denoted as *p < 0.05, ** p <0.001
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Dexamethasone has also caused significant up-regulation of CD163 (p< 0.01) and CD206
(p< 0.05). The IL-10 treatment has resulted in up-regulation of CD163 and TGF-β. There is downregulation of CD206 in response to IL-10 which is different than the profile generated by IL-4 and
dexamethasone treatment.
Figure 8 shows the gene expression profile of LPS, dexamethasone and IL-4 treated splenic
macrophages at 24 hour time point. Profiles generated by dexamethasone and IL-4 are
distinguishable at 24 hr time point that appeared similar at 6 hr time point. At 24 hours, iNOS is
significantly up-regulated at p<0.01 in LPS treated cells. Up-regulation of iNOS ~ 4 fold higher
than other treatments. At 24 hours, there is significant (p<0.05) up-regulation of Arg2 in IL-4
treated cells compared to LPS and dexamethasone treated cells where it is down-regulated. There
is significant (p<0.05) up-regulation of CD163 with the dexamethasone treatment.
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Figure 8. Gene expression of splenic macrophages at 24 hrs
Gene expression profile of LPS (50 ng/mL), IL-4 (50ng/mL), IL-10 (50ng/mL) and
Dexamethasone (50 nM) treated splenic-derived macrophages at 24 hour time point. The log base
2 transformed expression ratios (fold change) represent the mean values of 3 independent
experiments per treatment (±SD represented by error bars). GAPDH was used as reference gene
and control cells grown in media alone have been used as reference condition. Significance is
denoted as *p < 0.05, ** p <0.001
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This study provides a detailed gene expression analysis of known markers in differentially
activated macrophages in our rat model system. Here, LPS significantly up-regulates expression
of four genes; TNF, iNOS (NOS2), IL-10 and IL-12a. LPS is known to generate an M1 profile in
macrophages through classical activation via TL4 receptors. Dexamethasone, IL-4 and IL-10
generate what is generally classified as M2 macrophage phenotypes. At 6 hours, dexamethasone
(100 nM) caused significant up-regulation of IL-10, IL-12a, CD163 and CD206 while
inflammatory markers (iNOS and TNF) are down regulated. Macrophages treated with IL-4 at 25
ng/mL exhibit similar gene expression profile as dexamethasone-treated macrophages. IL-4 has
significantly up-regulated CD206 and IL12a. Up-regulation of CD206 is expected in response to
IL-4 and dexamethasone based on published literature. However, not enough literature is available
on IL-4 and dexamethasone mediated up-regulation of IL-12a. The expression ratio for IL-12a is
highest for LPS treatment which is expected based on the published literature. Dexamethasone and
IL-4 mediated IL-12a up-regulation is interesting at 6 hour time point and may be a phenomenon
unique to rat splenic macrophages. The expression ratio for Arg2 is highest in IL-4 treated
macrophages as compared to dexamethasone or IL-10 treated cells. There have been problems in
using Arg1 as a marker for IL-4 activation due to its up-regulation in response to LPS as well in
some studies [116, 117]. In this study, Arg2 is in fact down-regulated in response to LPS
suggesting that Arg2 can be a marker for IL-4 generated profile without any ambiguity.
IL-10 causes M2c like profile activation which are considered to be regulatory in nature.
Dexamethasone generated profile is different than IL-10 induced profile. It is evident from Figure
7 that IL-10 has caused down-regulation of all the genes analyzed except CD163 and TGF-β. This
is expected in response to IL-10. Overall, this data indicates successful generation of various
macrophage phenotypes in vitro in rat model system.
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2.4 Conclusion and Significance
In conclusion, this chapter shows the successful characterization of differentially activated
phenotypes of rat splenic macrophages cultured in vitro through a detailed gene expression
analysis, secreted cytokines measurement using ELISA and cell surface receptor expression
analysis using flow cytometry. Chitohexose in conjunction with LPS resulted in enhanced
inflammatory response which is contrary to what has been observed in vitro and in vivo for murine
macrophages. The data shows that Arg2 is up-regulated by IL-4 and remains unstimulated by LPS
hence can be used a marker for alternative activation in rat splenic macrophages. Further data
shows the overlapping expression of activation markers in IL-4 and dexamethasone generated
subsets is also time dependent varying between 6 hour and 24 hour post stimulation.
Overall Significance: Knowledge of in vitro macrophage activation biology has been acquired
majorly from the study of murine macrophages. Macrophage activation is a complex dynamic
process. Recent studies have shown interspecies differences as mentioned in Chapter 1. Within the
same species, macrophage phenotypes can vary depending on the microenvironmental conditions
and the source of macrophage derivation (alveolar, peritoneal, bone marrow, peripheral blood
monocytes, and spleen). Thus, the need to understand macrophage activation on a case-by-case
basis is highly crucial to fully elucidate the complexity of the process. Rats are used extensively
as model organisms in biomaterials studies. A detailed basic study describing activation and
characterization of rodent macrophages is sparse. This study is the first to compare five different
modulators (LPS, Dexamethasone, IL-4, IL-10 and Chitohexose) side-by-side and provide a
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detailed characterization of differentially activated rodent splenic macrophages. This study also
highlights deviation points from the data observed in murine macrophages.

Specific points of significance
1. Rats are the least sensitive species to LPS. Thus, how rat macrophages will respond to the
modulators is crucial to the study.

2. In vitro activation and characterization of macrophages not only provides information on
the biological efficacy of the modulators but also provide insights on how data falls in line
with what is already known with murine or human macrophages. Secreted IL-10 levels
remaining undetected in the cell culture supernatant in response to IL-4 and dexamethasone
was unexpected.

3. The majority of in vitro studies from mice and humans have utilized peripheral blood
monocytes or bone marrow macrophages. Macrophage populations from these sources are
known to be more homogenous, less differentiated and naïve which makes them relatively
more responsive to the modulators. This adds to the further complexity as responses will
vary according to the source of macrophage derivation. Also, culturing of peripheral blood
monocytes or bone marrow macrophages involves an additional 7 days for culturing and
differentiation, which makes it time consuming and prone to contamination due to longer
incubation times. The spleen is an important lymphoid organ that deploys macrophages to
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the wound site as well. This study provides insight on the ability of rat splenic macrophages
to be activated by various modulators. This adds to the novelty of this study.

4. Chitohexose, a small molecular weight oligosaccharide, was tested as a non-protein
potential modulator to avoid protein bioactivity loss issues, and feasibility of diffusion
across the dialysis probe owing to its smaller size. Chitohexaose in conjunction with LPS
resulted in enhanced inflammatory responses which is contrary to what was observed in
vitro and in vivo for murine macrophages. This combination can be tested for its potential
to enhance in vivo classical activation of macrophages where conditions call for necessary
inflammatory activation of macrophages (tumors where M2 like phenotype predominates).

5. The data shows that Arg2 is up-regulated by IL-4 and remains unstimulated by LPS, and
therefore can be used as a marker for alternative activation in rat splenic macrophages.
Arg1 as a marker for alternative activation is problematic as it is also expressed upon LPS
treatment. Thus, Arg2 results obtained in this study are of high significance. Also, this
study shows that Arg1 is also expressed upon IL-10 treatment. This shows another point
of significance that Arg2 is a marker to differentiate M(IL-4) vs M(IL-10) profiles.

6. Further, data shows the variations in expression of markers at 6-hour and 24-hour time
points. For example, TNF-α transcript remains undetectable at the 24-hour time point but
can be measured at the 6-hour time point. At the 6-hour time point, four different markers
(TNF-α, IL-12a, IL-10 and iNOS) can be used for M(LPS) characterization whereas at 24-
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hour time point, only two markers (IL-12a and iNOS) can be used. Similarly, four different
markers (IL-10, IL-12a, CD163 and CD206) can be used for M(dex) characterization at 6
hr time point whereas at 24 hr time point only CD206 remains specifically upregulated.
Also, IL-12a marker appears at 6 hr time point in both M(LPS) and M(dex) but remains
specific for M(LPS) at 24 hr time point. This has important implications with respect to
choice of markers when characterizing differentially activated phenotypes as expression
will vary according to the time point chosen for analysis.

7. Finally, in vitro data provided a guiding map with respect to expectation of markers in vivo
in the model organism (rat) under investigation.
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Chapter 3: Flow Cytometry Assays for the Cell Surface Receptor Assessment of Polarized
Macrophages

3.1 Introduction
The word flow cytometry literally means counting of cells that are moving in a stream.
Flow cytometry has been used extensively for cell counting, sorting and assessment of biomarkers.
It is a fluorescence-based method. Briefly, a flow cytometer has three main components 1) Fluidics
2) Optics and Detection, and 3) Signal Processing. Cells are tagged with fluorescent dyes and
passed in single file in a streamlined manner (hydrodynamic focusing), with the help of fluidics.
Lasers are used as a light source. Scattering of light and fluorescence emission by the target are
recorded. Light scattered in forward direction is known as forward scatter (FSC) which is collected
by the lens is indicative of the target size. The side scatter is measured at the 90º angle of the
excitation line. The side scatter (SSC) provides information about the granularity/internal
complexity of the target. Signal processing converts the analog to digital signals from FSC, SSC
or fluorescent signals from light to electrical signals.
As described in chapter 1, M1 macrophage profiles differ from M2 profiles in general.
Within M2 macrophages, M(IL-10)/M(Dex) subtypes can be distinguished from M(IL-4) by
relative expression analysis of cell surface receptors. Again, to summarize
M1 (LPS/IFN-γ) phenotype will expected to be:
MHCIIhigh CD86 highCD80high,CCR7highCD163lowCD204low
M(IL-4) profile will expected to be: CD209highCD206highCD163lowCD16low
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M(IL-10)/ M(Dex) profile will expected to be: CD163highCD16highCD206lowCD209low
Thus, using flow cytometry cell surface receptor expression can be analyzed and compared
between differently stimulated macrophages. Macrophage marker CD68 or CD11b is analyzed for
gating of macrophage population or in other words to select for macrophage population in a sample
that may have other cell types too. Thus, aim of these experiments were to develop flow cytometry
assays for the identification of activated states of macrophages based on differential cell surface
receptor expression profiles in rats and understand if these markers fall along the same pattern as
has been described in mouse and humans [36, 41].

3.2 Materials and Methods
3.2.1 Reagents
LPS from Salmonella typhimurium, dexamethasone, paraformaldehyde and non-enzymatic
cell dissociation reagent were purchased from Sigma-Aldrich (St Louis, Saint Louis, MO, USA).
Recombinant IL-4 and IL-10 were purchased from Rand D systems (Minneapolis, MN, USA).
FITC conjugated anti-rat mouse monoclonal CD86 antibody, PE conjugated anti-rat mouse
monoclonal CD11b antibody and APC conjugated anti-rat mouse monoclonal MHCII antibody
were purchased from eBioscience (San Diego, CA, USA). Alexaflour 647 conjugated rabbit
polyclonal CD206 antibody was purchased from Bioss (Woburn, MA, USA). PE conjugated antirat mouse monoclonal CD68 antibody and FITC conjugated anti-rat mouse monoclonal CD163
antibody were purchased from AbD Serotec (Raleigh, NC, USA). Insotype control for CD11b
antibody was mouse IgG2a K isotype control conjugated with PE. Isotype control for CD68
antibody was mouse IgG1 negative control-PE conjugated. Mouse IgG1 negative control
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conjugated with FITC was used as isotype for CD163 antibody. Mouse IgG1 K isotype control
conjugated with APC was used control for MHCII antibody and mouse IgG1 K isotype conjugated
with FITC was used as control for CD86 antibody. All the matched isotypes were bought from the
same vendors as their matched antibodies.

3.2.2 Isolation of Splenic Macrophages
Spleens were harvested from CO2 asphyxiated male adult Sprague-Dawley rats weighing
between 275-350g. Spleens were minced, processed and passed through 40 µm cell strainer (BD
Biosciences) to yield single cell suspension. Red blood cells were lysed by ACK lysis solution
(Life technologies) by adding 1 mL of ACK to the pellet for 15 min on ice. Selection of
macrophages was based on adherence on the flask surface within 2 hours of incubation times. After
2 hours, flasks were washed with warm PBS to remove non-adherent cells.

3.2.2 Cell Cultures
NR8383 (CRL 2192) rat alveolar macrophage cell line was obtained from American Type
Culture Collection (ATCC). Cells were maintained in Ham’s F12 K medium (ATCC)
supplemented with 15 % of heat inactivated fetal bovine serum (FBS, Hyclone) and 1 % antibiotic,
antimycotic solution (Sigma-Aldrich) according to ATCC recommendations. Splenic
macrophages were maintained in Ham’s F 12K medium supplemented with 10% FBS and 1 %
antibiotic and antimycotic solution (Sigma-Aldrich). All cultures were incubated at 37ºC in 5 %
CO2.
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3.3.3 In vitro Stimulation of Macrophages
Cells were seeded in 6 well or 12 well plates at concentrations from 106 to 2×106 cells
/well. Cells were treated with 50 or 100 nM of dexamethasone, 25 or 50 ng/mL of IL-4, 25 or 50
ng/mL of IL-10 and 50 or 100 ng/mL of LPS. Cells used as control were grown in the media alone.
Cultures were incubated for 18 or 24 hours.

3.2.4 Flow Cytometry Assays
After incubation times were over, cells were detached from the culture plates using cell
dissociation reagent, washed and re-suspended in FACS buffer (PBS with 1% BSA and 0.1%
sodium azide). Cell surface receptors were tagged with fluorescently-labeled primary antibodies
for 30-40 minutes in the dark at 4ºC followed by fixation with 2% paraformaldehyde for 15
minutes. Fixed cells were then washed and permeabilized with 0.3% saponin for intracellular
staining of pan macrophage marker CD68. Cells were fixed again with 2% paraformaldehyde,
washed and finally re-suspended in 200 µL of FACS buffer in BD polypropylene FACS tubes (BD
pharmingen). Three color analysis was performed using FACSort™ platform (Becton Dickinson
Immunocytometry Systems) at the Cell Isolation and Characterization multiuser facility at the
University of Arkansas.
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3.2.5 Data Analysis and Statistics
The generated data sets were analyzed using FlowJo software (Tree Star Inc. OR, USA).
ANOVA with a post hoc test (Bonferroni correction), to compare populations, was performed for
determination of statistical significance using Origin 9.1 data analysis software.
3.3 Results and Discussion

3.3.1 Optimization Experiments with NR8383 Cells and Splenic Macrophages
Initial experiments were initiated with NR8383 rat alveolar continuous macrophage cell
line. The purpose was to test the antibodies and get some ideas about the instrument parameters
for the rat macrophages. In Figures 9 and 10 histograms show the NR8383 staining profile with
CD68 (Pan Macrophage marker), and CD86 respectively overlaid with the matched isotype control
and unstained cells. It is evident from the histogram (Figure 9) that CD68 staining is weak when
matched with the isotype control. Histograms for isotype-PE match and CD68-PE have
considerable overlap. Figure 10 shows the histogram overlay of matched isotype-FITC and CD86FITC. Considerable overlap suggests either non-specific binding or lack of CD86 receptor
expression. A weak signal for CD68 staining and no signals for CD86 staining in NR8383 cells
were observed. This could be due to the differences in the phenotypes that arise in cell lines due
to handling in different laboratories with different serum conditions and number of divisions in
cells. This could also be due to the fact that NR8383 cells are a continuous macrophage cell line
and they do not behave as primary cells rather as monocytoid cells which could lead to differences
in the expression of cell surface receptor expression. Another possibility is not enough stimulation
for the enhanced expression of CD86 receptor.
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Figure 9. Histogram of CD68-PE stained NR8383 cells
Histograms of unstained NR8383 cells overlaid with CD68 stained cells and matched isotype
control (IC-PE)

Figure 10. Histogram of CD86-FITC stained NR8383 cells
Histograms of unstained NR8383 cells overlaid with CD86 stained cells and matched isotype
control (IC-FITC)
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At this point, it was decided to begin optimizing experiments with primary peritoneal
derived macrophages as ultimately goal was to use primary cells for differential activation,
derivation and characterization. However, this flow cytometry experiment requires usage of high
cell number but due to low yield of peritoneal derived macrophages (roughly 106 per sample which
is the approximate yield from one rat) spleen derived macrophages (~107 cells per spleen) were
adopted for further analysis. Histograms (Figure 11) below show single stain profile of spleen
derived macrophages for CD68-PE (A), CD163-FITC (B), CD86-FITC (C), CD206-AF647 (D)
and MHCII-APC (E).
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Figure 11. Histograms of single stained spleen derived macrophages
Histograms show the CD68-PE (A), CD163-FITC (B), CD86-FITC (C), CD206-AF647 (D) and
MHCII-APC (E) staining of spleen derived macrophages overlaid with the matched isotype
control.
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CD68 while measurable, results in a faint signal. Later it was found out that optimal
staining of CD68 antibody required intracellular staining that called for solubilization technique
of the cell membrane using saponin (amphipathic glycoside). Next, multi-color (triple staining)
flow cytometry experiments were performed to differentiate between cell surface receptor profiles
of spleen derived macrophages activated in response to LPS, IL-4, IL-10, Dexamethasone and
control cells grown in media alone without any stimulant.

3.3.2 Cell Surface Receptor Expression Analysis with CD68 as Macrophage Marker
Spleen derived macrophages were treated with 50 ng/mL LPS, 50 ng/mL IL-4, 50nM
Dexamethasone and 50 ng/mL IL-10. M0 or control cells (not stimulated) were grown in the media
alone. Incubation times were 16 hours (16 to 20 hrs time window).
For analysis of macrophage surface receptor expression, anti-rat CD68-PE, anti-rat CD 86FITC, anti-rat MHC II-APC, anti-rat CD163-FITC and rabbit anti-MRC1/CD206 polyclonal
antibody were used. Appropriate isotype controls were run for each antibody. Triple stains were
performed for each treatment. CD68 positive population was analyzed for CD163 and CD206
signal in FL1 and FL4 channel, respectively. These were initial triple-stain experiments
demonstrating that some shifts in the overall cell population have occurred (Figure 12).
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Figure 12. Contour plots of CD68+ (positive) population analyzed for CD163 (FL-1) and
CD206 (FL-4)
Top (color) dot plot shows the gate for CD68 positive population. Left: Isotype Control. Right:
CD68+ cells. Bottom: The contour plots above show the shift in CD68+ population between the
FL1 (CD163) and FL4 (CD206) channel for different treatments. From top left to bottom right the
populations are as follows: Control, LPS, Dexamethasone, IL-4 and IL-10.
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Based on a careful look at the epicenters of the population in contour plots, IL-10 causes
maximum shift of the population towards the FL1 region showing higher CD163 positives. For
LPS treatment, the epicenter has moved below in the low FL-1 positive region. This is the expected
shift with the treatments. There is change in the percentage positives for CD206 (FL4 channel)
signal. IL-4 treated cells have high CD206 positives than IL-10 treatment. However, LPS and
dexamethasone treatments resulted in comparable CD206 positives. All the treatments differ in
CD206 highs when compared to control population.
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Figure 13. Contour plots of CD68+ MHCII+(positive) population analyzed for CD86 (FL-1)
and MHCII (FL-4)
Top (color) dot plot shows the gate for CD68 positive population. Left: Isotype Control. Right:
CD68+ cell. Bottom: The contour plots above show the shift in CD68+ population between the
FL1 (CD86) and FL4 (MHCII) channel for different treatments. From top left to bottom right the
populations are as follows: Control, LPS, Dexamethasone, IL-4 and IL-10.
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Figure 13 shows the profile for CD68 and MHCII double positive macrophages with
various treatments. Double positive population was analyzed in FL1 and FL4 channel for CD86
and MHC II positives, respectively. The top colored dot plot shows the selection of MHCII and
CD68 double positive cells based on matched isotype controls. The selected population was then
analyzed for CD86 and MHCII profile for each treatment. Bottom contour plots show the shift in
populations between FL1 (CD86) and FL4 (MHCII) channel. From the contour plots (Figure 11),
LPS causes maximum shift of the population in high FL1 positive zone indicating high CD86
population when compared to other treatments. This is expected in response to LPS.
Dexamethasone decreases the signal in F1.

3.3.3 CD11b as Pan Macrophage Marker for Macrophage Identification
Previous preliminary experiments (Figure 12 and 13, N=1 for all treatments) were
performed with CD68 as pan macrophage marker. Usage of this antibody marker involved
intracellular staining which makes the experiment time consuming and labor intensive. Thus, it
was decided to use CD11b as a pan macrophage marker and test whether it would also enhance
the fluorescence signal intensity. CD11b is also known as macrophage-1 antigen (Mac-1 antigen),
is a part of heterodimeric integrin αMβ2 protein expressed on myeloid cells and monocytes. It takes
part in adhesive role of macrophages and uptake of complement coated particles [118]. CD11b has
widely been used in flow cytometric analysis of monocytes and macrophages [119-121].
Figure 14 shows the histogram comparing the staining of CD11b and CD68 with matched
isotype controls. It is clear from the histogram that CD11b staining is brighter than CD68. Signal
for CD11b goes to the log decade 4 whereas for CD68 it goes only to the log decade 3. Also,
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CD11b staining did not require additional steps of intracellular staining thus saving time and labor.
Final set of experiments with N=3 were performed with CD11b as Pan macrophage marker.
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Figure 14. Histogram shows the comparison of PE conjugated CD11b and CD68 markers
The histogram shows the overlay comparison of single staining profiles of CD68 and CD11b
stained spleen-derived macrophages matched with their isotype control. CD11b staining (red) is
brighter than CD68 staining (blue).

85

3.3.4 Cell Surface Receptor Analysis of Activated Macrophages using CD11b as Macrophage
Marker
Again, cells were treated with IL-4, IL-10 at 50 ng/mL, LPS (100 ng/mL), dexamethasone
(100 nM), and control cells were grown in media alone. All the treatments were set up in
triplicates. After 18 hours of incubation (16 to 20 hrs time window was chosen), cells were
detached and stained for CD11b, CD86, MHCII, CD163, and CD206 markers. Figure 15 shows
the selection of CD11b+ cells based on matched isotype control.
Figure 16 shows the representative contour plots of CD11b+ differentially activated
macrophages from triplicate experiments. The blue boxes on contour plot show the percentage of
highs for CD86 and MHCII double positives. From the contour plots, LPS has caused mild shift
of the population in the FL1 (CD86-FITC) region while FL4 (MHCII-APC) positive zone seems
to be unaffected when compared to the control cells (cells grown in media alone). Dexamethasone
has resulted in epicenter of the population to move down from FL1 and FL4 double positive
quadrant. IL-10 treatment does not seem to have much effect on CD86 and MHCII markers when
compared to the control cells. The IL-4 treatment has resulted in movement of the epicenter
towards FL4 high or MHCII high region. This seemed contrary to certain published studies from
mouse bone marrow derived macrophages (BMDM). However, it is in line with previously
published data where IL-4 enhances MHCII expression. This could be the difference when
activating splenic macrophages with IL-4 in rats [39, 122].
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Figure 15. Dot Plot showing the selection of CD11b+ cells based on matched isotype control
Figure shows the selection of CD11b positive cells. Dot plot on left shows the profile of cells
stained with the isotype. Dot plot on right side shows the cells stained with CD11b. Pink square
gate shows the selected population of macrophages positive for CD11b staining.
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Figure 16. Contour plot showing shift in CD11b+ macrophage population between FL1
(CD86-FITC) and FL4 (MHCII-APC) channel.
The contour plots above show the shift in CD11b+ population (from Figure 15) between the FL1
(CD86) and FL4 (MHCII) channel for different treatments. From top left to bottom right the
populations are as follows: Control, LPS, Dexamethasone, IL-4 and IL-10.
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Figure 17. Graph shows the % MHCII CD86 double positives
The graph shows the Data plotted as mean ±SD, N=3. ANOVA with Bonferroni post hoc test was
performed to test for significance. Significance denoted by * p<0.05. Dexamethasone generated
profile was found to be significantly different from Control, LPS, IL-4 and IL-10 generated
profiles. IL-4 generated profile was found to be significantly different from Control, LPS, Dex and
IL-10 generated profiles.
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Figure 17 shows the % of MHCII CD86 double positive highs from CD11b gated
macrophage populations in various treatments. Difference between LPS treatment and control
cells are not significant at p<0.5. Dexamethasone treatment has significantly (p<0.5) brought
down the double positive highs when compared to the other treatments. IL-4 has significantly
(p<0.5) raised the population of double positive highs due its enhancing effect on MHCII receptor.
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Figure 18. Contour plots showing shift in CD11b+ macrophage population between FL-1
(CD163-FITC) and FL-4 channel (CD206-AF647)
The contour plots above show the shift in CD11b+ population (from Figure 15) between the FL1
(CD163) and FL4 (CD206) channel for different treatments. From top left to bottom right the
populations are as follows: Control, LPS, Dexamethasone, IL-4 and IL-10.
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Figure 19. Graphs shows the % of CD163 positive population among different treatments
Data plotted as mean ±SD, N=3. ANOVA with Bonferroni post hoc test was performed to test for
significance. Significance denoted by * p<0.05. LPS, Dex and IL-4 treated populations are
significantly different from Control and IL-10 populations. No significant differences among LPS,
Dex and IL-4 populations were found. No significant differences between control and IL-10
generated profiles were found.
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Figure 18 shows the representative contour plots of CD163 and CD206 profile of CD11b+
differentially treated macrophages from triplicate experiments. The CD206 and CD163 stains were
weak as the signal only goes to the Log decade 2. However, profile changes based on the epicenter
shifts can be observed. Dexamethasone treatment has brought the maximum shift in the epicenter
moving it more towards the CD163CD206 double positive quadrant. IL-10 treatment has resulted
in the epicenter shift more towards the CD163 positive quadrant above the signal cut-off. IL-4
treatment has resulted in the down shift of the epicenter towards CD163CD206 double negative
quadrant. LPS treatment has not caused any dramatic shift in CD163 population when compared
to IL-4 towards double negative quadrant. However, when compared to untreated cell, a shift
seems to have occurred in LPS treated cells.
Figure 19 shows the percentage of CD163 positive population among various treatments.
Significant (p<0.05) differences were found among the treatments. Untreated control cells have
significantly higher population of CD163 positive cells when compared to LPS, IL-4 and
dexamethasone treatment. Although, IL-10 treatments appears to have higher CD163 positive
population than control cells, data could not reach statistical significance at p<0.05. However, IL10 has highest CD163 positive population when compared to other treatments which is expected.
LPS and IL-4 seem to have lower the expression of CD163 and thus % of CD163+ population is
significantly (p<0.05) less when compared to control cells and/or IL-10 treated cells.
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Figure 20. Graph shows the percentage of CD206 positive population among treatments
Data plotted as mean ±SD, N=3. ANOVA with Bonferroni post hoc test was performed to test for
significance. Significance denoted by * p<0.05. Dexamethasone treated population is significantly
different from Control, LPS, IL-4 and IL-10 treated populations.
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Figure 20 shows the percentage of CD206 positive population among various treatments.
Dexamethasone treatment has resulted in significantly (p<0.05) high percentage of CD206+
population when compared to control cells or IL-10 treated cells which would be expected. LPS,
IL-4 and IL-10 do not seem to affect CD206 receptor expression when compared to the control
cells.
Thus overall, LPS treatment resulted in only mild increase in CD86 expression while
MHCII expression appears unaffected. IL-10 did not affect CD163 or CD206 expression. IL-4
treatment enhanced the expression of MHCII and decreased CD163 expression while CD206
remained unaffected. Dexamethasone has resulted in most dramatic shift compared to all other
treatments.

Dexamethasone enhanced CD206 expression and lowered CD86 and MHCII

expression. Dexamethasone is a broad range anti-inflammatory agent. Its mechanism of action,
which are still not very clear, involve shut down of major signaling pathways in the cell [123, 124].
It could be the concentration of IL-10 may not have been optimal for a dramatic effect on splenic
macrophages. Similarly, the concentration of LPS used might not have been high enough for any
dramatic shift in M1 markers CD86 and MHCII as rats are the most resistant species in terms of
responsiveness to LPS.
The development of the flow cytometry assay allowed for assessment of protein expression
in individual cells within complex populations of activated macrophages. It appears that untreated
(control) splenic macrophages abundantly express the cell surface markers CD86, MHCII, CD163
and CD206 receptors. Thus, dramatic changes in receptor expression profile are not evident when
compared to other treatments. Splenic macrophages are also quite heterogeneous as discussed in
Chapter 1 (macrophage heterogeneity section). As mentioned before, most of the studies have been
done on mice bone marrow derived macrophages (BMDM) which are relatively naïve, less
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heterogeneous and undifferentiated compared to macrophages extracted from the spleen [125].
Thus, immunomodulation of BMDM seem to have dramatic shift in receptor expression profiles.
Nonetheless, it is evident that splenic macrophages do respond to the modulators.
The data provides interesting insight into receptor expression modulation in response to
modulators. IL-4 mediated enhanced MHCII expression is contrary to murine macrophages. From
chapter 2 and 3, through various assays including flow cytometry assays immunomodulation of
rat macrophages can be established in vitro with few possible interspecies differences from murine
macrophages. Taken together, the data so far obtained provides a roadmap for in vivo experiments
in terms of expectations for markers in response to IL-4 and IL-10 treatment.
3.4 Conclusion and Significance
To conclude, an in-house developed flow cytometry assay provided an alternative tool to profile
differentially activated states of macrophages. IL-4 mediated enhanced MHCII expression is
contrary to what is typically observed with murine macrophages where decreased MHCII
expression is observed. IL-4 decreased CD163 expression and did not affect CD206 expression.
Dexamethasone showed the most dramatic shift in both CD86 and CD206 receptor expression
which was expected. LPS slightly increased CD86 expression which was expected, but did not
affect MHCII and CD206 expression which was unexpected. IL-10 was expected to significantly
enhance CD163 receptor expression but appears to cause no effect. IL-10 mediated CD163
upregulation has been observed in murine peripheral blood macrophages and bone marrow derived
macrophages in vitro. CD163 upregulation has also been observed in vivo in wound macrophages.
Gene expression data suggest upregulation of CD163 in response to IL-10. The time point of
maximal CD163 receptor expression remaining off while samples were harvested, or high CV

98

between the triplicates resulting in statistically insignificant results could explain the lack of
observed significant enhanced CD163 receptor expression in response to IL-10 in flow cytometry
assays. The IL-10 treatment did not affect MHCII and CD86 expression as well.
Overall Significance: Assessment of surface receptor expression by flow cytometry is another
tool for further characterization of phenotypic profiles of macrophages. The motivation to perform
flow cytometry assays was to gain information on MHCII, CD28, CD68 and CD86 receptors of
differentially polarized macrophages that could not be established through ELISA. The qRT-PCR
assays were performed on only two of the surface receptor protein (CD163 and CD206) targets.
Thus, flow cytometry assays were performed to validate qRT-PCR mRNA transcript data on
CD163 and CD206 at protein level as well as to gain insight on above mentioned other surface
protein markers.
Specific Points of Significance
1. Flow cytometry assays on splenic macrophages demonstrate that resting (control) cells are
positive for MHCII, CD86, CD163 and CD206. Dramatic enhancement of receptor
expression in response to IL-4 and IL-10 may not have been observed as splenic
macrophages are relatively more differentiated (with positive expression for markers under
investigation) than bone marrow macrophages or peripheral blood monocytes. This again
highlights the point that depending on the source of macrophage derivation, variations in
data can arise. Thus, it is crucial to perform studies on macrophages derived from various
sources for in-depth understanding of macrophage activation biology. Use of rodent splenic
macrophages in the present study is new and adds to the growing knowledge base in the
field of macrophage activation.
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2. Gene expression data suggests upregulation of CD163 in response to IL-10 and CD206 in
response to IL-4. However, any significant differences in receptor expression using flow
cytometry assays were not found. The gene expression could be transient without the
significant enhanced receptor protein translation. This is a significant result as this
highlights the known problem of correlation between gene expression and protein
expression data due to different control mechanisms at transcription and translational
levels. Thus, combination of various assays are used for the characterization of
macrophages. Although, it is important to point out that lack of positive expression in flow
cytometry may not mean no change in phenotype. It could also be due to reagents not being
bright enough, and rare events remaining undetectable due to poor resolution as parent
population (CD11b+ macrophages) was only ~28%.

3. Direct analysis of receptor expression using flow cytometry provided further insights on
response to modulators. Significant enhancement of MHCII and down-modulation of
CD163 in response to IL-4 was observed. Significant enhancement of CD206 and downmodulation CD86 in response to dexamethasone was observed. Direct assessment of
receptor expression provide insights into translational level modulation by modulators.
Taken together results from Chapters 2 and 3 provide various methodologies for
characterization of differentially activated macrophages.
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Chapter 4: Directing Macrophage Activation with Microdialysis Probe Implants

4.1 Introduction
In previous chapters, the activation of macrophages in vitro in response to various
stimulants was demonstrated for rodent macrophages. The data suggest important differences with
respect to arginase isoform expression, and phenotype obtained in response to chitohexaose
treatment. These differences could be due to species and/or source of the macrophage derivation.
Nonetheless, these results demonstrate the efficacy of stimulants in driving macrophages to
respective activation states. Although it is well known that in vitro results may not translate in
vivo, these crucial in vitro experiments also serve as a roadmap in terms of what to expect when
trying immunomodulation in vivo and to understand how well data translate in vivo. As mentioned
in chapter 1, the long term aim of the research is in modulating the FBR around the implant site to
reduce fibrosis and enhance the longevity of the implant. The hypothesis is immunomodulation
of the macrophages toward pro-wound healing and tissue remodeling phenotype at the implant site
may result in better FBR outcome.
This chapter explores the in vivo efforts to immunomodulate macrophages in response to
localized delivery of IL-4 and IL-10 at the implant site. As described in chapter 1, microdialysis
is a diffusion-based sampling technique. A microdialysis probe has a semipermeable membrane
and an inlet and outlet tubing. A microdialysis probe can also be used to deliver the drug of interest
based on diffusion. The subcutaneous insertion of a microdialysis probe causes trauma and
subsequent FBR. In this regard, use of microdialysis serves as a model of FBR where drug can be
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delivered and sampling can be performed simultaneously as well over time, allowing for
monitoring of the microenvironment in response to drug.
The aim of these experiments was to locally deliver IL-4 or IL-10 in vivo via microdialysis
probes inserted in subcutaneous tissue and perform sampling of cytokines. The idea was that
differences in cytokine concentration between control and treatment would reflect modulation of
macrophages at the implant site. Additionally, histological analysis of tissue around the implant
would also be indicative of whether modulation was brought about by IL-4/IL-10 treatment.
According to the literature, IL-4 is a pro-fibrotic cytokine, and delivery of IL-4 would result in
more collagenous deposition around the implant. This chapter presents the results of IL-4/IL-10
delivery in vivo using microdialysis probes subcutaneously implanted in male Sprague-Dawley
rats.

4.2 Materials and Methods
4.2.1 Animals
Male Sprague-Dawley rats (Harlan Laboratories Inc.) weighing between 275 to 350 grams
were used in all experiments. All animals were housed in an environmentally-controlled facility
with a 12-hour on/off light cycle and had ad libitum access to food and water. Surgical procedures
followed approved protocols by the University of Arkansas, Institutional Animal Care and Use
Committee in compliance with National Institutes of Health guidelines for the care and treatment
of animals.
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4.2.2 Microdialysis Supplies and Perfusion Fluid
CMA-20 (10 mm (length) x 0.5 mm (outer diameter, o.d.)) 100 kDa molecular weight
cutoff (MWCO) polyethersulphone (PES) microdialysis probes (CMA Microdialysis, North
Chelmsford, MA, USA) were used for all experiments. The Baby Bee single channel (BASi, W.
Lafayette, IN) syringe pump was used with a 1000 µL BAS glass syringe (BASi, W. Lafayette,
IN, USA) to deliver the perfusion fluid through the microdialysis probe. The perfusion fluid used
was Ringer’s solution containing 150 mM NaCl, 4 mM KCl, and 2.4 mM CaCl2, and 0.1% (w/v)
bovine serum albumin, BSA, (Sigma-Aldrich, St. Louis, MO, USA). Dextran 70 (6% w/v) or 500
(4% w/v) was added to prevent fluid loss across the high MWCO membranes during sampling.
Perfusion fluids were prepared as needed and filter sterilized with a 0.2 µm PES membrane filter
(Whatman, Florham Park, NJ, USA).

4.2.3 In vitro Relative Recovery for IL-4 and IL-10
Three CMA20 probes were immersed in the standard cocktail from Luminex multiplex kit.
The outside probe concentration for IL-10 was 3650 pg/mL and the outside probe concentration
for IL-4 was 2540 pg/mL. The in vitro recovery experiment was performed under stirred
conditions, and perfusion fluid used was Ringer’s solution with BSA (0.1% W/V) and Dextran 70
(6%W/V). Samples were collected for 4 hours. Dialysates samples were then analyzed on a
Luminex Magpix multiplex platform using Luminex multiplex kit (Luminex Corp. Austin, TX,
USA)

104

4.2.4 Surgical Implantation of the Microdialysis Probe in Subcutaneous Tissue
The animals were anesthetized with 5% isoflurane and were maintained under anesthesia
at 2.5% isoflurane during the procedure. The dorsal side of the animals was shaved. Iodine was
applied to the shaved area and wiped off with a clean alcohol gauge pad. With the help of a sterile
surgical blade and forceps, T-shaped incisions were made. A subcutaneous pocket was created
following the incision. With the help of the needle and the introducer, microdialysis probes were
implanted on the dorsal subcutaneous tissue on either side of the midline in a symmetrical manner.
Microdialysis probe lines were tunneled through a subcutaneous pocket and were pulled out from
behind the neck. Lines were tucked under the subcutaneous pocket behind the neck after sampling
procedures were done with the help of sterile forceps and sterile wound clips. For long term
sampling from the same animals, animals were anesthetized, wound clips removed and lines pulled
out. Animals were brought out of anesthesia to perform delivery and sampling in awake and freely
moving animals.

4.2.5 Delivery of IL-4 and Sampling from Subcutaneous Implants
4.2.5.1 Set up 1
Two CMA 20, 100 kDa MWCO, 10 mm PES microdialysis probes were implanted into
the dorsal subcutaneous space in male rats. The treatment probe included 50 ng/mL of recombinant
rat (rr) IL-4 in the perfusion fluid. Ringer’s solution was used as perfusion fluid supplemented
with dextran 70 as an osmotic agent and 0.1% BSA. Sampling was performed on the day of
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implantation (day 0) and on day 3 post-implantation with a flow rate of 1 µL/min for a total of 4
hours in awake and freely-moving animals. Samples were collected every hour. On days 0, 1, 2
and 3, a flow rate of 0.5 µL/min was used for delivery of rrIL-4. LuminexTM multiplex assays
(Millipore) were used for the quantification of cytokines (IL-1β, IL-6, IL-10) in the dialysate
samples. On day 4, the rats were euthanized and tissues surrounding the implanted probes were
harvested for histological and immunohistochemical analysis.
4.2.5.2 Set up 2
Two CMA 20, 100 kDa MWCO, 10- mm PES microdialysis probes were implanted in the
dorsal subcutaneous space in male rats. The treatment probe included 50 ng/mL of rrIL-4 in the
perfusion fluid. Ringer’s solution was used as perfusion fluid supplemented with dextran 500 as
an osmotic agent. Sampling was performed on the day of implantation (day 0) and day 4 postimplantation with a flow rate of 1 µL/min for a total of 5 hours in awake and freely-moving
animals. Samples were collected every hour. On days 0, 1, 2 and 3, a flow rate of 0.5 µL/min was
used for delivery of rrIL-4. LuminexTM multiplex assays were used for the quantification of
cytokines (IL-1β, IL-6) in the dialysate samples. On day 4, the rats were euthanized and tissues
surrounding the implanted probes were harvested for histological and immunohistochemical
analysis.
4.2.5.3 Set up 3
Two CMA 20, 100 kDa MWCO, 10 mm PES microdialysis probes were implanted into
the dorsal subcutaneous space in male rats. The treatment probe included 1500 ng/mL of rrIL-4 or
1200ng/mL of rrIL-10 in the perfusion fluid. Ringer’s solution was used as perfusion fluid
supplemented with dextran 500 as an osmotic agent. Sampling was performed on day 2 postimplantation with a flow rate of 1 µL/min for a total of 5 hours in awake and freely-moving
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animals. Samples were collected every hour. On days 0 (day of implantation) and 1, a flow rate of
0.2 µL/min was used for delivery of rrIL-4. CCL2 ELISA (BD OptEIA) was performed for the
measurement of CCL2 concentrations in the dialysates. On day 2, after sampling was over, the rats
were euthanized and tissues surrounding the implanted probes were harvested for gene expression
assays.

4.2.6 Microdialysis Perfusion Effects on Wound Healing
To determine perfusion fluid effects, Two CMA 20, 100 kDa MWCO, 10-mm PES
microdialysis probes were implanted into the dorsal subcutaneous space in male rats. Ringer’s
solution was perfused in one probe for 4 days at 0.5 µL/min. The control probe was not perfused.
On day 7 post-implantation, the rats were euthanized. Tissues surrounding the implanted probes
were harvested for histological analysis. Extreme care was taken to excise ~ 1 cm tissue
surrounding the probe each time following aseptic techniques using sterile scalpel blades, forceps
and scissors.

4.2.7 Histology
Explanted probes and sponges were preserved and fixed in 10% neutral buffered formalin
at room temperature. Samples were processed and prepared by the Histology Laboratory at the
University of Arkansas. Samples were embedded in paraffin and sections 5-8 µm were cut.
Sections were stained with Masson’s Trichrome for examination of collagen and fibrous
deposition. Hematoxylin and eosin staining was also performed on the sections for the assessment
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of cellular infiltration. Prepared sections were imaged on a Zeiss Axioplan 2 microscope with 10X
/30 mm ocular lenses. Both 10X and 40X objective lenses were used. Images were recorded with
a high resolution charged couple device camera. Images were processed with the help of ImageJ
software (NIH).

4.2.8 Quantitative Real Time PCR Assays
Total RNA was extracted by a phenol/chloroform phase separation process from tissues
with the help of TRIzol® reagent (Life Technologies) followed by column clean-up using RNeasy
mini kit (Qaigen). RNA concentration was assessed by measuring the absorbance at 260 nm using
a Nanodrop spectrophotometer (Thermo Scientific). An RNA quality and integrity check was
performed by measuring the 260 nm/280 nm ratio and by agarose gel electrophoresis (Sigma, 1.2%
gel). RNA was converted to cDNA using the High Capacity RNA to cDNA kit (Applied
Biosystems). Techne TC-3000 thermocycler was used to perform the reverse transcriptase reaction
for 60 min at 37ºC, followed by 5 min at 95ºC. Quantitative real time PCR was performed in
duplicates. Each reaction was performed in a total volume of 50 µL using TaqMan® Gene
Expression Master Mix and pre developed TaqMan® probe/primer assay reagents (Life
technologies) using ABI prism 7500 sequence detection platform (Applied Biosystems). Relative
expression was normalized to the reference condition and to the levels of TAF9b gene.
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4.3 Results and Discussion
4.3.1 IL-4 Delivery Effects – Set up 1 Experiments
In vitro relative recovery for IL-10 was found to be 0.6% (±0.2%, N=3) and in vitro relative
recovery for IL-4 was found to be 3.5 % (±0.3%, N=3). In vivo delivery experiments were initiated
after getting the estimates of in vitro relative recovery for IL-4 and IL-10.
The treatment probe included rrIL-4 at 50 ng/mL concentration in Ringer’s solution that
had dextran 70 as an osmotic agent. Probes were perfused on day 1 and 2 at 0.5µL/min for 1 hour.
Sampling was performed on day 0 and on day 3. After sampling was over on day 4, the animals
were euthanized and the probes were harvested for histological analysis. Figure 21 shows the
whole set up of live and freely moving delivery and sampling. Figure 16 shows the Masson’s
Trichrome staining and Figure 22 shows the Hematoxylin and Eosin (H&E) staining of control
and treatment probes.
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Figure 21. The set up showing live and freely moving delivery and sampling of analytes in
rat
The figure shows entire set up of microsialysis delivery and sampling. The picture on the left
shows the rat with subcutaneously implanted microdialysis probe placed inside the rat bowl. Black
arrow indicates the implant location. The picture on the right shows the implanted probe hooked
up to the syringe pumps. Outlet tubing connects to the vials in the automated sampler.
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Figure 22. Masson’s Trichome staining of tissue section surrounding the probe
Tissue surrounding the probes were harvested on day 3 and prepared for histological analysis.
Collagen strands have been stained blue. Any noticeable differences with respect to collagen
deposition between the control probe and IL-4 (50 ng/mL) perfused probe were not found.
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Figure 23. Hemoatoxylin and Eosin staining of tissue section surrounding the probe
Tissue surrounding the probes was harvested on day 3 and prepared for histological analysis.
Collagen strands have been stained light pink. Cells have been stained as purple. Any noticeable
differences with respect to collagen deposition or cellular infiltration between the control probe
and IL-4 (50 ng/mL) perfused probe were not found.
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As evident from Figures 22 and 23, any noticeable difference in histological sections
between control and IL-4 treated tissue sections is not present. Masson’s Trichrome stains the
collagen in blue; thus, based on the implicated role of IL-4 in fibrosis, it would be expected to see
more collagen deposition in IL-4 treated tissue. Hematoxylin and Eosin staining is mainly
performed to gain insight into cellular infiltration. The nuclei of the cell are stained blue and red
blood cells are stained bright orange or cherry red. Collagen fibers are stained pinkish in this stain.
There is no marked difference between the control and IL-4 treated probe. The images shown here
are representative images. A total of six rats were used in the experiment. At 50 ng/mL IL-4
infusion per hour every day for 3 days, any noticeable differences in histology were not found. It
could be that IL-4 did not diffuse out of the probe, or it could be the dose was not high enough to
cause modulation.
Microdialysis sampling of cytokines was performed on day 0 and day 3. Tables 2, 3 and 4
show the concentration of IL-6, IL-1β and IL-10, respectively, in the dialysate samples.
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Table 2. Concentration of IL-6 in pg/mL on day 0 and day 4
IL-6 (pg/mL)
Day 1

Hour

Rat 1

Treatment

Rat 2

Control

Treatment
70

Control

1

50

50

2

35

70

3

35

50

NA

Low

4

70

35

NA

Low

5

70

Low

NA

Low

Not Available†
(NA)

Low
20

Day 4
(hours)
1

Low

290

20

Low

2

Low

100

Low

Low

3

Low

145

Low

Low

4

Low

180

Low

Low

5

Low

100

Low

Low

†Not Available (NA): indicates no dialysate collection due to random probe malfunctioning. Low
indicated dialysate value being below detection of the assay limit.

114

Table 3. Concentration of IL-1β in pg/mL in dialysate samples
IL-1β (pg/mL)
Day 1

Hour

Rat 1

Treatment

Rat 2

Control

Treatment

Control

1

8

Low

Low

Low

2

Low

Low

NA†

Low

3

20

5

NA

Low

4

30

10

NA

Low

5

30

12

NA

Low

1

Low

20

0

2

Low

Low

Low

Low

3

Low

Low

Low

8

4

Low

20

Low

45

5

Low

Low

Low

40

Day 4
(hours)
22

†Not Available (NA): indicates no dialysate collection due to random probe malfunctioning. Low
indicated dialysate value being below detection of the assay limit.
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Table 4. Concentration of IL-10 in pg/mL in dialysate samples
IL-10 (pg/mL)
Day 1

Rat 1

Hour

Treatment

1

Rat 2

Control
1265

Treatment
1750

Control
485

2

140

2610

NA†

275

3

60

2620

NA

230

4

65

4130

NA

110

5

38

3510

NA

NA

Day 4
(hours)
1

190

55

305

305

2

90

40

Low

Low

3

75

30

80

13

4

120

50

Low

110

5

130

35

Low

75

†Not Available (NA): indicates no dialysate collection due to random probe malfunctioning. Low
indicated dialysate value being below detection of the assay limit.
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The IL-10 concentration seems to be higher in all the control samples in Table 4. The
source of this anomaly was cross contamination from syringes that were used for other IL-10
delivery experiments. It is clear from Tables 2, 3 and 4 that no comparison could be drawn between
samples obtained from control probes and IL-4 perfused probes to determine whether perfusion of
IL-4 brought any changes in the cytokine microenvironment of the probe implant. Probe failure
and analyte remaining below detection limit were the main constraints.

4.3.2 Perfusion Effects at the Implant Site
At this point it was also imperative to figure out if constituents of the perfusion fluid and
perfusion itself were causing an inflammatory response. A series of experiments were undertaken
in which major components of the perfusion were compared to control, viz Ringer’s perfused probe
vs non perfused probe, Ringer’s with the dextran 70 vs Ringer’s alone and Ringer’s with BSA vs
Ringer’s with RSA (rat serum albumin). It was found out that dextran 70, which was being used
an osmotic agent, was leaking out of the probe causing inflammation, thus inclusion of dextran
500 as an osmotic agent was opted [126]. Results of perfusion and no perfusion (control) are
presented in this section. Figure 24 shows the Masson’s Trichrome staining of tissue sections
surrounding the probes that were perfused with Ringer’s solution only (not including dextran or
BSA) compared with the probe that was implanted as control and was not perfused at all. A total
of three rats were used in this experiment. Probes were explanted on day 7. Figure 25 shows the
normal subcutaneous tissue histology. It is clear from the Figures 24 and 25 that control probe
histology is much more like normal subcutaneous tissue histology.
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The normal subcutaneous tissue (non-traumatized, far away from the probe) histology
shows that the tissue had ample supply of blood vessels and has collagen fibrils. The non-perfused
probe at day 7 is also surrounded by collagen fibril deposition, and vasculature (blood vessels) is
developing.
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Figure 24. Masson’s Trichrome staining of tissue surrounding control non perfused probe
vs Ringer’s perfused probe (10X resolution)
Tissue surrounding the probes were harvested on day 7 and prepared for histological analysis.
Collagen strands have been stained blue. Noticeable differences with respect to collagen deposition
between the control non-perfused probe and perfused probe can be observed. The perfused probe
has less collagen fibril deposition and appear dense in cellular infiltration.
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Figure 25. Normal subcutaneous tissue histology
The Figure represents the normal subcutaneous tissue (non-traumatized, far away from probe)
histology stained with both Masson’s Trichrome, and Hematoxylin and Eosin stains. There is
ample collagen fibril network and abundant blood vessel supply (concentric ring like structures)
with sparse cellular presence.
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Overall, the comparison indicates that the non-perfused probe is healing in its natural
course after implantation to appear more like the normal subcutaneous tissue histology. On the
other hand, tissue surrounding the perfused probe still appears inflamed with less collagen fibril
networking. Dense cellular infiltration is clearly visible with little developed vasculature, present
only in areas away from the probe where collagen fibril deposition is seen.
It is clear that even the process of perfusion causes inflammation. However, perfusion is
necessary for sampling and delivery of the drug. These experiments gave insight on how natural
response to the implanted microdialysis probe looked like at day 7 when compared to normal
subcutaneous tissue histology and how it differed when the probe is perfused. Overall, the
conclusion was to stop the usage of dextran 70 as an osmotic agent.

4.3.3 IL-4 Infusion with Dextran 500 in Ringer’s fluid – Set up 2 Experiments
IL-4 infusion experiments were again initiated. This time, dextran 500 was used in the
perfusion fluid as an osmotic agent, as it was found dextran 70 was leaking out of the membrane,
leading to additional inflammation. It was anticipated that effects of IL-4 might be observed in this
set of experiments, as the inflammation due to dextran 70 that might be overwriting the effects of
IL-4 infusion has been taken care of. In this set of experiments, a total of 6 rats were used. A dose
of 50 ng/mL was infused on day 0 following sampling, and then on days 1, 2 and 3 a dose of
100ng/mL of IL-4 was infused for 1 hour at 0.5 µl/min, followed by sampling on day3. Animals
were euthanized on day 7 and tissue surrounding the probe was harvested on day 7. Figure 26
shows the day 7 explants of control and IL-4 treated probe. Again, the problem of random probe
failure on various time points of the study led to inconclusive data. In animals (N=2), where both
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the control and treatment probes worked, no differences in histology could be established.
Multiplex assays performed on dialysate samples obtained in these animals, also remained
undetectable for IL-1β and IL-6 leading to inconclusive data.
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Figure 26. Masson’s Trichrome staining of tissue sections surrounding the probe. (10X
magnification)
Tissue surrounding the probes was harvested on day 7 and prepared for histological analysis.
Collagen strands have been stained blue. Any noticeable differences with respect to collagen
deposition and cellular infiltration between the control probe and the IL-4 (50 ng/mL, in Ringer’s
with dextran 500 as an osmotic agent) perfused probe were not found.
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4.3.4 IL-4/IL-10 Infusion at Higher Dose – Set up 3 Experiments
The challenges with the previous experiments led to this set of experiments in which the
major motivation was to test infusion of a higher dose of IL-4 or IL-10 at a very slow flow rate
(0.2µl/min) for a total of 1.5 hours at time points 0 (right after probe insertion), 24 hours, 48 hours
and termination at 72 hours. Slow flow rate was chosen to enhance the concentration of analyte
around the probe, as the slower the flow rate, the more time for analyte to diffuse across the probe.
Thus, slow flow rate increases the local concentration, but decreases the total amount delivered.
IL-4 at 1500 ng/mL was included in Ringer’s solution without dextran and BSA. The rationale
was to avoid any kind of non-specific binding/clogging of membrane region with dextran and
BSA. At the 72 hour time point, animals were euthanized and probes were harvested for gene
expression analysis. Previous methods of multiplex cytokine assays and histology comparison did
not yield any conclusive results. Thus, the idea was to measure changes at the transcript level to
ascertain whether IL-4/IL-10 did affect the microenvironment at all. Figure 27 shows the gene
expression analysis of tissue surrounding the control probe and IL-4 (1500 ng/mL) infused probe.
Taf9b was used as a reference gene and normal subcutaneous tissue (far away from probe insertion
area) was used as a reference condition.
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Figure 27. Gene expression profile of tissue surrounding the control and IL-4 infused
probe
Gene expression profile of IL-4 (1500 ng/mL) infused tissue and control tissue around the
microdialysis probe. The log base 2 transformed expression ratios (fold change) represent the
mean values from 3 animals. (±SD represented by error bars). Normal subcutaneous tissue (far
away from probe) as reference sample and TAF9B gene was used as a reference gene. Significance
is denoted by * p<0.05.
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CCL2, NOS2 and IL-6 are significantly upregulated (p<0.05) in control probe tissue when
compared to the un-traumatized reference tissue. In IL-4 treatment tissue, only NOS2 is
significantly (p<0.05) upregulated when compared to the reference tissue. It is interesting to note
that inflammatory cytokines IL1β, IL6 and CCL2 are not upregulated in IL-4 probe tissue. This
suggests that there could be some effects of IL-4 on the probe site. Placement of both the probes
involved surgery, perfusions, osmotic effects and inflammation. The only variable was infusion of
IL-4 at 1500 ng/mL, as opposed to just Ringer’s solution in control probe. It is possible that at
concentration of 1500 ng/mL (with only ~3% diffusion across ie 45 ng/mL), changes might not be
stark enough to be picked up when directly comparing the control probe and IL-4 probe tissue.
4.3.4.1 IL-4 Infusion and Sampling at 72 hours
Based on above gene expression analysis in response to IL-4 infusion, a small pilot study
comprising of 3 rats was conducted. In this set of experiments, all the procedures were done the
same as above, except at the 72 hour time point microdialysis sampling (for 5 hours) was also
performed with both the control and IL-4 infused probe before euthanizing the animals. Based on
the results from gene expression studies (Figure 27), CCL2 was chosen for analysis.
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Table 5. CCL2 (pg/mL) levels in dialysates obtained from control and IL-4 probe
Animal 1

Animal 2

(CCL2 pg/mL)

(CCL2 pg/mL)

Hours

Control

IL-4

Hours

Control

IL-4

0

NA

200

0

580

240

1

170

400

1

410

260

2

70

220

2

190

140

3

70

225

3

150

100

4

60

220

4

110

140

5

50

250

5

85

110

Table 5 shows the CCL2 levels obtained from control probe and IL-4 infused probe from
two animals. Levels of CCL2 obtained from animal 1 appear to be higher in the treatment probe.
However, CCL2 levels obtained from animal 2 appear to be lower in the treatment probe than
would be expected from the gene expression assays. However, it could be possible that
implantation trauma might have been pronounced in animal 1 which could have let to the higher
levels of CCL2 in the dialysates. At this point, with N value of only 2, no conclusion can be drawn.
More experiments are needed to be performed to have enough statistical power.

4.3.4.2 IL-10 infusion and gene expression analysis at 72 hour time point
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In this set of experiments 3 rats were used. A similar experimental set up was used as for
IL-4 infusion in the above experiment. Briefly, two probes were implanted, one as a control probe
perfused with Ringer’s solution alone and a treatment probe perfused with 1200 ng/mL of IL-10
in Ringer’s solution. A flow rate of 0.2 µL/min was used and perfusions were done for a total of
1.5 hours on time points 0, 24, 48 hours followed by termination of animals at 72 hours and
extraction of tissue surrounding the probes for gene expression analysis. Figure 22 shows the gene
expression profile of control probe tissue and IL-10 probe tissue. TAF9B gene was the reference
gene, and non-traumatized normal subcutaneous tissue was used as reference condition. It is
interesting that CCL2 is mildly upregulated in IL-10 infused probe tissue. The log ratio for control
CCL2 is 9.6 (±5.6) and that for IL-10 treated probe is 9.9 (±5.7).
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Figure 28. Gene expression profile of tissue surrounding the control probe and IL-10
infused probe
Gene expression profile of IL-10 (1200ng/mL) infused tissue and control tissue around the
microdialysis probe. The log base 2 transformed expression ratios (fold change) represent the
mean values from 3 animals. (±SD represented by error bars). Normal subcutaneous tissue (far
away from probe) as reference sample and TAF9B gene was used as reference gene. Significance
is denoted by * p<0.05.
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It could be that IL-10 infusion resulted in transient CCL2 expression, but at this stage any
conclusive remarks cannot be made. It is clear that more experiments are required to have
confidence in the data. It may be possible that concentration of cytokines, especially IL-10 used
for infusion, were not enough to affect genes CD163, Arg2 and CD206, or it may be that early
infusion of cytokine followed by analysis at the 72 hour time point may not be as efficacious as
opposed to delayed infusions on later days as FBR/wound healing progresses. It could be that IL10 when introduced from the day of surgery and analyzed at the 72 hour time point may only
modulate the expression of CCL2 alone. As discussed in chapter 1 (progression of wound healing
and FBR) neutrophils infiltrate the site from 24 hour onwards and they remain on the site till 48
hours. Macrophages begin to infiltrate from 48 hours to 72 hours onwards. Thus, infusion at early
time points may give quite different modulation responses as opposed to the introduction of drugs
at later stages when macrophages dominate the site from 48 hours onwards.
More studies are needed to fully optimize, and ensure less variability and confidence in
the data.

Initial pilot experiments with IL-4 infusion at higher dose suggest significant

downregulation of CCL-2 expression. The sample size needed for further experiments can be
determined by power analysis. Below are the results of power analysis for this pilot study of IL-4
infusion (1500 ng/mL)
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Sample Size Needed in Each
Group
alpha level

Power

("p" value)

95%

90%

80%

50%

0.10

10

8

6

3

0.05

13

10

8

4

0.02

15

13

10

5

0.01

17

14

11

6

The above power analysis show appropriate sample sizes to have required statistical power.
Usually, 80% power is acceptable. If the differences are small, then the sample size required would
be large.
Most importantly, experiments are needed to confidently show diffusion of IL-10 (also,
IL-4) across the probe that could cause a biological response. It is very important to mention that
these experiments are completely novel with respect to the delivery of cytokine as drugs using a
microdialysis probe to cause immunomodulation around the implant site. There are several
constraints and challenges associated with these experiments.
The delivery of the analyte is estimated based on the in vitro RR% of that analyte. It is
assumed that diffusion of analyte out from the probe would be same as its RR%. In vitro relative
recovery of IL-4 and IL-10 was determined to be ~3.4% and 1% respectively. Thus, if 1500 ng/mL
concentration of IL-4 is used, then it would be estimated that delivered concentration would be
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roughly 50 ng/mL. Similarly, in vitro RR% of IL-10 is ~1%; thus, at a concentration of 1200
ng/mL, it would be estimated that roughly 12 ng/mL is being delivered. These are only estimates
based on the assumption that diffusion in and across the probe is the same but determination of the
exact concentration of the drug being delivered is an important factor and needs to be addressed.
Also, whether the drug/cytokine remains biologically active from the time it is filled in the syringe,
runs through the long FEP tubings (~15 inches) and reaches the microdialysis membrane region is
also a concern.
The advantage of a microdialysis system is that it can be employed for long term sampling
over time, on different days and the animal serves as its own control. However, it needs to be
established that targeted cytokines and chemokines relevant to these studies (that are affected by
IL-4 and IL-10 modulation) can be sampled effectively and reproducibly. Another major concern
is the variability of recovery between the control and treatment probes due to differences in
surgical implantation of the probes. There are inherent diffusion resistances to cytokines in the
microdialysis sampling process which can further vary between the probes due to differences in
surgical trauma. This could lead to question if the observed differences in the cytokines levels from
treatment probe and control probe are actually due to the changes brought about by the infused
drug or due to inherent diffusion constraints of the cytokines. This could be answered through
skilled surgical implantation of the probes, and the reproducibility of the data can ensure
modulation in response to the drug. Another concern is the recovery of the target analyte/cytokine.
In the microdialysis sampling process, the collected analyte is only a certain percentage of what is
present in the extracellular space. Thus, if the changes brought about by the drug between control
and treatment are not vast enough, it might be hard to be picked up as the recovery might not be
very different.
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It is important to be aware of and acknowledge the above-mentioned concerns while
optimizing the experiments. Overall, it could be concluded from this chapter that these experiments
are novel and challenging, needing a lot more optimization. Based on the gene expression profile
of tissues surrounding the IL-4/IL-10 infused probe and control probe, it seems that there are
effects; however, concentration of IL-4/IL-10, length of IL-4/IL-10 infusion and time points for
end point analysis also need careful consideration for future studies.

4.4 Conclusion and Significance
To conclude, microdialysis mediated delivery of IL-4/IL-10 to modulate the macrophage
responses at the implant site is novel. The gene expression profile of tissues surrounding the IL4/IL-10 infused probe and the control probe suggest modulation in IL-6, CCL2 and iNOS
transcripts. However, concentration of IL-4/IL-10 for delivery, length of IL-4/IL-10 infusion and
time points for end point analysis need further optimization for future studies.
Overall Significance: Macrophage activation and modulation is a new area and extensive
exploration is necessary, both in vitro and in vivo on a case-by-case basis to fully elucidate the
macrophage activation dynamics. Especially, there is a lack of in vitro to in vivo translational
research in this area. Studies attempting to characterize macrophage phenotypes in response to
modulators in vivo in the biomaterials field are not available as of now. Based on in vitro data,
there are speculations and hypotheses about utilizing macrophage immunomodulation for clinical
purposes. To be able to utilize the clinical potential of macrophage plasticity, basic in vivo
translational studies are imperative. This study is completely novel in attempting localized
immunomodulation at the implant site using the microdialysis technique in rats as model
organisms.
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As mentioned in Chapter 1, the advantage of microdialysis lies in the fact that it allows for
the simultaneous localized delivery of a modulator and sampling of target analyte/s. This can
provide information about effects or changes brought about by the modulator over time. Cytokines
are signaling proteins and govern the progression of FBR. Thus, knowledge of localized changes
in the cytokine’s profile in response to modulators is of particular significance. Unexpected probe
failures and the sampled analytes remaining below detection were major constraints. However, the
significance of the work lies in its novelty and attempt to understand in vitro to in vivo translation
of the data. Preliminary gene expression data comparing IL-4 infused tissue and control tissue is
promising. As mentioned before, optimizations are required to successfully employ a microdialysis
model of delivery for immunomodulation.
Specific Points of Significance
1. Once fully optimized, microdialysis will allow for the direct sampling of cytokines released
at the implant site in response to the modulators. This will provide valuable knowledge of
localized cytokine profiles that play crucial roles in the progression of FBR.

2. The microdialysis model, together with cytokine sampling and tissue end-point analysis of
modulator infused versus control tissue, will provide a means to investigate in vitro to in
vivo translation of macrophage activation data.
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Chapter 5: Directing Macrophage Activation with Polyvinyl alcohol (PVA) Sponge
Implantation Model

5.1 Introduction
The use of the PVA-sponge as a model for immunomodulation of macrophages was
undertaken to have a rapid turnaround of the information about modulators with respect to FBR.
As mentioned in Chapter 1, the use of sponges allows for the extraction of wound fluid from an
explanted sponge at a chosen time point which can provide cytokine information present in the
local milieu. Wound cells of interest can be harvested from the sponges at a chosen time point and
analyzed for phenotypes using gene expression assays or flow cytometry alone or in combination
(depending on the cell yield). This provides a rapid screening method for the macrophage
modulator of interest in the wound healing/FBR model.
The aim of this chapter was to assess the effects of IL-4 and IL-10 on the cytokines IL-1β,
CCL2 and IL6, obtained from sponged wound fluid at day 3 and day 7. A secondary goal was to
analyze the phenotypic profile of macrophages extracted from the sponges in response to IL-4 and
IL-10 as compared to the control sponges.

5.2 Materials and Methods
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5.2.1 Animals
Male Sprague-Dawley rats (Harlan Laboratories Inc.) weighing between 275 to 350 grams
were used in all experiments. All animals were housed in an environmentally-controlled facility
with a 12-hour on/off light cycle and had ad libitum access to food and water. Surgical procedures
followed approved protocols by the University of Arkansas Institutional Animal Care and Use
Committee in compliance with National Institutes of Health guidelines for the care and treatment
of animals.

5.2.2 Preparation of PVA Sponges

PVA sponge disks were sourced from PVA Unlimited (Warsaw, IN, USA) measuring 12
mm × 3 mm in size. Sponges were soaked in 0.9% saline overnight and then sterilized by
autoclaving at 121ºC for 30 minutes. Afterwards the remaining preparatory procedures were
performed in a sterile culture hood. Sponges were taken out in a sterile tissue culture plate and
excess saline was allowed to be drained, and sucked out with the help of sterile pipettes and sterile
forceps. To load with the modulator of interest (IL-4, IL-10 in this case), sponges were then soaked
in either IL-4 or IL-10 (200 ng/mL) solution in PBS in sterile Lobind Eppendorf™ vials and kept
on ice. IL-4 and IL-10 come as sterile tissue culture tested lyophilized powder. IL-4 and IL-10
powders were reconstituted with sterile PBS in their original vials at 50 µg/mL concentration,
according to the manufacturer’s instructions (R&D systems). Aliquots were made in sterile
Eppendorf LoBind™ and stored at -80º C. All the steps were performed under the tissue culture
hood.
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5.2.3 Subcutaneous Implantation of the Sponges
Animals were maintained under isoflurane anesthesia as described in chapter 4. The ventral
side was shaved and sterilized with the help of iodine solution and further cleaned with the alcohol
swab. Incisions were made and subcutaneous pockets were created with the help of sterile scissors
and forceps. Sponges were implanted in the subcutaneous pockets. Incisions were then sealed with
the help of Vetbond surgical glue. Animals were then returned to housing. Animals were
euthanized either at day 3 post implantation or day 7 post implantation with day 0 being the day
of surgical implantation. In experimental set ups where sponge incubation times were 7 days, a
booster of dose of either IL-4 or IL-10 (200 ng/mL, a total of 150µL) was given on day 3 by direct
injection into the treatment sponge. A vehicle (sterile PBS) was injected into the control sponges.

5.2.4 Harvest of Wound Fluid and Cells from Sponges
The PVA-sponge-implanted rats were euthanized at specified (day 3 or 7) time points by
CO2 asphyxiation. Sponges were explanted with the help of sterile scissors, scalpels and forceps.
Sponges were squeezed into sterile Eppendorf tubes with the help of forceps to extract the
accumulated wound fluid. Sponges were stored in 10% neutral buffered formalin for fixing and
were later sectioned and processed for histological studies. Extracted wound fluid was stored at 80ºC until analyzed.
For the extraction of cells, sponges were squeezed and fluid was centrifuged at 1500 rpm
for 5 minutes to pellet the cells in the fluid. Cell-free wound fluid was stored at -80ºC for ELISA
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analysis (no more than 3 days). Sponges were minced into small sections in sterile petri dishes
with sterile PBS. Minced sections were pushed through 10 mL syringes (no needle) to push cells
out embedded in sponge sections by the help of compression. Cells from the minced sponge and
fluid were then pooled (of same sponge sample) and treated with ACK lysis solution to lyse the
red blood cells for 10 min on ice. The pellet was washed with PBS and finally resuspended in 1
mL of PBS. A cell count was then performed at this stage by trypan blue dye exclusion method
using an automated cell counter, Countess™ (Life technologies, Grand Island, NY, USA). Cells
were then resuspended in Ham’s F12k media (supplemented with 10% FBS and 1%
antibiotic/antimycotic solution). These cells were allowed to adhere for hours and adherent cells
were selected for subsequent gene expression assays.

5.2.5 RNA Extraction and qRT-PCR Assays
Sponge-derived macrophages were lysed by Trizol™ reagent and RNA was separated by
chloroform-based phase separation. The RNA was cleaned up using RNeasy column kit. RNA
concentration was assessed by measuring the absorbance at 260 nm using a Nanodrop
spectrophotometer (Thermo scientific). The RNA quality and integrity check was performed by
measuring the 260 nm/280 nm ratio and by agarose gel electrophoresis (Sigma, 1.2% gel). RNA
was converted to cDNA using the High Capacity RNA to cDNA kit (Applied Biosystems). A
Techne TC-3000 thermocycler was used to perform the reverse transcriptase reaction for 60 min
at 37ºC, followed by 5 min at 95ºC. Quantitative real time PCR was performed in duplicates. Each
reaction was performed in a total volume of 50 µL using TaqMan® Gene Expression Master Mix
and pre-developed TaqMan® probe/primer assay reagents (Life Technologies) using the ABI
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prism 7500 sequence detection platform (PE Applied Biosystems). Relative expression was
normalized to the reference condition (cells extracted from control sponges) and to the levels of
TAF9B. The following TaqMan® probe/primer assay reagents were used
1) Arg2: Rn00567522_m1
2) CD163: Rn01492519_m1
3) CD206: Rn01487342_m1
4) IL-10: Rn01483987_m1
5) IL-12a: Rn00584538_m1
6) NOS2: Rn00561646_m1
7) TGF-β: Rn00572010_m1
8) TNF-α : Rn01525859_g1

5.2.6 ELISA
IL-6 and CCL2 OptEia ELISA kits were sourced from BD Biosciences (San Jose, CA,
USA) and IL1-β was sourced from Rand D systems (Minneapolis, MN, USA). Assays were
according to the manufacturer’s protocol. Typical sample volume obtained from the pooling of
two sponges yielded approximately 100 to 125 µL volume. ELISA measurements were done in
duplicates per sample. Total protein content was also measured using Nanodrop (Thermo
Scientific) by A280 measurement using 2µL of the sample volume. Quantified cytokine levels
were normalized to the total protein levels in the wound fluid.
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5.3 Results and Discussion

5.3.1 Preliminary Data with PVA sponges
In these preliminary experiments sterile PVA sponges were implanted for two different
time points: that is, at 65 hours and day 7. The 65 hour time point is not indicated as day 3 as
explants were made 8 hours early. Only 3 rats were used for the preliminary experiment. Two
sponges per rat were implanted. At the 65 hour time point, only one rat was used and for day 7 two
rats were used. Both the sponges were pooled in each rat to have enough wound fluid for further
analysis. Multiplex cytokine assays and histological analysis of sponge sections were performed.
Table 6 shows the concentration of cytokines obtained from sponges in each rat. The N value is 1
here with measurement performed in duplicates. From the cytokine profile, it appears that IL-10
is present (105 pg/mL) in collected wound fluid at 65 hours but was below detection on day 7.
VEGF is present at a higher concentration on day 7 but is also present at the 65 hour time point.
This is expected, as published literature suggests expression of VEGF at later stages of wound
healing. Concentration of IL-6 at 90 pg/mL is present at 65 hours but is not detectable in both the
rats at day 7.
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Table 6. Cytokines levels in wound fluid extracted from sponges
IL-10

VEGF

IL-1β

IL-6

CCL2

(pg/mL)

(pg/mL)

(pg/mL)

(pg/mL)

(ng/mL)

105 (±20)

1440
(±200)

2385
(±440)

90 (±10)

800 (±1)

Rat 2

Not

880 (±210)

Not

460 (±10)

(Day 7)

Detected

1070
(±100)

Rat 3

Not

1050 (±40)

770 (±52)

(Day 7)

Detected

Rat 1
(65 hours)

Detected
Not

530 (±30)

Detected

The N value is 1. Measurements have been made in duplicates for each sample (represented by
±SD)
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The concentration of IL-1β appears to be lower on day 7 in both the rats than at 65 hours.
Concentration of CCL2 appears to decrease at day 7, as opposed to the 65 hour time point.
Figure 29 shows the Masson’s Trichrome staining of sponge sections. At time point 65
hours, cellular infiltration seems to be sparse as compared to the day 7 time point. At day 7, cellular
encapsulation in and around the sponge section can be clearly seen (indicated by the black arrow
on the Figure). This is expected and is in line with previously published studies as discussed in
Chapter 1.

Preliminary data with treated PVA sponges
In this experiment one rat was used. Two sponges treated with IL-10 (200 ng/mL) were
implanted in the dorsal and ventral subcutaneous pockets. One sponge treated with IL-4 (200
ng/mL), one sponge with LPS (200 ng/mL) and control sponge with just PBS alone were also
implanted in the ventral subcutaneous pocket of the rat. On day 2, a booster dose of all the analytes
at same 200 ng/mL concentration was given. Sponges were explanted on day 8 post implantation,
wound fluid was extracted and sponge sections were prepared for histological analysis. Figure 30
shows the cytokine profile of wound fluid extracted from differently treated sponges.
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Figure 29. Masson’s Trichrome staining of sponge sections harvested at different time
points.
Sponges were harvested at the 65 hour or day 7 time points. The black arrow indicates the dense
cellular infiltration at day 7 time point.
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Figure 30. Cytokine profile of wound fluid extracted from treated sponges.
The graph shows the concentration of IL-1β, VEGF, IL-6 and IL-10 in wound fluid extracted from
the LPS, IL-4 and IL-10 treated sponges (200 ng/mL) at day 8. Control sponge had PBS alone. N
value is 1 (One sponge for each treatment in one rat). Error bars represent the ±SD of duplicate
measurements of each sample.
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The concentration of inflammatory cytokine IL-1β appears to be highest in the LPS treated
sponge sample (2000 pg/mg of total protein) compared to all other sponge samples, which would
be expected as LPS is an inflammatory mediator. The IL-4 treated sponge sample has less
concentration of IL-1β around 990 pg/mg of total protein, when compared to the LPS treated or
control sponges (1130 pg/mg of total protein). IL-1β concentration is the lowest in IL-10 treated
sponges (520 and 420 pg/mg of total protein), which would be expected, as IL-10 is a potent antiinflammatory cytokine. Concentration of IL-6 is highest in the control sponge (660 pg/mg of total
protein) and the LPS treated sponge (510 pg/mg of total protein). Concentration of VEGF seems
to be highest in IL-10 treated sponges at around 920 pg/mg of total protein.
Figure 31 shows the Masson’s Trichrome staining of sponge sections from different
treatments. The LPS and control sponge sections appear inflamed with dense cellular infiltration
(shown by the black arrow). The IL-4 treated sponge section appears less dense in terms of cellular
infiltration and has collagen deposition developing. Cellular infiltration appears to be sparse in
the IL-10 treated sponge when compared to the LPS, control and IL-4 treated sponge sections. The
preliminary histology data combined with cytokine profile of wound fluid collected from treated
sponges provided encouraging data indicating modulation of the microenvironment in response to
treatments occurred.
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Figure 31. Masson’s Trichrome staining of treated sponge sections
The Figure shows the histological sections of sponges implanted in one rat. Sponges were treated
with LPS, IL-4 and IL-10 at 200 ng/mL. Control sponge had PBS alone. Sponges were harvested
at day 8. The black arrows indicate the area of dense cellular infiltration in LPS and control
sponges.
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Next steps were to repeat the experiments with IL-4 and IL-10 treatment, that involved
wound fluid analysis as well as gene expression analysis of macrophages extracted from the
sponge at day 7 time point and day 3 time point.

5.3.2 Effects of IL-4 on Wound Microenvironment at Day 7
In this set of experiments a total of 6 rats were used. IL-4 loaded (200 ng/mL) sterile PVAsponges were implanted in the ventral subcutaneous pockets (2 per rat). Control sponges were
soaked in PBS alone (2 per rat). On day 3, a booster dose of IL-4 (150 µL of 200 ng/mL) was
injected directly into the sponges. PBS (150 µL) was injected into the control sponges. On day 7,
sponges were explanted and processed as described in methods section. Wound fluid and cells
from both the IL-4 sponges were pooled in each rat. Similarly, wound fluid and cells from both
the control sponges were pooled in each rat. Thus, providing one treatment and one control sample
each rat.
Table 7 shows the count of cells extracted from the control and IL-4 sponges. Figures 32,
33 and 34 show the CCL2, IL-1β and IL-6 levels in the wound fluid, respectively. CCL2 levels in
control samples were found to be 10 (±3, N=6) pg/µg of total protein. In the IL-4 treated sample,
CCL2 levels were 9 (±2, N=6) pg/µg of total protein. Only CCL2 levels have been expressed as
pg/µg due to high concentrations obtained from wound fluid. The control sample IL-6 levels were
13 (±3, N=3) pg/mg of total protein and the IL-4 treated sample IL-6 levels were 17 (±4, N=3)
pg/mg of total protein. Difference in the concentration of CCL2 and IL-6 levels between the
control and IL-4 treated sponges did not reach any statistical significance. IL-6 levels were lowest
and only samples from 3 rats gave detectable concentration during ELISA. Levels of IL-1β in the
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wound fluid extracted from IL-4 treated sponges (112 ±30 pg/mg total protein, N=5) are
significantly lower at p<0.05 when compared to the levels in the control sponges (160 ±40 pg/mg
of total protein, N=5).
Figure 35 shows the gene expression profile of macrophages extracted from control and
IL-4 treated sponges. Any statistically significant differences between the control and the IL-4
treatment were not found. Although IL-1β protein levels are significantly lower in IL-4 treated
sponges, the gene expression data for IL-1β did not reach statistical significance value. Correlation
between gene expression and protein expression may not occur due to differences in regulatory
mechanisms of genes and proteins. This has to be kept under consideration. Lower concentrations
of IL-1β in IL-4 treated sponges when compared to control sponges are consistent with the
preliminary experiment detailed in the previous section.
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Table 7. Total number of cells extracted from sponges

Rat 1

Rat 2

Rat 3

Rat 4

Rat 5

Rat 6

Average

Control

IL-4

Total = 1.4×106

Total = 4.7×105

Viability = 62 %

Viability = 67 %

Total = 1.4×106

Total = 1.2×106

Viability = 70 %

Viability = 70 %

Total = 2.3×106

Total = 1.2×106

Viability = 61 %

Viability = 72 %

Total = 1.9×106

Total = 8.5×105

Viability = 71 %

Viability = 73 %

Total = 1.9×106

Total = 1.1×106

Viability = 70 %

Viability = 60 %

Total = 1.6×106

Total = 4.4×105

Viability = 72 %

Viability =81 %

1.7×106 (±3.5×105 )

8.7×105 (±3.5×105 )

Each rat was implanted with two control and two treatment sponges. Both the control and treatment
sponges were pooled in each rat to have enough cells. Thus, one control and one treatment sample
from each rat.
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Figure 32. CCL2 levels in wound fluid from control and IL-4 treated sponges
Wound fluid was extracted from the control and IL-4 (200 ng/mL) treated sponges on day 7. CCL2
levels were determined through ELISA and were normalized to total protein concentrations. Data
has been plotted at the mean value of samples from 6 rats. Error bars represent the ±SD.
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Figure 33. IL-1β levels in wound fluid extracted from control and IL-4 treated sponge
Wound fluid was extracted from the control and IL-4 (200 ng/mL) treated sponges on day 7. IL1β levels were determined through ELISA and were normalized to total protein concentrations.
Data has been plotted at the mean value of samples from 5 rats. Error bars represent the ±SD.
Significance is denoted by * p<0.05
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Figure 34. IL-6 levels in wound fluid extracted from control and IL-4 treated sponge
Wound fluid was extracted from the control and IL-4 (200 ng/mL) treated sponges on day 7. IL6 levels were determined through ELISA and were normalized to total protein concentrations.
Data has been plotted at the mean value of samples from 3 rats. Error bars represent the ±SD.
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Figure 35. Gene expression profile of macrophages extracted from control and IL-4 treated
sponge
Gene expression profile of macrophages extracted from control and IL-4 (200 ng/mL) treated
sponges at day 7. The log base 2 transformed expression ratios (fold change) represent the mean
values from 4 animals (±SD represented by error bars). TAF9B gene was used as a reference gene.
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5.3.3 Effects of IL-10 on Wound Microenvironment at Day 7
Similar experimental set up was used as described in previous section for IL-4 treated
sponges. IL-10 (200 ng/mL) loaded sponges (total of 2 per rat) were implanted in a total of six
rats. Control sponges had PBS alone (total of 2 per rat). On day 3 a booster dose of IL-10 (150µL
at 200 ng/mL) was given and PBS was injected in the control sponges. The Total volume of
injection was 150µL in each sponge. Sponges were explanted on day 7. Wound fluid and
macrophages were extracted from the sponges for further analysis. Samples were pooled from both
the control and the IL-10 treated sponges in each rat. Table 8 shows the number of cells extracted
from the sponges. Figure 36 shows the CCL2 and Figure 37 shows the IL-6 profile in the wound
fluid.

154

Table 8. Total number of cells extracted from the sponges
Control

IL-10

Total = 1.2×106

Total = 1.2×106

Viability = 76%

Viability = 67 %

Total = 7.8×105

Total = 9.6×105

Viability = 77 %

Viability = 70 %

Total = 1.3×105

Total = 1.6×105

Viability = 66 %

Viability = 72 %

Total = 5.5×105

Total = 7.5×105

Viability = 60 %

Viability = 54 %

Total = 1.2×106

Total = 1.4×106

Viability = 74 %

Viability = 70 %

Total = 1.2×106

Total = 1.4×106

Viability = 70 %

Viability = 67 %

8.4×105 (±4.4×105 )

9.7×105 (±4.7×105 )

Rat 1

Rat 2

Rat 3

Rat 4

Rat 5

Rat 6
Average

Each rat was implanted with two control and two treatment sponges. Both the control and treatment
sponges were pooled in each rat to have enough cells. Thus, one control and one treatment sample
from each rat.
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Figure 36. CCL2 levels in wound fluid extracted from control and IL-10 treated sponges
Wound fluid was extracted from the control and IL-10 (200 ng/mL) treated sponges on day 7.
CCL2 levels were determined through ELISA and were normalized to total protein concentrations.
Data has been plotted at the mean value of samples from 5 rats. Error bars represent the ±SD.
Significance is denoted by * p<0.05
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Figure 37. IL-6 levels in wound fluid extracted from control and IL-10 treated sponge
Wound fluid was extracted from the control and IL-10 (200 ng/mL) treated sponges on day 7. IL6 levels were determined through ELISA and were normalized to total protein concentrations. Data
has been plotted at the mean value of samples from 5 rats. Error bars represent the ±SD.
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Administration of IL-10 resulted in significantly lower concentrations of CCL2 (13 pg/µg
of total protein) in the wound fluid compared to that of the control sponges (18 pg/µg of total
protein). From Figure 37, IL-6 levels obtained from IL-10 treated sponges and control sponges
were not statistically different. IL-6 levels were lower in all experiments at day 7, and no
statistically significant difference between the control sponges and IL-4 or IL-10 treated sponges
was found. This suggests that expression of IL-6 protein at this time point might not be influenced
by either IL-4 or IL-10. Also, the early appearance of IL-6 during FBR between day 0 to day 3
has been documented [127, 128]. This could also be the reason for lower levels of IL-6 in the
wound fluid at this time point which remain unaffected by either IL-4 or IL-10 administration.
Figure 38 shows the gene expression of the profile of macrophages extracted from control
and IL-10 treated sponges. IL-10 administration resulted in the significant down-regulating of IL1β, CCL2 (which correlates with the protein concentration too), IL-12a and NOS2 genes.
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Figure 38. Gene expression profile of macrophages extracted from control and IL-10
treated sponges
Gene expression profile of macrophages extracted from control and IL-10 (200 ng/mL) treated
sponges at day 7. The log base 2 transformed expression ratios (fold change) represent the mean
values from 4 animals (±SD represented by error bars). TAF9B gene was used as a reference gene.
Significance is denoted by * p<0.05.
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Recalling from Figure 4 (TNF-α dampening in response to IL-4/IL-10) in Chapter 2, it was
concluded that at same molar concentrations, IL-10 was more effective in dampening the TNF-α
release from the LPS induced macrophages. IL-10 is a known potent anti-inflammatory cytokine;
thus, its down-regulating effects on inflammatory markers can be seen from Figure 35. However,
the hallmark gene of in vitro IL-10 activation, which is CD163, was not found to be significantly
upregulated. Similarly, the hallmark genes of in vitro IL-4 activation, Arg2 or CD206 were not
significantly upregulated in vivo.
There are differences in IL-4 and IL-10 mediated anti-inflammatory effects, as discussed
above. It could be the dosage used for IL-10 (200 ng/mL), given at the time of implantation and
on day 3 only, did affect the inflammatory markers, but it may not have been optimal to induce a
stark shift in the CD163 expression profile. Also, it is important to point out what is known about
CD163 expression in response to IL-10 comes from in vitro studies. How it correlates to in vivo
delivery of IL-10 is still not known in the context of FBR. It could also be possible that IL-10
might not affect CD163 expression in vivo due to multiple signals present in the microenvironment
that also control macrophage phenotypes.

5.3.4 Effects of IL-10 on Wound Microenvironment at Day 3 Time Point
In this set of experiments, control and IL-10 (200 ng/mL) treated sponges were explanted
at the day 3 time point. A total of 7 rats were used. Four rats were implanted with a total of four
sponges each that were soaked in PBS alone as controls. In the other 3 rats, a total of 4 sponges
that were loaded with IL-10 were implanted in each rat as treatment. No booster dose was given
during the three day incubation period after implantation. After termination of the animals, sponges
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were explanted for the wound fluid and macrophage extraction. Wound fluid and cells from all
four sponges in each animal were pooled to be able to have enough sample for later analysis. At
the day 3 time point, it was anticipated that enough cellular infiltration would not occur to provide
enough number of cells for further analysis.
Table 9 shows the total number of cells extracted from the control and IL-10 treated
sponges. It is clear from the table that enough cells could be extracted from the sponges at the day
3 time point by pooling all the four sponges in each rat. As discussed before, according to the
literature, migration of macrophages starts from 48 hours to 72 hours and later macrophages
dominate the site. The ample number of cells extracted could be representative of this time point
when cellular infiltration progresses. Figures 39, 40 and 41 show the levels of IL-1β, CCL2 and
IL-6 respectively, in wound fluid extracted from the control and IL-10 treated sponges.
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Table 9. Total number of cells extracted from control and IL-10 treated sponges at day 3
Control

IL-10

Total = 5.6×106
Rat 1

Viability = 62 %
Total = 5.5×106

Rat 2

Viability = 67 %
Total = 12.4×106

Rat 3

Viability = 50 %
Total = 9×106

Rat 4

Viability = 65 %
Total = 8×106

Rat 5

Viability = 60 %
Total = 9×106

Rat 6

Viability =67 %
Total = 7.5×106

Rat 7

Viability =65 %

Average

8.1×106 (±3.2×106)

8.1×106 (±7.6×105 )

A total of four sponges either as control or IL-10 treatment were implanted in each rat. All four
sponges in each rat were pooled to give either one control sample per rat or one treatment sample
per rat.
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Figure 39. IL-1β levels in wound fluid extracted from control and IL-10 treated sponges at
day 3
Wound fluid was extracted from the control and IL-10 (200 ng/mL) treated sponges on day 3. IL1β levels were determined through ELISA and were normalized to total protein concentrations.
Data has been plotted at the mean value of samples from 4 rats. Error bars represent the ±SD.
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Figure 40. CCL2 levels in wound fluid extracted from control and IL-10 treated sponges at
day 3
Wound fluid was extracted from the control and IL-10 (200 ng/mL) treated sponges on day 3.
CCL2 levels were determined through ELISA and were normalized to total protein concentrations.
Data has been plotted at the mean value of samples from 4 rats. Error bars represent the ±SD.
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Figure 41. IL-6 levels in wound fluid extracted from control and IL-10 treated sponges at
day 3
Wound fluid was extracted from the control and IL-10 (200 ng/mL) treated sponges on day 3. IL6 levels were determined through ELISA and were normalized to total protein concentrations. Data
has been plotted at the mean value of samples from 4 rats. Error bars represent the ±SD.
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Levels of IL-1β are higher at day 3 in both control and IL-10 treated sponges when
compared to the day 7 time point (Figure 33). Similarly, levels of IL-6 are higher at day 3 when
compared to the day 7 time point (Figure 34 and 37). No statistically significant differences
between cytokine levels in wound fluid from the control and IL-10 treated sponges were found for
CCL2, IL-1β and IL-6 levels. Interestingly, IL-10 administration at the time of implantation
without a further booster dose did not affect the levels of inflammatory cytokines in the wound
fluid. There are two possible interpretations for this result. Firstly, the administration of IL-10 only
at the implantation time could have been degraded by the proteases as the incubation times
progressed and was not optimal to sustain the anti-inflammatory effects without the booster dose.
Secondly, it could be possible that IL-10 administration might not have any effects due to early
administration with the analysis time point as day 3.
Figure 42 shows the gene expression profile of macrophages extracted from the control
and IL-10 treated sponges. It is interesting that CCL2 expression is significantly (p<0.001) upregulated in IL-10 treated sponges compared to the control. At day 7, IL-10 significantly downregulated CCL2 at both the gene and protein levels. However, at day 3 when the dose is given at
the time of implantation (day 0, IL-10 loaded sponges), CCL2 levels are upregulated. Also, CCL2
protein levels in wound fluid from control and IL-10 treated sponges are not significantly different.
Interestingly, in Figure 28 from chapter 4, the IL-10 treated probe mildly upregulated the
expression of CCL2 at 72 hours. This suggests that initial delivery of IL-10 right at the time of
implantation may enhance the CCL2 expression.
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Figure 42. Gene expression profile of cells extracted from control and IL-10 treated
sponges at day 3
Gene expression profile of macrophages extracted from control and IL-10 (200 ng/mL) treated
sponges at day 3. The log base 2 transformed expression ratios (fold change) represent the mean
values from 4 animals (±SD represented by error bars). TAF9B gene was used as a reference gene.
Significance is denoted by * p<0.001. TAF9b gene was used as reference gene.
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When a booster dose of IL-10 was given at day 3, a significant down-regulation of
inflammatory mediators was observed. It could be that macrophage infiltration is maximum
around 72 hours and a dose given at that time point leads to maximum effects. This suggests the
importance of the time point chosen for the delivery of drugs as this leads to differential effects on
the targets chosen. This also suggests possibilities of modulating the micro-environment to have
different outcomes depending on the time point and concentration of the drug chosen.
Overall in this chapter, the effects of IL-4 and IL-10 at 200 ng/mL dose were studied using
the PVA-sponge model. Inflammatory cytokine and gene expression was affected in response to
IL-10 at day 7, but at the day 3 time point IL-10 resulted in CCL2 upregulation. IL-4 did
significantly affect the IL-1β at protein level but its effects on gene expression profile of other
markers were not significant. As mentioned before, in either case IL-4 and IL-10 did not
significantly influence CD206 /Arg2 and CD163 which are the hallmark markers of IL-4 and IL10 activation in macrophages in vivo, respectively.
Studying the effects of cytokines in vivo is not straightforward and is challenging due to
the multitude of factors (cellular, proteins and other mediators) in the microenvironment that
govern the progression of a condition. As discussed in chapter 1, alteration and activation of
macrophages has emerged as a key area in the fields of biomaterials and regenerative medicine.
IL-4 and IL-10 both are anti-inflammatory cytokines and have been implicated in the progression
of FBR. The observation that macrophages adapt phenotypically to exogenous stimulants in vitro
such as IL-4 and IL-10 and the chronic presence of macrophages at the implant site led to the
hypothesis of modulating the response to macrophage to induce better out comes in FBR. A
majority of studies have been done in vitro on macrophage (especially murine macrophages)
activation in response to modulators. It is a new area with a lot of unknowns in terms of translation
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of these studies in vivo, especially in the context of FBR and wound healing. It is important to
emphasize that the experiments that were undertaken in chapter 4 and 5 are novel in their approach
in trying to address a very challenging biological problem. Due to the novelty of these experiments,
it is hard to find published studies to compare and contrast results with. There are multiple issues.
First, in vitro to in vivo translation of data with respect to macrophage phenotypes, and markers
needs to be addressed. Secondly, even if in vitro to in vivo translation is achieved, how it would
actually influence the FBR needs to be determined.
The IL-4 is a pleiotropic cytokine affecting various cell types and mediates antiinflammatory effects. In vitro studies showed the formation multinucleated FBGCs in response to
IL-4 treatment in vitro in murine macrophages [56, 129, 130]. Helming et al., showed that IL-4
mediated FBGC formation is a multistep process and also depends on the source of macrophages
[130, 131]. The presence of FBGC around the implant sites suggests the possible role of IL-4 in
fibrosis based on in vitro observations. However, there is a scarcity of literature to confirm local
administration of IL-4 at the biomaterial implant site will worsen the situation, leading to more
FBGC formation, which in turn would have poor fibrotic outcomes.
On the contrary, there are reports that suggest accelerated cutaneous wound healing in
response to IL-4 administration. Connie et al., studied the effects of local administration of IL-4
on ligament healing in rats [132]. They found that the early administration of IL-4 (100 ng/mL) up
to day 5 favored the wound healing while administration up to day 11 resulted in antagonistic
responses. They showed that healing was favored in response to IL-4, but it was time dependent.
Veronique et al., showed positive effects of IL-4 administration (250 ng) on rat excisional wounds
leading to accelerated healing [42]. They also found that expression of IL-4 was present in wounds
as early as day 1, which peaked at day 4 but started to decline after day 5. In an another interesting
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study by Mokarram et al., on peripheral never repair in rats showed accelerated healing in response
to IL-4 administration [133]. The concentration of IL-4 used was 1 µg/mL. They attributed the
accelerated healing to modulation of macrophage phenotypes brought about by IL-4. Interestingly,
the ratios of CD206+ to CCR7+ macrophages were higher in the IL-4 treated scaffold.
Contrary to the above discussed beneficial roles, IL-4 helps progression of pulmonary lung
fibrosis. An interesting study by Huaux et al., compared the effects of bleomycin induced
pulmonary fibrosis in wild type (IL4+/+) mice and IL-4 deficient (IL-4-/-) mice. They found that
in earlier stages, IL-4 mediated anti-inflammatory effects but in later stages lead to chromic fibrotic
progression in wild type mice, while IL-4 deficient mice developed significantly less pulmonary
fibrosis. Other studies have also pointed out the critical role of IL-4 in pulmonary fibrosis [44,
134].
A study by Daley et al., studied the phenotype of murine wound macrophages utilizing the
PVA-sponge model [135]. Their results were very interesting. They could not detect IL-4, the
cytokine that is considered important for alternative activation of macrophages, in the wound
environment, though, they found that wound macrophages on days 1, 3 and 7 expressed markers
of alternative activation. Wound macrophages were found to be complex and mice lacking the IL4 receptor did not affect the phenotype. In experiments presented in this dissertation, the IL-4
transcript could not be detected in macrophages extracted from the sponges. Taken together, the
role of IL-4 seems to be complex and its effects vary from situation to situation and are also time
dependent. It is very likely that IL-4 administration on day 0 and day 3 in sponge experiments
could have only affected the inflammatory cytokine IL-1β that we observed but could not influence
other markers due to the timing and dosage used.
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As discussed in chapter 1, IL-10 is a potent anti-inflammatory cytokine. It is pleiotropic in
its action that affects various cell types. The observation that scar-less healing of fetal wounds
was attributed to IL-10 led to it being a potential candidate in regenerative healing. Its role as a
therapeutic agent is under investigation for various conditions including, but not limited to,
psoriasis, arthritis, Crohn’s disease and pulmonary fibrosis [136-139]. Kradin et al., compared the
outcomes of bleomycin-induced lung fibrosis in wild type and IL-10 deficient (IL-10-/-) mice.
Their finding suggested the protective role of IL-10 against inflammation but did not impart
protection against fibrosis [140]. Nakagome et al., delivered the IL-10 gene to mice to alleviate
bleomycin induced lung fibrosis[141]. The contrasting results from both the studies suggest that
in wild type mice IL-10 did not affect fibrosis, but exogenous gene delivery attempted at over
expression of IL-10 did impart protective role against pulmonary fibrosis. The point to conclude
is that dosage of IL-10 might play a critical role in alleviating a condition.
In the context of biomaterials, not many published studies are available that focus on its
exogenous administration in vivo to alleviate FBR and fibrotic encapsulation. In a recent study by
Boehler et al., lentiviral mediated gene delivery of IL-10 was proposed at the implant site to sustain
an alternative phenotype of macrophages that would mark down the inflammation. The study was
performed in vitro using murine macrophages. As discussed, various in vitro studies have shown
IL-10-mediated anti-inflammatory effects of macrophages and generation of CD163+ phenotypes
that have been implicated in tissue remodeling. However, in vivo studies are scarce that can provide
insights about in vitro to in vivo translation. The data presented here show modulation of
inflammatory cytokines by IL-10 at day 7. This indicates that IL-10 at the concentration chosen
causes anti-inflammatory effects. However, how it would affect the outcome of FBR with respect
to fibrosis needs further evaluation through histological analysis. This would require a separate set
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of experiments. It could also be possible that at this concentration (200 ng/mL), it may just cause
anti-inflammatory effects and not modulate the fibrosis. No other effects were observed at day 3
except upregulation of CCL2 in response to IL-10. From recent studies, IL-10 has been shown to
enhance the CCL2 expression [76, 142]. This effect could be time dependent.
In psoriasis and Crohn’s disease, concentrations of IL-10 being administered were 8
µg/kg/day and 25 µg/kg/day, respectively [138, 143]. A high dose range might be required to have
dramatic shift in the macrophage phenotype or a daily delivery of IL-10 dose may be required to
have profound effects on macrophage modulation at day 3 or at day 7. Ultimately, how those
dramatic phenotypic shifts will dictate the outcome of FBR needs further evaluation. In conclusion,
it is evident that IL-4 and IL-10 function in complex ways, exerting contrasting effects in different
situations. In the situation presented in this dissertation, some immunomodulation is observed at
the 200 ng/mL dose tested on two different time points, but more studies are required to test these
and/or other time points at higher dosages, and how it would ultimately influence the FBR and
encapsulation needs evaluation.

5.4 Conclusion and Significance
To conclude, effects of IL-4 and IL-10 at a 200 ng/mL dose were studied in this chapter using the
PVA-sponge model. Inflammatory cytokine gene expression was affected in response to IL-10 on
day 7, but at the day 3 time point, IL-10 resulted in CCL2 upregulation. IL-4 significantly affected
IL-1β at the protein level but its effects on the gene expression profile of other markers were not
significant. As mentioned before, in either case IL-4 and IL-10 did not significantly affect the
expression of CD206 /Arg2 and CD163, which are the hallmark markers of IL-4 and IL-10
activation in macrophages in vitro, respectively.
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Overall Significance: As mentioned in the Significance section of Chapter 4, in vivo translational
studies need to be performed to provide in-depth insight into in vivo aspects of macrophage
plasticity. Without the basic in vivo translational studies, the full clinical potential cannot be
achieved.

The significance of this study lies in its attempt to understand in vivo

immunomodulation in rat model organisms.
In Chapter 4, a novel localized IL-4/IL-10 delivery using the microdialysis model was
employed for studies directing the in vivo macrophage activation. Comparative cytokine analysis
could not be performed due to random probe failures. Conclusive inferences could not be drawn
from tissue histological analysis. Directing macrophage activation using the microdialysis
technique requires further optimization. Thus, in Chapter 5, the same questions sought to be
answered utilizing a different approach. The PVA-sponge model has been used extensively in
wound healing studies. The target drug/s can be injected directly into the sponge. How injected
drug/s affect the wound microenvironment and infiltrating cells can then be studied. The in vivo
sponge model allowed for the extraction of wound exudate for cytokine analysis and macrophages
phenotype analysis that infiltrated the sponges. Again, these are novel experiments with respect
to attempting in vivo IL-4/IL-10 mediated immunomodulation and characterization of macrophage
phenotypes. The data obtained adds to the knowledgebase of existing sparse in vivo studies, and
provides a fundamental framework for future studies.
Specific Points of Significance
1. The sponge infiltrated macrophages were harvested for phenotypic analysis through gene
expression assays. The gene expression profile shows a mixed phenotype that expresses
IL-1β, IL-10, CCR7, CD163 and CD206 transcripts, suggesting a mixed phenotype in in
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vivo situations. Data provides assessment of macrophage phenotypic profiles directly
harvested from the sponge implants. This is of high significance as knowledge of what
phenotypes are actually present in vivo in a given condition is crucial.

2. IL-6 levels were higher in day 3 wound exudates than day 7 wound exudates. Both IL-4
and IL-10 treatments did not affect IL-6 levels, which suggests its expression may not be
regulated by either of the cytokines in vivo in the wound model employed. This data
provides new insight on IL-6 immunomodulation in the chosen model system at chosen
modulator concentration.

3. The levels of IL-1β were affected by IL-4 treatment at the day 7 time point. No significant
differences in other markers were found. Whereas IL-10 treatment down-modulated
inflammatory markers IL-1β, CCL2, IL12a and iNOS. Data provides insight into
differences in responsiveness to IL-4 and IL-10 treatments, and their affected targets.

4. At the day 3 time point, IL-10 enhanced CCL2 expression, whereas at day 7 it downmodulated the CCL2 expression both at transcriptional and translational levels. The study
shows how dose timings influence the responses and have to be an important consideration
in in vivo immunomodulation.

5. Combined together, this new study provides an initial groundwork for future in vivo
immunomodulation studies with respect to IL-4/IL-10 dose concentrations, timings and
their affected targets.
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Chapter 6: In Vivo Microdialysis Sampling of Adipokines CCL2, IL-6 and Lepin in the
Mammary Fat Pad of Adult Female Rats
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6.1 Introduction
Adiposity has been linked with increased breast cancer risk [144]. By volume, breast tissue
contains approximately 90% adipocytes that comprise the white adipose tissue and 10% epithelial
cells. Adipocytes within the white adipose tissue secrete signaling proteins which are collectively
called adipokines [89]. Many different adipokines exist including CCL2, IL-6, IL-8, resistin, TNFα, and VEGF [145]. Cancer is believed to start from the breast epithelial cells and growth factors
and cytokines secreted by adipocytes are suspected to significantly contribute to breast cancer
progression [146-148]. CCL2, a 13 kDa monomer that forms a dimer to be biologically active,
plays a potent role in macrophage recruitment at the site of injury or infection [149]. IL-6 is a 20.8
kDa pleiotropic cytokine exhibiting both pro- and anti-inflammatory properties, depending on cell
context [150]. The primary function of IL-6 is the initiation of acute phase response during
inflammation and infection [59, 151]. IL-6 activates multiple signaling pathways to control
cellular proliferation and apoptosis. Upregulation of IL-6 and CCL2 in breast cancer promote
inflammation which in turn is linked to tumor progression. Leptin is a 16 kDa non-glycosylated
protein hormone secreted mainly by adipose tissues in proportion to body mass index and is
essential for normal mammary gland development [91]. Leptin expression occurs in normal
mammary tissues, in breast cancer cell lines, and in tumors [152].
Microdialysis is a well-established diffusion-based in vivo sampling technique that has been
used for chemical sampling from extracellular fluid space in the fields of neuroscience, drug
metabolism and pharmaceutics [153, 154]. A microdialysis probe is made up of a semipermeable
dialysis membrane with a defined molecular weight cut-off (MWCO) and inlet and outlet tubing.
A perfusion fluid that matches extracellular fluid in ionic strength and composition is pumped (at
flow rates ~ 0.5 µL to 2 µL min-1) through the inlet and dialysate containing the diffusible solutes
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is collected from the outlet. Relative Recovery (RR) or extraction efficiency (EE) can be defined
as the ratio, EE = Coutlet/CECF where Coutlet is the concentration of the analyte in the outlet and
C∞ECF is the concentration of the analyte in the tissue extracellular fluid at far-field distance from
the implanted probe [155]. Since microdialysis sampling is a diffusion-based separation process,
the collected solute concentrations from any tissue will be a function of the mass transport
properties for the solute through the tissue, dialysis membrane, and the dialysate [156]. Analytes
with smaller diffusion coefficients such as the adipokine proteins will generally exhibit EE values
of roughly 10% or less [154].
Microdialysis sampling has been employed for the sampling of large protein molecules
such as cytokines and adipokines [157-163]. The microdialysis sampling technique has several
merits, the most important being the ability to provide continuous sampling of the extracellular
fluid space within tissues. The microdialysis sampling procedure is considered to be minimally
invasive due to small size of the probe (500 µm), thus causing less tissue disruption when
implanted. Dialysate samples obtained from the device are analytically clean, requiring no further
sample clean up and can be directly subjected to immunoassays or other quantitation methods.
The goal of the present study was to employ microdialysis sampling to collect and quantify
adipokines from the mammary fat pad of young adult female rats. Rats are a commonly-used
animal model for human breast cancer [164-166]. While Xu et. al. employed microdialysis
sampling technique to sample osteopontin, clusterin and cystatin-c from mammary tumors in
female rats, to our knowledge no reports of microdialysis sampling in normal mammary glands
of rodents has been reported [167]. CCL2, IL-6, and leptin were selected for the study as they are
important mediators of inflammation underlying mammary tumor development and progression.
A critical issue with microdialysis sampling, particularly with larger molecules, is the calibration
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of the dialysate concentrations relative to actual tissue concentrations [168]. Dialysate
concentrations are representative of a certain percentage of the tissue concentrations. While whole
tissue extracts would also represent any cytokines stored in granulocytes, we chose to also compare
dialysate protein concentrations with those extracted from whole tissue.

6.2 Materials and Methods
6.2.1 Microdialysis Supplies and Perfusion Fluid
CMA-20 (10 mm (length) x 0.5 mm (outer diameter, o.d.) 100 kDa molecular weight cutoff
(MWCO) polyethersulphone (PES) microdialysis probes (CMA Microdialysis, North Chelmsford,
MA) were used for all experiments. The Baby Bee single channel (BASi, W. Lafayette, IN) syringe
pump was used with a 1000 µL BAS glass syringe (BASi, W. Lafayette, IN) to deliver the
perfusion fluid through microdialysis probe. Perfusion fluids contained phosphate-buffered saline
(PBS), containing 0.137 M NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4 and 1.4 mM KH2PO4 with 6%
(w/v) Dextran 70 (Sigma-Aldrich, St. Louis, MO) and 0.1% (w/v) bovine serum albumin, BSA,
(Sigma-Aldrich, St. Louis, MO). Dextran was added to prevent fluid loss across the high MWCO
membranes during sampling and BSA was used to reduce non-specific adsorption of adipokines
to membrane materials. Perfusion fluids were prepared as needed and filter sterilized with a 0.2
µm PES membrane filter (Whatman, Florham Park, NJ).
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6.2.2 In vitro Microdialysis Recovery Experiment
The calibration of the probe to determine the relative recovery of CCL2, IL-6 and leptin was
conducted in vitro. Briefly, CMA 20 microdialysis probes (100 kDa MWCO and 10 mm length)
were immersed into a solution containing 2 ng mL-1 of each protein, with stirring at 37°C. The
perfusion flow rate was set at 2 µL min-1 and dialysates were collected every hour for a total of
five hours. Samples were quantified as outlined below.

6.2.3 Animals and Probe Implantation Procedure
Sixteen adult female Sprague-Dawley rats (Harlan Laboratories Inc., Madison, WI)
weighing between 220 to 250 g were used in this study. The first set of experiments used ten rats
(Set 1) while the second set had six rats (Set 2). All animals were housed in an environmentallycontrolled facility with a 12-hour on/off light cycle and had ad libitum access to food and water.
Surgical procedures followed approved protocols by the University of Arkansas Institutional
Animal Care and Use Committee in compliance with National Institutes of Health guidelines for
the care and treatment of animals. The animals were anesthetized with 5% isoflurane (Butler
Schein, Dublin, OH) (in oxygen). The body temperature was monitored using a rectal thermometer
and maintained using a temperature-controlled heating pad (CMA microdialysis, USA). An 18gauge needle was used to place the microdialysis probe in the abdominal mammary fat pad of the
animal while under 2.5% O2 inhalation.

The needle was inserted from one side and the

microdialysis probe was tunneled through the needle; the needle was then pushed out from the side
of insertion leaving the microdialysis probe embedded in the mammary fat pad (Figure 43). Post
mortem analysis was performed to confirm probe location in the mammary fat pad.
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Figure 43. Microdialysis sampling probe implantation into the mammary fat pad
An increasing microscopic view of the probe implantation is illustrated from left to right. Farthest
right: The circle indicates the location of microdialysis probe implanted in the right abdominal
mammary fat pad.
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6.2.4 Microdialysis Sampling
Animals remained under anesthesia (2.5 % isoflurane in oxygen) throughout the sampling
procedure. Prior to implantation, microdialysis probes were perfused with perfusion fluid at a flow
rate of 3 µL min-1 for a total of 20 minutes. The tubing lines were then flushed with perfusion
fluid (flow rate of 3 µL min-1) for 15 minutes. The flow rate was then reduced to 1 µL min-1 and
samples were collected every hour for a total of three hours. Dialysates were collected into
Eppendorf 0.5 mL protein LoBindTM tubes (Eppendorf, NY) in ice.

To prevent protease

degradation of adipokines, protease inhibitor cocktail (HaltTM, Thermo Scientific, Rockford, IL)
was added to the collection tubes at 2X final concentration. All dialysate samples were stored at
-80°C until analysis was performed within 2 days of collection.

6.2.5 Tissue Harvest and Protein Extraction
Rats were euthanized by CO2 asphyxiation immediately after microdialysis sampling.
Mammary tissue (weighing between 0.4 to 0.5 g per rat) was harvested from right (probe implant
side) and left (control side) abdominal mammary fat pad of each rat (Set 1). For Set 2, mammary
tissue within ~2 mm of the region where the probe was implanted was harvested. An equivalent
amount of mammary tissue was also excised from tissue with no implanted probe. Tissue samples
were frozen immediately in liquid nitrogen and stored at -80°C until analysis within 2 days of
tissue collection. T-PER buffer (Pierce Protein Research Products, Thermo Scientific, Rockford,
IL) was used for tissue protein extraction, following the manufacturer’s guidelines. Briefly, tissue
samples were thawed on ice, weighed and divided into 0.25 g minced sections. T-PER buffer
containing 1 X Halt Protease inhibitor cocktail was added (4 µL mg-1 of tissue), and tissues were
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lysed by at least 5 freeze/thaw cycles, followed by homogenization using a Bullet Blender (Next
Advance Inc., Averill Park, NY). Tissue homogenates supernatant was collected by centrifugation
at 8000g for 15 minutes at 4°C. Total protein concentration in tissue lysates was determined using
a bicinchoninic acid (BCA) assay kit (Calbiochem, San Diego, CA) as per the manufacturer’s
protocol.

6.2.6 Adipokine Quantification
The amounts of CCL2, IL-6, and leptin in 25 µL of dialysate samples were determined
using the Multiplex MAP kit (Millipore, Billerica, MA) following the manufacturer’s instructions.
Sample concentrations (pg mL-1) were determined by comparing median fluorescence intensity
(MFI) against a standard curve of known protein concentrations, using a LuminexTM 100 IS
analyzer (Luminex Corp, Austin, TX). The concentration range for the leptin assay was 2.4 –
10,000 pg mL-1 and 4.88 – 5000 pg mL-1 for the CCL2 and IL-6. In vitro dialysates samples and
tissue extracts were quantified by ELISA using Leptin (Millipore, Billerica, MA), IL-6 and CCL2
(BD Pharmingen, San Diego, CA) ELISA kits.

6.2.7 Statistical Analysis
Origin 8 software platform (OriginLab Corp, Northampton, MA) was used for statistical
analysis. The normality of the concentrations of the samples from microdialysis and protein
extraction experiments was analyzed using a Shapiro-Wilk test. Data are presented as box and
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whiskers plots. Comparisons between samples were made using a Kruskal-Wallis ANOVA with
a Bonferroni post hoc test and were considered significant at p< 0.05.

6.3 Results and Discussion
6.3.1 In vitro Relative Recovery Values
The average relative recovery values of leptin, IL-6 and CCL2 were found to be 11.6 ±
1.2%, 3.3 ± 0.6% and 18.6 ± 9% (n = 5), respectively with a 2 µL min-1 flow rate. These relative
values for IL-6 and CCL2 are within the range of values reported previously [154]. By contrast,
the relative recovery of leptin (~12%) is an order of magnitude higher than previously described.
Dostalova et al. reported in vitro recovery of leptin at 5.85 % (flow rate of 1 µL/min) and 5.17 %
(flow rate of 2 µL min-1), while Duo et al. reported recoveries of 4% and 2% using flow rates of
1 µL min-1 and 2 µL min-1 respectively [158, 169, 170]. Variations in experimental conditions (37°
C under stirred conditions in our studies) which maximized in vitro recovery may account for these
observed differences.

6.3.2 Probe Implantation in Rat Mammary Fat Pad
Given the anatomical structure of the mammary fat pad, the use of a linear microdialysis
probe for collection would have been ideal [171]. In our initial studies, we attempted to use the
CMA 31 PES 55 kDa MWCO linear probes. While this probe could be inserted into the fat pad
and its membrane positioned within the fat pad itself, no adipokines were collected using these
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probes. Additional studies using in vitro standards demonstrated that for the 55 kDa MWCO
probes, neither CCL2 (13 kDa) or leptin (16 kDa) could be recovered in quantifiable levels across
this membrane at a low flow rate of 0.5 µL min-1. It is important to note that MWCO values for
the membranes used here are based on the values used for standard kidney dialysis methods. Since
MWCO values are obtained using bulk or equilibrium measurements performed under different
conditions than microdialysis sampling, it is common with microdialysis sampling to see recovery
rates far lower for solutes with molecular weights under the MWCO[172],[173]. We subsequently
selected the CMA 20 microdialysis probes with the 100 kDa MWCO based on our previous
experience for cytokine collection.

6.3.3 In vivo Microdialysis Collection and Protein Extraction from Tissue
Two sets of rats (with ten and six animals, respectively, in Sets 1 and 2) were used to
compare cytokine dialysate and extracted tissue protein concentrations. In contrast to those for
CCL2 and IL-6, the multiplex assay carried out for leptin in set 1 did not result in standard curves
that were appropriate for quantitative measurements. This is a common problem with these beadbased assays in that they do not behave as ruggedly and reliably as standard ELISA [174].
However, given the low volumes obtained using microdialysis sampling, the bead-based assays do
allow for multiplexed measurements in our low µL samples. In the second set of six rats, the
multiplex assay for CCL2, IL-6 and leptin yielded standard curves that subsequently permitted the
comparisons between dialysate and tissue concentrations for all adipokines.
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6.3.4 CCL2, IL-6, and Leptin Concentrations in the Dialysates
Figure 44 depicts the dialysate concentrations obtained for CCL2 and IL-6 for the two
independent experiments. The concentrations obtained for each adipokine between the two groups
are comparable, indicating reproducibility of the experimental procedures. During the sample
collection periods, the concentrations of both IL-6 and CCL2 gradually increased temporally
during collection. By the end of the collection period (180 minutes), CCL2 concentrations
increased from ~20 to 175 pg mL-1 (median values) while IL-6 concentrations increased from
median values of 30 to 105 pg mL-1. The increase in CCL2 and IL-6 concentrations reflects the
anticipated wounding response from insertion of the microdialysis probe.
Analyses by the non-parametric Kruskal-Wallis ANOVA followed by the Bonferroni post
hoc test were performed on this data giving the following results. For set 1 animals, there is a
significant difference in the protein concentrations at 60 min and 180 mins for both CCL2 and IL6 (p < 0.05). However, there is no significant difference in the protein levels between 60 min and
120 mins and similarly between 120 mins and 180 mins for both CCL2 and IL-6. For set 2 animals,
there is no significant difference between the protein levels obtained at the different time points
for CCL2, IL-6 and leptin. This is likely due to the different outlier concentrations in this smaller
data set. Finally and more important, there is no significant difference in CCL-2 and IL-6
concentrations at comparable time points between set 1 and set 2 animals.
The dialysate concentrations of leptin obtained from the 2nd set of animals did not change
at the different collection points, with median values of 750 pg mL-1 (Figure 45). This result is
consistent with leptin, unlike that of CCL2 and IL-6, to be unresponsive to a foreign body insult.
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Thus, the lack of change in leptin concentrations after probe insertion suggests that dialysate leptin
concentration may reflect basal levels within the extracellular fluid space in the mammary gland.
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Figure 44. CCL2 and IL-6 dialysate profile
CCL2 (left) and IL-6 (right) concentrations from 1 µL min-1 perfused microdialysis probes in two
sets of female rats during a three-hour collection period following probe implantation. The “n”
value is 10 for set 1 (ten animals) and 6 for set 2 (six animals) and represents the number of animals
that provided detectible adipokine concentrations out of total animals used in the study. The box
represents the 25-75 percentile. The line through the box represents the median, whiskers represent
the fence and ▫ represents the mean.
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Figure 45. Leptin concentration in dialysates
Leptin dialysate concentrations collected (1 µL min-1) from set 2 animals during the three hour
collection period following probe implantation. The “n” value is 6 representing the number of
animals that provided detectible adipokine concentrations out of six total animals used in the study.
Box represents the 25-75 percentile. The line through the box represents the median, whiskers
represent the fence and ▫ represents the mean.
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6.3.5 IL-6 and CCL2 Concentrations in Tissue Extracts
The concentrations of CCL2 and IL-6 in mammary tissue extracts are shown in Figure 46.
For these studies, tissues around the areas with and without implanted probes were used. No
significant differences in tissue CCL2 and IL-6 concentrations were observed.

Figure 47

summarizes the adipokine concentrations in tissue extracts when analyzed tissue was limited to an
area within 2 mm surrounding the microdialysis implant. For CCL2, concentrations were found
to be significantly higher in tissue with than without probe. For IL-6, the concentrations did not
differ for tissue with and without implants. It is worth noting the concentrations of CCL2 and IL6 in control tissue in the second experiment (Figure 47) differed significantly from those in the
first set. However, one of the significant advantages of microdialysis sampling procedures is that
the animals serve as their own control. Thus, despite the differences in the absolute values in
control tissues between the two experiments, their relative values with respect to those for probeimplanted tissue within each experiment did not change.

191

Figure 46. CCL2 and IL-6 concentration in tissue lysates
CCL2 (left) and IL-6 (right) concentrations in the probe-implanted vs. control tissue lysates from
animals in set 1. In this set of animals, 1 cm tissue surrounding the probe was harvested. The “n”
value is 7 representing the number of animals that provided detectible adipokine concentration out
of ten animals in this set. The box represents the 25-75 percentile. The line through the box
represents the median, whiskers represent the fence and ▫ represents the mean.
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†

Figure 47. CCL2 and IL-6 concentration in tissue lysates
CCL2 (left) and IL-6 (right) concentrations in probe-implanted vs. control tissue lysates from
animals in set 2. In this set of animals, ~2 mm tissue surrounding the probe was harvested. Probe
vs. control tissue concentrations are significantly different for CCL2 (†), but not IL-6 using a
Kruskal-Wallis ANOVA with a Bonferroni post hoc test (p < 0.05). The “n” value is 6 representing
the number of animals that provided detectible adipokine concentration out of six animals in this
set. The box represents the 25-75 percentile. The line through the box represents the median,
whiskers represent the fence and ▫ represents the mean.
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6.3.6 Comparison of Tissue vs. Dialysates Concentrations
During microdialysis sampling, solute concentrations obtained in the dialysates represent
a fraction of the free and unbound solute concentration in tissues. The in vitro recovery values
obtained under stirred conditions for the adipokines represent the maximum recovery that might
be expected for any solute. This is because tissue properties and other processes (binding to tissue
components such as glycosaminoglycans or tissue receptors) can cause an increase in mass
transport resistance in a tissue which is otherwise lacking in aqueous solutions. The median IL-6
concentration in dialysates was found to be 1% of the average IL-6 concentration in probeimplanted tissues. Similarly, the median CCL2 concentration in dialysates was 3% that in probe
tissue. These values are much lower than the in vitro recoveries of 3.3 % and 18.6% for IL-6 and
CCL2, respectively. Additional sources of variance between tissue and dialysate concentrations
include the presence of various proteins in adipocytes that can bind cytokines or of immune cells
recruited to the adipocyte microenvironment due to the implant. Further, differences in the
analysis platforms (ELISA for tissue lysates and bead-based assays for dialysate) may contribute
to the discrepancies, although the comparable sensitivities of these platforms have been reported
previously [175-178].
A challenge to all in vivo microdialysis sampling work is the issue of microdialysis probe
calibration. Known differences exist between microdialysis calibration in vitro vs. in vivo. For
collection of pharmaceutical solutes, different in vivo calibration procedures exist and require
solute steady state concentrations typically achieved with drug infusions [179]. For endogenous
solutes such as the adipokines that may not exist at steady-state concentrations, in vivo calibration
methods are not available to determine the true extracellular space concentration. For this reason,
we chose to compare total tissue concentrations to the dialysate concentrations.
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Analyte transport through any tissue is related to various tissue properties including the
metabolism and uptake within the tissue, vascularity, and density of the tissue [180, 181]. Any
process that influences solute mass transport through a tissue space will affect the amount of solute
that eventually is collected with microdialysis sampling [156, 182]. Additionally chemokines and
other cytokines are known to bind to the glycosaminoglycans in the tissue [183]. Solutes that bind
to tissue components cannot be collected via the microdialysis sampling approach and thus this
binding influences the amount of protein recovered into a microdialysis probe.
Another tissue factor that would have to be considered in longer term studies with
microdialysis probes in breast tissue would be differences in tissue density. Rats in different age
groups of 21, 28 and 63 days of age have exhibited differences in the tissue density [184]. To
minimize this variable, we chose to use a narrow weight range among the animals used for this
study.
The placement of microdialysis probe in target tissue requires either incision with removal
of enough tissue fascia or use of a guide needle. It is well known that trauma associated with
microdialysis probe insertion causes some tissue damage, local blood flow perturbations, and
release of inflammatory mediators [185-187]. Trauma stimulates the release of IL-6, IL-8 and
CCL2. In previously published data from this lab, CCL2 levels from first day implant in
subcutaneous tissue gradually increased from 20 to 135 pg/mL between 40 to 160 min while those
from IL-6 increased from 20 to 950 pg/mL [188]. In human subcutaneous tissue studies using
microdialysis sampling, the levels of IL-6 and IL-8 were undetectable within the first hour of probe
insertion but continuously increased in the next 6 hours [168, 189, 190]. The data presented here
showing the temporal concentration increases for CCL2 and IL-6 are consistent with others.
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Traditional methods of assessing adipokine expression involve using either qRT-PCR for
measurement of mRNA levels or total protein analysis from tissue. While the microdialysis
sampling technique is minimally invasive, there are advantages of the microdialysis sampling
technique when compared the traditional methods to determine protein expression or
concentrations [191]. Microdialysis sampling allows collection of only unbound solutes. This
means all the adipokines collected within the dialysis probe were not bound to other tissue
components and were released into the extracellular space and not stored within cells. The other
advantage of the microdialysis technique is the possibility for reduction of total animals if you can
dose the animal while the probe is implanted.
Conclusions
Microdialysis sampling techniques have been successfully applied to the collection of
adipokines (CCL2, IL-6 and leptin) from adult rat mammary glands. CCL2 and IL-6
concentrations steadily increased after microdialysis probe implantation. Leptin concentrations
did not differ between the sampling points indicating these levels may reflect basal concentrations
and not levels induced by microdialysis probe insertion trauma. We suggest that this procedure
has significant potential for application in basic studies related to further understanding the
signaling biology of the mammary fat pad as targets of inflammatory and obesogenic instigators
of breast cancer development and progression. Additionally, the microdialysis sampling technique
could be used to collect adipokines during different variable conditions such as animals with
different ages, tumors or those given chemotherapeutic agents during the sampling process.
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Chapter 7: Summary and Future Directions

This dissertation explored the rodent macrophage phenotypic changes in response to
modulators both in vitro and in vivo. As mentioned in Chapter 1, there has been an enormous
interest in the macrophage activation biology in the context of regenerative medicine and wound
healing due to their phenotypic plasticity. It has been hypothesized that immunomodulation of
macrophages can be applied to various clinical scenarios, including FBR in an effort to potentially
reduce fibrosis around an implant site. However, in order to utilize the full clinical potential of
macrophage plasticity, in-depth understanding of the phenotypic plasticity on a case-by-case basis
is imperative due to interspecies differences and inherent complexity of the phenomenon.
Many studies have been published demonstrating macrophage activation in response to
different modulators in murine macrophages. Also, in vivo studies demonstrating translation of the
in vitro data are lacking. In the context of biomaterials, rats serve as common model organisms.
Studies describing macrophage activation biology in rats are sparse. In this research, rats have
been used.
Before trying the modulators in vivo to direct macrophage polarization in rodent systems,
it was important to derive, characterize and establish various phenotypic states of macrophages in
vitro in response to the modulators. Splenic macrophages were used to study the in vitro responses.
In murine models both peripheral blood monocytes (PBMC) and bone marrow derived
macrophages (BMDM) have been used for studying macrophage polarization/activation. Recently,
one study demonstrated the activation potential of macrophages derived from mice spleen [192].
Macrophages derived from various sources can respond differently to the modulators depending
on homogeneity, stages of differentiation and naivety which add to the further complexity. Thus,
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for in depth understanding of the macrophage activation responses, more studies that compare and
contrast immunomodulation of macrophages derived from variety of sources (lung, spleen, blood
and bone marrow) are to be performed. These experiments can highlight the differences in
responses to the modulators, if there are any, between macrophages derived from various sources.
This information would be useful when translating research in vivo as macrophage responses at
one implant location might vary from other implant location. Thus, the use of splenic macrophages
from rats in this study added to the novelty of the research as spleen also deploys macrophages to
the wound site.
Differentially activated macrophages differ from each other in their secretory
cytokine/chemokine profile, arginine metabolism and expression of cell surface receptor proteins.
As seen in above figure (for example), M1 profile secrete inflammatory cytokine TNF, IL-1, IL6. The iNOS expression goes up as arginine metabolism is shifted to produce NO for enhance
bacterial killing. Surface expression of MHCII CD80 and CD86 is enhanced. While on the M2
spectrum anti-inflammatory cytokine IL-10 is secreted. Arginase expression is enhanced. Surface
receptor expression of CD163, CD206 is enhanced compared to the M1 profile. Thus,
differentially activated states of macrophages can be distinguished from each other by variety of
assays such as ELISA for differences in secreted cytokine profiles, flow cytometry assays for
differences in surface receptor expression profiles and gene expression assays for differences in
target genes of interest. There is no agreed upon consensus in the scientific community as to which
assay should be used. Some studies reply only on flow cytometry assays for the phenotypic
analysis and some studies utilize only RT-PCR assays to establish phenotypic profile based on
gene expression profiles. Usually, combination of assays are used to establish profile changes at
various levels viz secreted proteins, receptor changes and changes in gene expression.
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Thus, to establish phenotypic profile at various levels, different assays were used in this
study. ELISA were performed to measure secreted proteins in response to the modulators (Chapter
2). Flow cytometry assays were performed to establish phenotypic changes at surface receptor
expression level (Chapter 3). RT-PCR assays were performed for further validation of the
phenotypic changes at the gene expression level and also, to establish changes in expression profile
of iNOS and arginase (Chapter 3).
In Chapter 2, gene expression assays on differentially activated macrophages were
performed at two different time points. The data from rat-derived macrophages was similar to what
has been observed with murine macrophages. The IL-10 significantly enhanced the CD163
expression which was expected. As expected, CD206 expression was significantly enhanced by
dexamethasone and IL-4. The arginase-1 expression was found to be significantly upregulated in
all the treatments (LPS, IL-4 and IL-10) except dexamethasone where it was down-modulated.
This suggests ambiguity in using arginase-1 as a marker for alternative activation, a problem that
recent literature has pointed out. On the contrary, arginase-2 expression was found to be specific
for IL-4 activation. The arginase-2 isoform has not been investigated much in macrophage
activation studies.

The present research has compared both the isoforms side-by-side in

differentially activated macrophages and shows that argiase-2 can be used as a specific marker for
alternative activation (M(IL-4)) in rat splenic macrophages.
ELISA assays were also performed on the supernatants collected from the differentially
activated splenic macrophages. Secreted proteins TNF, IL-6 and IL-10 had higher concentrations
in LPS treated macrophages compared to the resting macrophages or IL-4/IL-10 stimulated
macrophages. This information is in agreement with information obtained from the gene
expression assays. The secreted IL-10 could not be quantified in the cell culture medium in
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response to IL-4/Dex. However, RT-PCR shows a mild upregulation in IL-10 transcripts for these
treatments. The IL-10 ELISA limit of detection was 15 pg/mL. It is possible that IL-10
upregulation corresponds to the secretion concentration that remained below the assay detection
limit. It is also possible that IL-10 mRNA transcript is present that was detected in the gene
expression assays but may not have been translated to secreted protein due to other translation
control mechanisms.
Also, chitohexose that activated murine macrophages to alternative pathway caused
synergistic inflammatory responses when combined with LPS in rat macrophages. Interestingly,
chitohexose had no effects on macrophages alone. The combination of LPS with chitohexose
resulted in increased secretion of TNF-α, IL-6 and IL-10 in the culture medium. These could be
possible interspecies differences which needs further exploration. A gene expression analysis of
arginase isoforms, iNOS, CD163, and CD206 from macrophages activated by this combination
can be performed in future studies to understand how these markers of activation get affected by
this combination or if the observed synergistic response is limited to the secretion of inflammatory
cytokines. Also, for future studies this combination could be tested for its potential to activate
macrophages towards M1 profile where classical activation is necessary (for example M2 like
tumor associated macrophages).
In Chapter 3, flow cytometry assays were developed for the analysis of cell surface receptor
expression. In Chapter 2, gene expression assays and ELISA were performed for the
characterization of differentially activated macrophages. The cell surface receptor expression also
varies in differentially activated macrophages. The motivation to perform flow cytometry assays
was to gain information on MHCII, CD80, CD86, CD163 and CD206 receptors of differentially
polarized macrophages that could not be established through ELISA. The qRT-PCR assays were
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performed on only two of the surface receptor protein (CD163 and CD206) targets. Thus, flow
cytometry assays were performed to validate qRT-PCR mRNA transcript data on CD163 and
CD206 at protein level as well as to gain insight on above mentioned other surface protein markers.
In splenic macrophages, dexamethasone showed the most dramatic shift towards enhanced
CD206 expression. The gene expression data for CD206 in response to dexamethasone also
showed significant upregulation for this marker. This is in agreement with the results obtained
from the gene expression assays for cells stimulated with dexamethasone. The IL-4 was found to
enhance MHCII expression but did not affect CD206 expression. The gene expression data in
Chapter 3 shows significant upregulation of CD206 in response to IL-4 treatment. The CD163
surface protein expression was expected to be enhanced in response to IL-10 treatment. However,
significant CD163 enhanced expression was not observed in flow cytometry assay though gene
expression data in Chapter 3 showed significant upregulation for this marker. The lack of
correlation between gene and protein expression data is a known biological problem. A positive
gene expression result does not necessarily correlate to positive protein expression. Similarly,
positive protein expression may not show positive results for gene expression assay. The transient
expression of CD163 and CD206 transcripts without detectable functional protein expression
could explain the observed lack of correlation between flow cytometry and gene expression data
for CD163 and CD206 proteins. However, lack of positive expression in flow cytometry does not
mean no expression. Chromophores not having sufficient concentration to detect combined with a
small parent population (~28% CD11b+ macrophages) may have resulted in poor resolution. To
further confirm positive protein expression of CD163 and CD206 in response to IL-10 and IL-4,
respectively, western blot assays could be performed in future studies.
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LPS treatment did not result in any significant enhanced MHCII and CD86 cell surface
receptor expression. However, in Chapter 2, ELISA measurement of secreted TNF-α and IL-6
protein, and enhanced iNOS and IL-12a expression confirmed modulation to M1 phenotype in
response to LPS. Overall, in vitro data from various assays, cytokine ELISA, gene expression and
surface receptor analysis through flow cytometry confirmed the successful derivation and
characterization of differentially activated macrophages. The data also laid the guiding map for
what to expect with respect to markers in vivo.
In vivo experiments were then initiated after successful characterization of macrophages in
vitro. The IL-4 and IL-10 doses were important considerations in in vivo experiments. The IL-4
(50 ng/mL), IL-10 (50 ng/mL), LPS (100 ng/mL) and Dexamethasone (100 µM) doses in in vitro
cell culture experiments were based on dose response study experiments conducted as well as on
previously published literature that confirm immunomodulation of macrophages with these doses.
Similar concentrations were used for in vivo microdialysis delivery studies. Initially, 50 ng/mL of
IL-4 was used for the delivery of IL-4 but no changes between the tissue surrounding the control
probe and the treatment probe were observed. Then concentration of IL-4 and IL-10 were increased
to account for low in vitro relative recovery values 3.5 % for IL-4 and 1% for IL-10 on the
assumption of recovery percentage would be same as delivery. Previously, published study from
Ao and Stenken (Methods, 2006) have discussed in vitro relative recovery and delivery of
cytokines [152].
The 200 ng/mL concentration of IL-4 and IL-10 were chosen for sponge experiments. Few
studies have used IL-4 in vivo in the context of macrophage polarization in wound healing.
Different doses have been utilized in different experiments. Table below shows the list of
references for doses of IL-4
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IL-4 Dose

Purpose

Reference

in In
vitro
rat
alveolar
cell
Mokarram, Nassir, et al. "Effect of modulating
culture.
1 µg/mL in vivo
macrophage phenotype on peripheral nerve
Subcutaneous,
repair." Biomaterials (2012). [130]
Nerve repair
50 ng/mL
vitro

In vivo
0.1, 1 and 100
administration in
ng/mL in vitro
ligament healing
1 and 100 ng/mL model in wistar
in vivo
rats

250 ng/mL

4 day
administration in
experimental
wound healing in
mice

0.1, 1 and 10 mg Sprague-Dawley
in wounds
rats.
Subcutaneous
healing in
diabetic rats

Chamberlain, Connie S., et al. "The influence of
interleukin‐4 on ligament healing." Wound Repair and
Regeneration 19.3 (2011): 426-435. [128]

Salmon-Ehr, Véronique, et al. "Implication of
interleukin-4 in wound healing." Laboratory
investigation 80.8 (2000): 1337-1343. [129]

Schwarz, Martin A., et al. "Method for enhancing
wound healing/repair with IL-4. U.S. Patent No.
5,723,119. 3 Mar. 1998.

In Chapter 4, in vivo experiments to direct macrophages towards an alternative pathway
were initiated with IL-4 and IL-10 delivery using microdialysis probes. These experiments were
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completely novel. The microdialysis model was not trivial, and proved to be challenging especially
due to random probe malfunctioning, probe failures and sampled analyte being below the limit of
detection of the cytokine assays. From microdialysis infusion studies where high concentration of
IL-4 and IL-10 were used, it appears that some changes in CCL2 and IL-6 gene expression profiles
occurred. However, it is too early to derive any conclusion from those experiments as studies need
to be repeated with more animals to have statistical power. Also in vitro delivery of active IL-4 or
IL-10 has to be established and tested as well. It could be possible that IL-4/IL-10 did not diffuse
out of the probe at all, and thus no changes have been observed. Thus, establishment of successful
delivery of analyte has to be addressed first and foremost in future experiments.
In Chapter 5, sponge experiments were undertaken as an alternative methodology to answer
whether or not IL-4 and IL-10 would cause any effects in vivo in rat. In microdialysis delivery
experiments, sampled cytokine were below detection limits. Any conclusive data could not be
derived from cytokine analysis. Histological analyses of tissue surrounding the control probe and
treated probe appeared similar. As discussed in Chapter 1, collection of wound fluid and cells
from sponges makes them highly desirable in wound healing studies. However, animals have to
be terminated to explant the sponges to study a particular time point thus many animals have to be
sacrificed for studies involving different time points. Whereas, with long term microdialysis
sampling fewer animals can be used. This is one of the contrasting differences between the two
methodologies. The cytokines extracted from the sponge wound fluid can be considered as
representative of the near true tissue concentrations. However, cytokines sampled from the
microdialysis probe are only a certain fraction of what is present in the extracellular fluid space
(<1%). The in vitro relative recovery for a given analyte can be used as an estimate for the in vivo
recovery of that analyte. The in vitro relative recovery of cytokines (depending on the size and
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structure) can vary from ~1% (for IL-10) to ~15% (CCL2). Also, there are differences in the
impact surface area of the two implants. The microdialysis probe surface area is 15 mm2 and, on
the other hand the surface area of sponge is 1131 mm2. Thus, the sponge implants had a
significantly larger surface area resulting in larger tissue impact than the microdialysis probes.
Another contrasting point between the two implants is regarding the delivery of IL-4/IL-10. With
microdialysis, the delivered cytokine concentration is only a certain fraction of what is present
inside the dialysis probe and can be estimated based on the in vitro relative recovery values. The
exact concentration of the cytokines diffused out of the probe is hard to estimate. Whereas, the
sponges could be impregnated or injected with the known concentration and volume of the target
cytokine.
Interesting results were observed through the sponge experiments in this research. At day
7 time point, IL-4 treatment resulted in significantly lower concentrations of IL-1β compared to
control sponge wound exudate. On the other hand, IL-10 treatment resulted in significant down
regulation of inflammatory genes. Also, CCL2 levels in wound exudate were significantly lower
in IL-10 treated sponge. At the day 3 time point, no significant differences in IL-1β, CCL2 and IL6 protein concentrations were found between the control and IL-10 treated sponges. However, in
gene expression assays, CCL2 was found to be upregulated in cells extracted from IL-10 treated
sponges. This data suggests that time point is an important consideration as to when to administer
the cytokine. It is important to note that gene expression data from macrophages extracted from
the sponges also suggests a mixed phenotype that does not fit completely into M1 or M2 paradigm
and is not influenced by the infusion of IL-4 and IL-10 at chosen concentration but downmodulates the inflammatory cytokines IL-1β, TNF-α and CCL2. Overall, from the gene expression
and protein assays, minor extent of immunomodulation could be established. The major conclusion
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from the lack of observed dramatic shift in macrophage phenotype suggests the need for the
prolonged presence of modulator cytokine in the biological matrix. This brings to another question
of how dramatic the shift in should be in phenotype to cause a desirable anti-fibrotic outcome.
These questions cannot be answered without performing further exploratory research. However,
this research presents the first step towards the in vitro to in vivo basic translational research with
respect to macrophage activation.
From chapter 6, successful collection and quantification of important breast cancer
biomarkers using microdialysis sampling is established in the mammary fat pad of female rats.
The study has important future implications. The technique can be employed to sample breast
cancer cytokine markers in tumor microenvironment in model organisms. An altered type-2 like
macrophage phenotype is present in breast tumors. The interaction and cytokine signaling between
M2 like altered macrophages and adipose tissue contribute significantly to the progression of
breast tumors. This technique can also be employed to deliver potential drugs right at the action
area (mammary tissue) followed by cytokine sampling to monitor the changes in response to the
drug candidate.
Combined together, this research presents interesting results and provides an opportunity
for further research and exploration in the area of macrophage activation in response to various
modulators. Many possibilities can be tested and characterized. As mentioned before, optimization
of microdialysis experiments are important which will further allow its use in localized delivery
of cytokines with confidence. Immediate next step would be to confirm the in vitro delivery of
bioactive protein via microdialysis probe using a culture system. A simple experiment would be
to induce the NR8383 macrophages with LPS at 100 ng/mL concentration as already performed
in this research. Then inserting the microdialysis probe and performing the delivery of IL-4/IL-10
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for 4 hours (as a starting point). Then measuring and comparing the secreted TNF-α concentrations
between IL-4/IL-10 infused LPS treated macrophage wells and non-infused LPS treated
macrophage wells. The concentration of IL-4/IL-10 and length of infusion would need
optimization based on the results of preliminary experiments. Upon unambiguously establishing
the delivery of IL-4/IL-10 with observable biological effects in vitro, in vivo delivery experiments
can be initiated again.
For future studies, if robust probes can be procured, then it would be interesting to employ
the delivery of IL-4 or IL-10 (with simultaneous sampling) for up to the day 14 and monitor the
long term delivery effects of these cytokines on fibrosis, as fibrosis starts and begins to peak around
this time point. Results of long-term experiments can provide a detailed time profiling of cytokines
in response to IL-4 and IL-10 delivery without sacrificing many animals. Tissue around the probe
can be decellularized and analyzed by flow cytometry for phenotypic changes in macrophages in
response to the cytokines. This has not been done yet in microdialysis experiments but could be
employed in the future experiments.
The immediate next step with the sponge experiments would be to perform a dose response
study. As mentioned before, data from the sponge experiments show a lack of dramatic shift in the
macrophage phenotype at 200 ng/mL (with booster dose on day 3) of IL-4/IL-10, suggesting the
need for a higher dose or everyday administration of the booster dose. The following experimental
plan can be carried out as next step to test two possibilities;
1) Lower dose of 200 ng/mL administration on day 0 followed by booster doses of same
concentration administered every day. Analysis at day 7 time point.
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Group 1, n=6

Group 2, n=6

2)

2 IL-4 treated sponges and 2
untreated
sponge
control
subcutaneously
implanted
along the midline on each side
in each rat

Dose of IL-4 : 200 ng/mL
on day 0 (day of
implantation)

2 IL-10 treated sponges and 2
untreated
sponge
control
subcutaneously
implanted
along the midline on each side
in each rat

Dose of IL-10: 200 ng/mL
day 0 (day of implantation)

On day 3, 4, 5 &6: booster
dose
of
starting
concentrations would be
injected in each sponge

On day 3, 4, 5 &6: booster
dose
of
starting
concentration would be
injected in each sponge

Higher dose of 1000 ng/mL administration on day 0 followed by booster dose on day 3.
Group 1, n=6

Group 2, n=6

2 IL-4 treated sponges and 2
untreated
sponge
control
subcutaneously
implanted
along the midline on each side
in each rat

Dose of IL-4 : 200 ng/mL
on day 0 (day of
implantation)

2 IL-10 treated sponges and 2
untreated
sponge
control
subcutaneously
implanted
along the midline on each side
in each rat

Dose of IL-10: 1000 ng/mL
day 0 (day of implantation)

On day 3: booster dose of
respective 1000 ng/mL
would be injected in each
sponge

On day 3: booster dose of
1000 ng/mL would be
injected in each sponge

End point analysis by cytokine measurement, sponge histology and macrophage phenotype
determination from these experiments can provide following insights;
1) An estimation of whether to utilize even higher concentrations of IL-4/IL-10 to cause
more dramatic shift in macrophage phenotype.
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2) Whether the sustained presence of low doses or administration of higher dose followed
by one booster dose is more desirable for resolution of wound healing while sustaining
the shift in the macrophage phenotype

The sponge experiments can be taken up further to study day 14 and day 21 time points as
well in future studies. If the complete shift in the macrophage phenotype is achieved in vivo, how
this would actually affect the fibrosis needs to be determined by long term studies.

Based on current understanding, it is difficult to answer how the research would translate
in clinic as of now. It is too early to answer the hypothetical question as activation and
immunomodulation of macrophage is a new area in the fields of regenerative medicine and
requires further exploration in the context of FBR. To briefly summarize, the observation that
scar-less healing of fetal wounds was attributed to IL-10, led to it being a potential candidate in
regenerative healing. Its role as a therapeutic agent is under investigation for various conditions
including, but not limited to, psoriasis, arthritis, Crohn’s disease and pulmonary fibrosis. Various
in vitro studies have shown IL-10 mediated anti-inflammatory effects of macrophages and
generation of CD163+ phenotypes that have been implicated in tissue remodeling. The hypothesis
that M(IL-10) activation will lead to scar-less healing is based on what has been observed in in
vitro studies. However, in vivo studies are scarce that can provide insights to in vitro to in vivo
translation. Some of the studies where exogenous application of IL-10 in the context of pulmonary
fibrosis was tested, have given contradictory results. Kradin et al., compared the outcomes of
bleomycin induced lung fibrosis in wild type and IL-10 deficient (IL-10-/-) mice. Their finding
suggested protective role of IL-10 against inflammation but did not impart protection against
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fibrosis [140]. Nakagome et al., delivered IL-10 gene to mice to alleviate bleomycin induced
lung fibrosis [141]. The contrasting results from both the study suggest in wild type mice IL-10
did not affect fibrosis but exogenous gene delivery attempted at over expression of IL-10 did
impart protective role against pulmonary fibrosis. This suggests the dosage of IL-10 required
would be a critical factor and it is going to depend on the severity of the situation.
In the context of biomaterials, not many published studies are available that focus on its
exogenous administration in vivo to alleviate FBR and fibrotic encapsulation. In a recent study
by Boehler et al., lentiviral mediated gene delivery of IL-10 was proposed at the implant site to
sustain an alternative phenotype of macrophages that would mark down the inflammation. The
study was performed in vitro using murine macrophages. As mentioned, various in vitro studies
have shown IL-10 mediated anti-inflammatory effects of macrophages and generation of CD163+
phenotypes that have been implicated in tissue remodeling. However, in vivo studies are scarce
that can provide insights to in vitro to in vivo translation.
In the present study IL-10 at 200 ng/mL concentration marked down the inflammatory
cytokines but had no significant effect on CD163 gene expression.
Points to consider are;
1. More basic research needs to be performed with various dosage of IL-10 and timing of
administration. The question is whether small dose of IL-10 needs to be administered
every day or a higher dose needs to be administrated in a week needs to be tested.

2. How this dose would affects the CD163 expression in macrophage phenotypes needs
to be determined.

216

3. How the shift in CD163 positive macrophages would affect the FBR outcome needs to
be determined.

4. How dramatic shift in macrophage phenotype is needed? Does recurrent doses would
be beneficial or permanent shift in the macrophage phenotype at a certain stage of FBR
would be important to alleviate the fibrosis?

However, to answer the hypothetical question with present limited knowledge, a gene
delivery of IL-10 can be considered as an option once it is determined that permanent shift in the
macrophage phenotype in the FBR stages would be required to alleviate the fibrosis. Drug
releasing hydrogels and tissue scaffolds are under investigation for chronic wounds and tissue
injuries. These scaffolds can be used provided they do not interfere with the continuous glucose
sensor functioning.
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